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CHAPTER 1 - INTRODUCTION 
1.1 - Importance of gut microbiota in human health. 
The gut microbiota plays a significant role in human health, participating in several functions 
beneficial to the host (Patel and DuPont 2015; Kristensen et al. 2016). It has been implicated 
in preventing pathogen colonization (Hand 2016), shaping our immune system (Round and 
Mazmanian 2009; Patel and DuPont 2015; Macpherson, de Agüero and Ganal-Vonarburg 
2017), stimulating the production of gastrointestinal hormones (Saulnier et al. 2013), and 
regulating brain behaviour (De Palma, Collins and Bercik 2014; De Palma et al. 2017) through 
production of neuroactive substances (Steenbergen et al. 2015; Kristensen et al. 2016).  
The gut microbiota has been involved in the fermentation of nondigestible carbohydrates 
reaching the colon. This process leads to the production of short chain fatty acids (SCFA), 
which elicit health benefits (den Besten et al. 2013). The human gut microbiota can be 
manipulated through either passive or active processes. Passive factors include hygiene, 
lifestyle, and diet. For instance, primary colonizers of the gut involved in the immune 
development are shifted by sanitary practices (Zhou 2016). In addition, dietary constituents 
can promote phylogenetic variations in the microbiota (Graf et al. 2015). In this context, 
prebiotics are defined as “a substrate that is selectively utilized by host microorganisms 
conferring a health benefit” (Gibson et al. 2017). Prebiotics act as growth substrates (Patrascu 
et al. 2017) to enhance the activity of bacterial genera (Scott el al. 2015) such as bifidobacteria 
and butyrate-producing clostridia (Rivière et al. 2016). SCFA and vitamins resulting from the 
fermentation of these components are crucial for human health (Graf et al. 2015). In terms of 
lifestyle factors, physical activity is known to positively impact the diversity of gut microbiota. 
In fact, gut microbiota of athletes is more diverse than that of non-athletic subjects (Clarke at 
el. 2014). Amongst the active processes affecting microbiota composition are antibiotics and 
probiotics. Antibiotic use has been linked to dysbiosis (Langdon et al. 2016), even leading to 
low diversity, evenness, and taxonomic richness (Francino 2016; Dethlefsen and Relman 
2011). These detrimental outcomes may lead to decreased SCFA, glycolysis, vitamin 
production, homeostasis of the immune system, and impaired protection against pathogens 
(Guarner and Malagelada 2003). As a result, antibiotic associated diarrhea (AAD) and 
recurrent infectious diseases like Clostridium difficile infection (CDI) may occur (Francino 
2016).  
On the other side of the spectrum are probiotics, which can affect the host either directly or 
through their products, or even influence the activity of resident bacteria in the host (Scott et 
al. 2015). Probiotics are defined as “live microorganisms which when administered in adequate 
amounts confer a health benefit on the host” (WHO/FAO 2006; Hill et al. 2014). The effect of 
probiotics in preventing metabolic syndromes such as obesity, type 2 diabetes (Kasińska and 
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Drzewoski 2015), and dyslipidemia has been reported (Asemi et al. 2013). For instance, 
administration of Bifidobacterium (Wang et al. 2014; Chen et al. 2011; Savcheniuk et al. 2014; 
Yin 2010; Reichold et al. 2014; Plaza-Diaz et al. 2014) and Lactobacillus species reduced body 
weight gain and adipose tissue in mice fed high-fat diet through stimulation of adiponectin 
production (Kim et al. 2013; Kobyliak et al. 2016). In addition, lactobacilli have been proven to 
have therapeutic effects in different pathologies (Di Cerbo et al. 2016). Moreover, probiotics 
regulate the mucosal immune response (Klaenhammer et al. 2012) by improving the activity 
of macrophages (Sang 2010) and changing the expression of the genes associated. Even 
though these outcomes depend on specific bacteria and strains, probiotics may interact with 
Toll-like receptors (TLR) and downregulate the expression of NF-κB and pro-inflammatory 
cytokines (Plaza-Diaz 2014; Ng et al. 2009). For instance, peptides of microbial anti-
inflammatory molecules (MAM) that are found in the F. prausnitzii supernatant inhibit the NF-
κB pathway in vitro and in vivo (Breyner et al. 2017), confirming the anti-inflammatory and 
therapeutic properties of F. prausnitzii (Martín et al. 2014). These properties and protective 
effects of F. prausnitzii were identified in different models such as dinitrobenzene sulfate 
(DNBS)-induced colitis model, dextran sodium sulfate (DSS)-induced colitis (Breyner et al. 
2017), and 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced acute colitis in mice (Miquel et 
al. 2015).  Additionally, levels of anti-inflammatory cytokines and immunoglobulins, immune 
cell proliferation, and production of proinflammatory cytokines produced by the T cells may be 
modulated following probiotic supplementation (Nazemian et al. 2016; Miettinen et al. 1996). 
Furthermore, probiotics can be alternative strategies for inflammatory disorders, as they 
upregulate the production of CD4+Foxp3+ regulatory T cells (Tregs) (Kwon et al. 2010; Yan and 
Polk 2011).  
Different effects on the immune function may be species- and strain-related (Klaenhammer et 
al. 2012). It has been reported that probiotics have therapeutic effect on the central nervous 
system by reducing the intestinal inflammation. In this way, the regulation of HPA axis and the 
activity of the neurotransmitters may be improved (Wallace and Milev 2017). Probiotics from 
Bifidobacterium and Lactobacillus genera are usually delivered through fermented products 
such as yogurts, milk, and cheeses, or they can be delivered as food supplements (Besseling-
van der Vaart et al. 2016). 
 
1.2 - Manipulation of the gut microbiome using antibiotics 
Antibiotics, which are used to prevent the growth or kill a microorganism that causes disease, 
have been considered the miracle drugs and are frequently prescribed in most countries 
(Quigley 2011; Nami et al. 2015). However, this is accompanied by antibiotic resistance, which 
is a major public-health threat, and which has been reported for almost every antibiotic 
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discovered (Nami et al. 2015). The common use of antibiotics in humans and the broad-
spectrum activities of these antibiotics has led the human microbiome to take on substantial 
responsive changes to this therapy; this urges the need to investigate the different antibiotics 
to which the microbiome has developed resistance genes (Carlet 2012; Kazimierczak and 
Scott 2007; Nami et al. 2015). Indeed, this emphasizes the need to restrict antibiotic use to 
prevent treatment failure and the spread of antibiotic resistance (Jakobsson et al. 2010; Nami 
et al. 2015). Moreover, antibiotic use has been reported to impact the microbial intestinal 
metabolism, and potentially lead to obesity, type 2 diabetes and low-grade inflammation 
(Mikkelsen et al. 2016). A study by Perez-Cobas et al. (2013) verified that antibiotics targeting 
specific pathogens may drastically alter gut microbial ecology and interactions with host 
metabolism. In contrast, probiotics are considered living drugs that can enhance human health 
and reduce antibiotic use (Nami et al. 2015). 
Microbial ecology research has proven the crosstalk between residing members of the gut 
microbiota and the host immune system. This tight interrelationship has been linked to the 
microbial metabolites responsible for the cell-to-cell communication through quorum-sensing, 
and through the activation of the eukaryotic cells by host defensins and modulation of cytokine 
profiles (Mikelsaar et al. 2011). As a result, such host functions can be positively influenced by 
the residing probiotic bacteria in our gut. However, these commensals require evaluation in 
human studies to elucidate their community composition and metabolic activities (Mikelsaar et 
al. 2011).   
1.3 - Monostrain and Multistrain probiotics  
Probiotics have been categorized into monostrain or multistrain/multispecies products 
(Timmerman et al. 2004). Different studies have confirmed positive effects on health when 
multistrain probiotics are used, due to the symbiosis among strains (Timmerman et al. 2004). 
Strains in multispecies probiotics can be from different genera. For instance, the efficacy of the 
multispecies probiotic consortium VSL#3 (Streptococcus thermophilus, Eubacterium faecium, 
Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus 
acidophilus, Lactobacillus plantarum, Lactobacillus casei and Lactobacillus delbrueckii 
subspecies bulgaricus) was proven for the treatment of ulcerative colitis (Timmerman et al. 
2004; Venturi et al. 1999). Besides, VSL#3 supplementation in women with gestational 
diabetes mellitus (GDM) may help regulate inflammatory markers and positively influence 
glycemic control (Jafarnejad et al. 2016). In addition, Chapman, Gibson, and Rowland (2011) 
described that probiotic mixtures were more effective than single-strain probiotics in inhibiting 
pathogen growth and atopic dermatitis, suggesting further application on other diseases like 
Inflammatory bowel disease (IBD). Another multispecies probiotic called 
Ecologic®Tolerance/Syngut™ was developed using four different probiotic strains 
(Bifidobacterium lactis W51, Lactobacillus acidophilus W22, Lactobacillus plantarum W21 and 
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Lactococcus lactis W19). Strains of this consortium have been proven to strengthen the gut 
barrier function, have beneficial effects on post immunological induced stress, inhibit Th2, and 
stimulate IL-10 levels, thus providing beneficial effects in patients with food intolerance 
(Besseling-van der Vaart et al. 2016).   Moreover, a multispecies probiotic consortium, Ecologic 
AAD (B. bifidum W23, B. lactis W18, B. longum W51, E. faecium W54, L. acidophilus W37 and 
W55, L. paracasei W72, L. plantarum W62, L. rhamnosus W71, and L. salivarius W24), 
reduced diarrhea-like bowel movements when administered in healthy volunteers taking 
amoxicillin (Koning et al. 2008). Multispecies probiotics also prevented rise in fasting plasma 
glucose (FPG), to decrease high sensitivity C-reactive protein (hs-CRP), and to increase 
plasma glutathione (GSH) in diabetic patients (Asemi et al. 2013). Van Minnen et al. (2007) 
provided evidence that manipulation of the intestinal microbiota with multispecies probiotics 
reduced bacterial translocation, morbidity and mortality in a rat model of acute pancreatitis.  
Furthermore, multispecies probiotics rapidly relieved IBS symptoms and shifted the microbiota 
composition (Yoon et al. 2013). According to these results, combining specific probiotic effects 
from diverse strains can lead to an additive and more synergetic multispecies probiotic 
consortium (Timmerman et al. 2007).  
However, the phylogenetic origin of probiotics is currently limited to conventional formulations 
of Bifidobacterium, Lactobacillus species and other lactic acid bacteria (Govender et al. 2013) 
or yeast strains. This may decrease the probiotic effectiveness in the prevention or therapy of 
diseases entailing severe dysbiosis. Hence, a functionally and phylogenetically diverse 
probiotic product may be desirable when alterations in the gut microbiota composition are 
present (Marotz and Zarrinpa 2016). For instance, CDI and recurrent CDI are major medical 
conditions that need urgent treatment when conventional antibiotics fail. As a result, 
development of complex communities with targeted functions is needed.  
 
1.4 - The dilemma of Fecal Microbiota Transplant (FMT)  
“Fecal microbiota transplantation (FMT) is the introduction of a fecal suspension derived from 
a healthy donor into the gastrointestinal (GI) tract of a diseased individual” (Borody, 
Paramsothy and Agrawal 2013). Fecal microbiota transplant (FMT) or fecal bacteriotherapy is 
an alternative strategy successfully used for the treatment of CDI (Kelly 2013). Severe 
antibiotic therapy and CDI trigger dysbiosis, reducing diversity and functionality of the gut 
endogenous microbiota (Brandt 2012). In this case, Clostridium difficile spores can germinate, 
colonize, and thrive in the gut. Treatment of CDI requires additional antibiotics, which increases 
the risk of recurrent CDI (rCDI) after cessation of treatment (Becattini, Taur and Pamer 2016; 
Francino 2016), due to infection with the original strain (Barbut et al. 2000; Marsh et al. 2012) 




Poor colonization resistance from the gut microbiota and the patient’s poor immune response 
further contribute to CDI risk (Pérez-Cobas et al. 2015). Recurrent CDI risk is 10-20% after 
initial CDI (Surawicz et al. 2013), and it increases to 45% after a first relapse, and to 60% for 
those with 2 or more recurrences (Bartlett 1990). However, FMT can resolve both CDI and 
rCDI (Bakken 2009), with a success rate of 90% when further antibiotic treatments fail (Rao 
and Safdar 2015; Youngster et al. 2014). Given the success of FMT, it is now being considered 
as potential treatment for disorders such as ulcerative colitis (Shi et al. 2016), irritable bowel 
syndrome (Distrutti et al. 2016) and metabolic syndrome (Hartstra et al. 2015). For instance, 
FMT induced remission in patients with active ulcerative colitis (Moayyedi et al. 2015), 
potentially as a result of the introduction of normal microbiota and the subsequent correction 
of the imbalance in the microbiota caused by the disease (Bakken et al. 2011). The complexity 
of the fecal sample can be the key factor behind the positive shift in the microbiota composition 
generated by the FMT (Marotz and Zarrinpa 2016). Thus, diversity of the donor microbiome 
may be crucial (Leszczyszyn et al. 2016).  Indeed, some patients do not respond to FMT, 
probably because only specific bacterial phylotypes can be therapeutic when effectively 
transferred (Vermeire et al. 2015). Hence, FMT efficacy for treating gastrointestinal disorders 
is controversial (Sbahi and Di Palma 2016). Adverse effects after FMT include nausea, vomit, 
fever, abdominal pain, and diarrhea (Pigneur and Sokol 2016; Vermeire et al. 2015). Data for 
long-term effects of FMT is lacking, but theoretically, certain disease phenotypes from the 
donor can be transferred to the patient (Sbahi and Di Palma 2016). This could be expected, 
as the uncharacterized nature of FMT may result in undetected or unmonitored risk factors 
such as viruses, pathogens or even allergens being passed to the FMT recipient, causing 
disease. To overcome this problem, Petrof et al. (2013) developed a characterized synthetic 
bacteria cocktail to substitute FMT. Alternatively, a thorough pre-screening should be 
performed on the donor before the actual FMT procedure. Thus, the French Group of Faecal 
microbiota Transplantation (FGFT) was created to secure and evaluate the practice in this field 
(Sokol et al. 2016). Despite having experience treating CDI, FMT is not yet the top treatment 
choice of physicians (Zipursky et al. 2014). However, the majority of gastroenterologists and 
physicians in metropolitan areas were supportive to the idea of creating a fecal transplantation 
center, and a high percentage of the physicians would refer their patients to those centers 
(Jiang et al. 2013).  
1.5 - Alternatives for Fecal Microbiota Transplant  
Additional microbiome therapeutics using characterized microbial communities of selected 
fecal bacteria could be developed to replace FMT and yield the desired outcome (Sbahi and 
Di Palma 2016). For instance, Petrof et al. (2013) described a stool substitute constituted by 
33 different purified intestinal bacteria isolated from a healthy donor (Table 1.1), to treat rCDI. 
In this study, the synthetic bacterial mixture was infused through the colon of the infected 
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patient causing a change in the stool microbial profile. Major shifts reflecting the isolates of the 
synthetic mixture were still detectable six months after treatment. Thus, the concept of 
“RePOOPulate” the gut microbiome was coined. Authors of the study suggested that using a 
synthetic stool substitute may be an effective method to replace the use of FMT for treating 
rCDI. Although further validation is needed, complete resolution of the infection was achieved. 
Several advantages of this synthetic stool substitute can be highlighted. The composition of 
the administered bacterial cocktail is accurately characterized, facilitating registration. Further, 
assembly of the synthetic bacterial cocktail is highly reproducible, enabling standardization and 
upscaling. In addition, patient safety can be guaranteed, because the bacterial mixture can be 
rendered pathogen- and virus-free (Petrof et al. 2013). These data suggest that a multi-species 
community such as that in the RePOOPulate study, can be more effective than single-strain 
probiotics or mixed cultures of probiotic species. This can be because the RePOOPulate 
community preserved its structure and thus successfully colonized a new environment (Petrof 
et al. 2013). Moreover, RePOOPulate consisted of phylogenetically diverse community 
including strains with beneficial health effects that can be candidates for next generation 
probiotics.  
Table 1.1: Strains composing the RePOOPulate consortium 
Composition of Stool Substitute (RePOOPulate) 
Acidaminococcus intestinalis Eubacterium rectale (four different strains) 
Bacteroides ovatus Eubacterium ventriosum 
Bifidobacterium adolescentis (two different 
strains) 
Faecalibacterium prausnitzii 
Bifidobacterium longum (two different strains) Lachnospira pectinoshiza 
Blautia producta Parabacteroides distasonis 
Clostridium cocleatum Raoultella sp. 
Collinsella aerofaciens Roseburia faecalis 
Dorea longicatena (two different strains) Roseburia intestinalis 
Escherichia coli Ruminococcus obeum (two different strains) 
Eubacterium desmolans Ruminococcus torques (two different strains) 
Eubacterium eligens Streptococcus mitis 
Eubacterium limosum  
 
1.6 - Next Generation Probiotics  
Looking at its internationally recognized definition, probiotics are live microorganisms that, 
when administered in adequate numbers, confer health benefits on the host. Probiotics are 
usually isolated from our commensal gut bacteria but cannot be given the definition of 
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probiotics until their stability, content, and health effect are characterized (Sanders 2008). 
Probiotics are thought to improve the balance in the host, prevent disturbances, and decrease 
the risk of pathogen colonization (Goldenberg et al. 2013). Probiotics may additionally impact 
the gut-brain axis. For example, Bifidobactrium longum NC3001 had beneficial effects on 
psychiatric comorbidities, which in turn could temporarily improve the quality of life in IBS 
patients, indicating that this probiotic reduces limbic reactivity (Pinto-Sanchez et al. 2017). 
They have been referred to as functional foods or beneficial bacteria, and they have been 
considered for the prevention and treatment of C. difficile-associated diarrhea (CDAD) 
(Goldenberg et al. 2013). Probiotics can be found as capsules or food supplements in health 
food stores and supermarkets (Goldenberg et al. 2013). Pattani et al. (2013) reported that 
Lactobacillus-based formulations combined with antibiotics reduced the risk of antibiotic 
associated diarrhea (AAD) and CDI. They however suggested that larger studies are needed 
to decide on the use of probiotic/antibiotic combination as a therapy over the single species 
probiotic (Pattani el al. 2013). Furthermore, findings from randomized control trials (RCT) and 
meta analyses suggest that there is moderate evidence on the ability of probiotics to prevent 
primary CDI (people at risk of CDI), but there is no enough evidence suggesting the probiotics 
can prevent secondary CDI (recurrent CDI) (Evans and Johnson 2015). There are still some 
evidence gaps for the use of probiotics in the prevention of CDI such as the interaction between 
specific classes of antibiotics with the probiotics used on CDI risk, the bacterial taxa that 
provides the best efficacy in the prevention of CDI, and the use of probiotics in 
immunocompromised or critically ill patients (Rao and Young 2017). Hence, future RCT should 
consider these different concerns (Rao and Young 2017).  
Overall, classical probiotics show limited effects on the human gut microbiota, seeking the 
need for a better selection and formulation of bacterial strains (Neef and Sanz 2013). Results 
from previous studies show promising outcomes in the treatment or prevention of diverse 
metabolic and inflammatory diseases by specific bacteria (Neef and Sanz 2013). Those 
probiotics encompass species different from Lactobacillus and Bifidobacterium (Cani and Van 
Hul 2015; Patel and DuPont 2015). Nevertheless, the gut microbiome is a complex community, 
which makes it difficult to define the host-microbe interaction.  
The United Nations Food and Agriculture organization (FAO) definition of probiotics is broad, 
allowing flexibility in terms of the phylogenetic origin of probiotics. Information generated from 
previous studies assisted in the selection of next generation probiotics, which include members 
from Clostridium clusters IV, XIVa and XVIII, Faecalibacterium prausnitzii, Akkermansia 
muciniphila, Bacteroides uniformis, (Neef and Sanz 2013, Patel and Du Pont 2015), 
Bacteroides fragilis (Round et al. 2011), and Eubacterium hallii (Udayappan at al. 2016). These 
next generation probiotics were evaluated in preclinical trials and yielded positive outcomes 
for inflammatory and metabolic disorders (Neef and Sanz 2013; Patel and Du Pont 2015). In 
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addition, new techniques are required for the development of novel probiotic products 
containing strains from human origin. This is to say, these strains must come from the major 
groups of the intestinal microbiota, they must be defined to have a safe status and proven to 
have potential beneficial effects (Martin el al. 2017). In the following sections, we will discuss 
some of the most promising bacterial species that are currently under consideration for being 
used as next-generation probiotics. 
1.6.1-  Faecalibacterium prausnitzii  
F. prausnitzii is an extreme oxygen sensitive (EOS) bacterium (Martin et al. 2017) belonging 
to the Clostridium cluster IV, and it accounts for 3-5% of the total fecal bacteria, and it is one 
of the predominant groups in the human feces (Breyner et al. 2017). Quévrain et al. (2016) 
reported low proportions of this species in the fecal and mucosa-associated microbiome in 
Crohn’s disease (CD). F. prausnitzii may possess in vivo and in vitro anti-inflammatory effects. 
Breyner et al. (2017) confirmed the anti-inflammatory properties of MAM, and their ability to 
reduce Th1 and Th17 pro-inflammatory cytokines in Mesenteric Lymphatic Node (MLN) and 
colon tissues in both DNBS and DSS colitis model. MAM also increased TGFβ cytokine 
production, which is involved in activation of NF-kB in DNBS model, thus protecting the host 
and decreasing intestinal inflammation (Breyner et al. 2017). In addition, F. prausnitzii can 
induce the Clostridium-specific IL-10-secreting regulatory T cell subset, present in several 
human colonic cells. Its capacity for lowering IL-12 and IFNγ production indicates that the 
interaction between F. prausnitzii and the host shape and maintain the gut barrier immune 
function (Quévrain et al. 2016). In this way, anti-inflammatory molecules from F. prausnitzii 
may be used as targeted anti-inflammatory drugs for CD. Moreover, MAM could function as a 
CD biomarker, predicting loss of F. prausnitzii functionality. However, further research should 
be conducted to elucidate the MAM production mechanisms, before considering it for CD 
management. Sokol et al. reported that low levels of F. prausnitzii on ileal Crohn’s mucosa 
were associated with CD recurrence after 6 months (Sokol et al. 2008). In addition, the oral 
administration of live F. prausnitzii or its supernatant in mice could reduce the severity of TNBS 
colitis and correct the associated dysbiosis (Sokol et al. 2008). The results from this study 
suggest that F. prausnitzii can be considered as a promising probiotic candidate for the 
treatment of pathologies characterized by chronic gut inflammation (Sokol et al. 2008). 
Besides, all F. prausnitzii strains have proven anti-inflammatory properties, which allows them 
to further be tested in murine models to determine their beneficial effects before moving to 
human trials (Martin el al. 2017). 
1.6.2- Akkermansia muciniphila  
Recent evidence shows that there is a link between the altered gut microbiota and metabolic 
diseases like obesity, diabetes mellitus, and cardiovascular disease (Schneeberger et al. 2015, 
Li et al. 2016, Dao et al. 2016). In contrast, higher abundance of A. muciniphila, a mucin 
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degrading microbe, was associated with healthier metabolic status. Schneeberger et al. (2015) 
and Everard et al. (2014) studied the effects of high fat diet on metabolic parameters and the 
human gut microbiota composition over time, and they found that A. muciniphila was 
decreased. The negative impact on A. muciniphila was associated with expression of lipid 
metabolism, inflammatory markers in adipose tissue, and different parameters like increased 
blood glucose, insulin resistance and plasma triglycerides (Schneeberger et al. 2015). This 
prompted the research towards investigating the putative positive role of A. muciniphila in 
adipose tissue homeostasis and metabolism. Dao et al. (2016) assessed clinical parameters 
and A. muciniphila abundance before and after a 6-week calorie restriction period, followed by 
stabilization diet. The results of this intervention study indicated that the higher abundance of 
A. muciniphila at baseline was associated with improvement in blood glucose homeostasis, 
lipid profile, and body fat distribution after the intervention. Thus, A. muciniphila can be used 
as a prognostic tool for the success of diet interventions (Dao at al. 2016). Moreover, Li et al. 
(2016) reported that administration of A. muciniphila could reverse atherosclerotic lesions, 
improve metabolic endotoxemia-induced inflammation, and ultimately restore gut barrier 
function (Li et al. 2016). 
1.6.3- Bacteroides fragilis and Bacteroides uniformis 
Bacteroides species are commensal bacteria that represent 25% of our gut bacterial 
population. They are gram negative, anaerobic, bile resistant, and non-spore forming bacteria. 
Bacteroides can be passed from the mother to the child during vaginal delivery, thus becoming 
primary colonizers of the gut. When retained in the gut, Bacteroides act as commensals and 
can be beneficial for the host (Wexler 2007). The most common isolate from the clinical 
specimens is B. fragilis, which is the most virulent Bacteroides species (Wexler 2007). 
Bacterial colonization of the gut can greatly affect the immune system, either through direct 
host-bacteria interaction, or by molecules produced by our commensal bacteria. B. fragilis 
produces polysaccharide A (PSA), which is an immunomodulatory molecule that activates the 
T-cell dependent immune responses (Troy and Kasper 2011). Those responses are involved 
in the development and homeostasis of the host immune system (Troy and Kasper 2011). 
Furthermore, Round et al. (2011) demonstrated that B. fragilis activates TLR pathways. This 
occurs because PSA signals through TLR2 on forkhead box P3 (Foxp3+) regulatory T cells to 
boost immunologic tolerance. As a result, PSA can be considered as a model symbiosis factor, 
because it preserves the balance between T cell types and maintains the immune system 
homeostasis (Round et al. 2011).  
As for Bacteroides uniformis (B. uniformis) CECT 7771, it is considered a potential probiotic 
strain originally isolated from the feces of healthy breastfed infants. Oral administration of this 
specific strain in high fat diet-fed mice improved lipid profile, reduced glucose insulin and leptin 
levels, increased TNF-α production by dendritic cells (DCs) in response to LPS stimulation, 
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and increased phagocytosis (Cano et al. 2012). Thus, administration of B. uniformis CECT 
7771 can ameliorate metabolic disorder and immunological dysfunction related to intestinal 
dysbiosis in obese mice (Cano et al. 2012, Yang et al. 2016). Furthermore, acute 
administration of this strain to mice did not promote adverse effects on health status or food 
intake, and there was no bacteria translocation to blood, liver, or lymph nodes. This indicates 
that there are no safety concerns for this strain in mice, but further investigation should be 
completed in humans (Fernández-Murga and Sanz 2016).  
 
1.6.4- Eubacterium hallii    
E. hallii is an important anaerobic butyrate-producer resident in our gut, which influences the 
intestinal metabolic balance (Engels et al. 2016). Butyrate has been proposed to lower mucosal 
inflammation and oxidative status, strengthen the epithelial barrier function, modulate intestinal 
motility and being an energy source for colonocytes (Cani et al. 2011). E. hallii can also yield 
propionate from a broad range of substrates. This versatility may further support the host-gut 
microbiota homeostasis (Engels et al., 2016). Moreover, administration of E. hallii in obese and 
diabetic db/db mice increased energy metabolism and improved insulin sensitivity (Udayappan 
et al. 2016). However, increasing dosage of E. hallii did not impact body weight or food intake, 
indicating that this strain can be used to develop safe and effective alternatives for insulin 
sensitivity (Udayappan et al. 2016). 
 
1.6.5- Single strain bio-therapeutics 
Bacteroides thetaiotaomicron is a prevalent species within the Bacteroides genus of the human 
gut microbiota. It has previously been shown that this bacteria can increase mucosal barrier 
function and can limit pathogen invasion (Delday et al. 2018). Bacteroides thetaiotaomicron 
has been proven to have potent anti-inflammatory effects in vitro and in vivo as it modulates 
molecular signalling pathways of NF-κB (Kelly et al. 2004). This works by stopping the binding 
of the active component (RelA) of NF-κB to key genes in the nucleus, thus preventing the 
activation of pro-inflammatory pathways (Kelly et al. 2004). The full genome of B. 
thetaiotaomicron was sequenced and annotated by the Gordon Group (Washington University 
School of Medicine, USA) in 2003. As a result, Bacteroides thetaiotaomicron had been 
investigated in different studies and had been disclosed for its use in the prevention of 
inflammatory disorders.  Moran (2014) discussed the possibilities for commercial manipulation 
of the microbiome, specifying the single bacterial species that act as a Live Biotherapeutic; for 
instance, Bacteroides thetaiotaomicron can act as a treatment for paediatric Crohn’s disease. 
Moreover, the patent WO 03/046580 disclosed the use of Bacteroides thetaiotaomicron as a 
medicine for the treatment of inflammatory disease. According to the background describing 
the efficacy of Bacteroides thetaiotaomicron against inflammatory disorders, a new patent for 
21 
 
Bacteroides thetaiotaomicron strain BT201 as a treatment of inflammatory disorder and/or an 
autoimmune disorder has been published (European Patent office 2017).  
Another study by Delday et al. (2018) has investigated the effect of Bacteroides 
thetaiotaomicron type strain DSM 2079 in different rodent models of irritable bowel disease 
(IBD). The efficacy of the freeze-dried bacterial formulation and the purified recombinant 
protein of B. thetaiotaomicron was also investigated. The results revealed that Bacteroides 
thetaiotaomicron showed protective effects against the disease, and this has been 
demonstrated by the significant amelioration of weight loss, colon shortening, histopathological 
damage and immune activation. This efficacy has observed in both the actively growing cells 
and the freeze-dried cells of Bacteroides thetaiotaomicron. It was reported that the anti-
inflammatory effect caused by this strain was due to the presence of pirin-like protein (PLP) 
identified by microarray analysis during the coculture of the bacterial strain with Caco-2 cells, 
and that reduced pro-inflammatory NF-κB signalling in these intestinal epithelial cells. This data 
indicate that this strain be may a novel alternative to current treatment options for Crohn’s 
disease (Delday et al. 2018).  
Another single strain live biotherapeutic product that has been developed is BlautixTM (BHT). 
This product was developed for the treatment of irritable bowel syndrome (IBS). The active 
ingredient of this product is a strain of Blautia hydrogenotrophica (B. hydro) which is lyophilized 
and formulated in gastro-resistant enteric capsules for oral administration. This strain works by 
restoring the functional composition of the of the microbiota to a healthy state which is 
important in order to alleviate IBS-related symptoms (Weinberg et al. 2018). 
A new study at Imperial College in London, has also reported a new single strain 
biotherapeutic. The strain of bacteria - Enterococcus gallinarum - known as to MRx0518 was 
given to treat up to 120 patients suffering from breast, prostate, ovarian, bladder, lung, head, 
neck and skin cancer in the weeks before surgery. The hypothesis of this study is that after the 
surgery the bacteria will help the body to increase its ability to fight off the cancer. Other studies 
will also be held to investigate the effect of this bacterium in asthma and in IBD patients. This 
bacterium has been isolated from the healthy human faeces and multiplied in the lab. It has 
then been freeze-dried to put it into a kind of suspended animation to be administered orally in 
a daily pill. The bacteria stay alive in the gut for two to three weeks before being flushed out. 
This strategy in safer than faecal transplants since not the entire microbiome is transferred, so 





1.7 – Cocktails of Clostridium cluster IV and XIVa members  
As previously described, Tregs can regulate immune homeostasis and serve as a therapeutic 
target for different gut inflammatory disorders. Induction of the colonic Tregs is dependent on 
special properties of our commensal bacteria. Clostridium spp. belonging to clusters IV and 
XIVa (also known as Clostridium leptum and coccoides groups, respectively) are exceptional 
inducers of Tregs in the colon and can be considered as therapeutic options for IBD and allergies 
(Atarashi et al. 2011). Previous work indicated that a cocktail of strains isolated for the human 
gut microbiota could be more effective than a single strain in preventing or treating disease. 
Thus, Atarashi et al. (2013) isolated 17 strains belonging to Clostridia clusters XIVa, IV and 
XVIII from a human faecal sample, which were effective in Treg cell differentiation and 
accumulation in mouse colon. Authors proposed that the short chain fatty acids produced by 
this community influenced the expression of Foxp3+, a key gene controlling Treg cell 
development (Atarashi et al. 2013). Incidentally, Clostridia clusters XIVa and IV are decreased 
in fecal samples from patients with inflammatory bowel disease, and thus the cocktail of the 
17 strains could potentially reverse this dysbiosis (Atarashi et al. 2013). 
 
1.8- Industrial applications and interests  
1.8.1- Current Developments  
Since the manipulation of the gut microbiota has been proven to be promising to prevent and 
treat different diseases, pharmaceutical and food industries are interested in the potential 
therapeutic approaches described before. For instance, Seres health and Rebiotix companies 
are working on developing a defined microbial cocktail and a standardized commercially-
prepared FMT, respectively. These therapeutic approaches are intended to treat CDI, and can 
be used as an alternative for FMT. Synthetic microbial communities designed for transplants 
are expected to meet production, mode of action and safety standards (Orenstein et al. 2015; 
van der Lelie et al. 2017). For instance, Seres health developed SER-109, a novel biological 
agent proposed to restore the balance in the gut microbiome, promoting resistance to 
pathogenic invaders like C. difficile (Khanna et al. 2016). Seres health also developed SER-
287 for the treatment of IBD and specifically ulcerative colitis ("Inflammatory Bowel Disease | 
Seres Therapeutics" 2017). Rebiotix commercially developed RBX2660, a mix of live human 
microbes for effective treatment of recurrent CDI (Ramesh et al. 2016). Moreover, other 
formulations including strains belonging to Clostridia classes IV and XIVa were designed to 
modulate the immune response (Atarashi et al. 2013). The original community of 17 strains 
(VE202) was developed by Vendanta Biosciences and Johnson & Johnson, and has provided 
an effective treatment for autoimmune disorders (Reardon 2014; Ratner 2015; van der Lelie 
et al. 2017). 
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1.8.2 – Technical Challenges                                                                                      
Several challenges concerning the stability of the probiotic during the commercial production 
are still unsolved. Microorganisms require strict conditions to grow, such as specific nutritional 
media and environmental conditions (suitable temperature, pH, water activity, oxygen content, 
among others). The product manufacturing and storage processes may impact the viability of 
bacterial strains, influencing probiotic potency and properties. In addition, it is fundamental to 
consider the viability of the probiotics after consumption. Bacterial strains should remain viable 
at sufficient numbers through the gastrointestinal tract (GIT) passage. Therefore, the selection 
of optimal culture medium and cell protectants is crucial to enhance the efficacy of the probiotic 
product. Moreover, as most probiotic strains are strict anaerobes or facultative anaerobes, 
oxygen permeation into carriers should be reduced, or oxygen scavengers should be 
introduced to reduce the redox potential (Shah et al. 2010). Probiotic bacteria can also be 
protected by microencapsulation, which has been proposed to improve the stability of the 
strains and can adapt to the GIT conditions (Heidebach et al. 2012). Nowadays, yogurts and 
fermented milk are the best-established vehicles for probiotics in the market. Fermented milk, 
typically contains three times the amount of probiotic cultures than yogurts (The Globe and 
Mail 2013). However, some probiotic strains are sensitive to the different conditions in 
fermented products, like oxygen and pH, which can, in turn, affect the stability of probiotics 
through post acidification during their storage in the fridge. To minimize this phenomenon, 
strains that lack the ability to post acidify should be selected (Damin et al., 2008). As a result, 
this can cause an economic burden for manufacturers, limiting the addition of probiotics in 
different products (Gueimonde and Sánchez 2012). Furthermore, manufacturing the probiotic 
product in a reproducible manner is a critical aspect (Silva and Freitas 2014). Shah et al. (2010) 
reported that changes in the number of viable probiotic bacteria during the storage of functional 
foods should be studied more extensively, as studies have shown  poor viability of probiotic 
bacteria in functional foods (Shah et al. 2010).  
1.8.3 – Regulatory Challenges  
Probiotics are classified in different categories across countries. Their names and use as 
functional foods may vary according to different systems. For instance, probiotics fall in the 
Qualified presumption of safety (QPS) list provided by the European Food Safety Authority 
(EFSA) and referred to as functional foods since there was no legal definition for probiotics. 
The market for probiotics as functional foods expanded, as a result of probiotic food products 
like yogurts and fermented milk (Baldi and Arora 2015), containing conventional lactic acid 
bacteria (LAB). The QPS list is periodically updated according to the safety assessment of the 
biological products recommended to be added, and not all can be approved ("Scientific Opinion 
on The Maintenance of The List of QPS Biological Agents Intentionally Added to Food and 
Feed (2013 Update)" 2013; Ricci et al. 2017). A similar system applies in the USA as Generally 
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Recognized as Safe (GRAS) products should be approved by the FDA. However, if a probiotic 
is used as a dietary supplement in the USA, then it is considered as “food” and should be 
regulated by the Dietary Supplement Health and Education Act (DSHEA). If the probiotic was 
considered to have therapeutic purpose, the probiotic drug should be proven to be safe and 
effective to be approved by the FDA. Nevertheless, for both the FDA and EFSA, probiotics can 
not be used in health claims. On the other hand, Japan acts as a global market leader, where 
probiotics are considered as both foods and drugs. According to the Japanese regulations, 
probiotic products are in different category than foods and Foods for Specific Health Uses 
(FOSHU). Efficacy claims for probiotic products are prohibited on the labelling until the product 
gets the permission from the Ministry of Health and Welfare (MHLW) to be considered FOSHU, 
for which efficacy and safety validation is mandatory. FOSHU categorizes the food claims 
according to the scientific evidence and the strength of the supporting data provided. The 
government then divided the FOSHU health claims into subcategories, in which their effect 
could be in GIT, metabolism, cholesterol moderation, or bone health. Japanese regulations 
also approve new health claims on a regular basis (Baldi and Arora 2015). 
As the definition and classification of probiotics by regulatory agents throughout the world is 
different, the status of probiotic products is still uncertain. Thus, reservations about probiotic 
products claims may arise among regulatory bodies, producers, and consumers. Since the 
probiotic concept is invading the world, further investigation for probiotic traits is needed. 
Moreover, most probiotics only include lactic acid bacteria, which possess limited phylogenetic 
diversity and functionality. Hence, critical update of the screenings required by regulatory 
agents is urgently needed. 
1.8.4- Regulatory challenges for live bio-therapeutics 
According to FDA, a live bio-therapeutic product (LBP), is a biological product that contains 
live organisms such as bacteria, that is able to prevent, treat or cure a certain disease or a 
condition in human, and that is not a vaccine. LBPs are not filterable viruses, oncolytic bacteria, 
or products intended as gene therapy agents, and they are not administered by injection (FDA 
2016). An example of an LBP would be a lactobacilli strain that is administered orally to treat 
patients with ulcerative colitis. Other examples include Bifidobacteria, some Streptococcal 
species, Bacillus clausii, and the yeast Saccharomyces cerevisiae var boulardii. A recombinant 
LBP is composed of microorganisms that have been genetically modified through adding, 
deleting, or modifying their genetic material. A recombinant LBP is likely to raise additional 
considerations, which would require additional information to be submitted in an Investigational 
New Drug Application (IND). Prior to submission of their IND, the potential sponsors of an IND 
for a recombinant LBP are encouraged to contact FDA to attain additional guidance.” In 2008, 
FDA issued a guidance entitled, “Guidance for Industry: CGMP for Phase 1 Investigational 
25 
 
Drugs” dated July 2008 (Ref. 4). The guidance identifies that manufacturing controls needed 
to achieve appropriate product quality not only between investigational and commercial 
manufacture, but also among the various phases of clinical trials (FDA 2016). It has also been 
stated that during phase 1 of the studies, the emphasis should be placed on elements to assure 
the safety of the subjects. This includes the control of the raw materials and drug substance, 
assurance, stability, and where applicable, the non-clinical safety assessments. Quality control 
and quality assurance should be refined as product development proceeds. Sufficient 
information is required in each phase of the investigation to assure proper identification, quality, 
purity and strength of the investigational drug, and the amount of information differs between 
phases. For preparing an IND, one should refer to the FDA guidance for the content and format 
of the INDs for Phase 1 studies entitled, “Guidance for Industry: Content and Format of 
Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-
Characterized, Therapeutic, Biotechnologyderived Products” dated November 1995 (Ref. 5). 
Drug Substance and Drug Product section of this guidance detail the information that should 
be included in an IND in order to support proceeding to clinical evaluation of an LBP’s safety 
in human subjects (FDA 2016). There are many LBPs available on the European market, 
however, until now, standards have not set out in the European Pharmacopoeia (Ph. Eur.) to 
ensure their quality. To address this issue, the European Pharmacopoeia Commission has 
ratified a general monograph laying down harmonized requirements for LBPs for human use 
and two general chapters addressing microbiological contamination of LBPs (EUROPEAN 
PHARMACOPOEIA PH. EUR. COMMISSION 2019). Methods for enumeration of 
contaminants and for detection of specified microorganisms were described in these two 
chapters. In addition, these chapters provided decision diagrams describing how to establish 
a suitable testing method and a supplementary tool to control the quality of LBPs (EUROPEAN 
PHARMACOPOEIA PH. EUR. COMMISSION 2019). 
As the therapeutic characteristics are strain specific, requirements include a full morphological, 
biochemical, serological, and molecular characterization of the strains used. The tests aim to 
ensure the absence of antimicrobial resistance or any other virulence factors in LBPs. Other 
important requirements include verification of the potency by enumeration and microbial 
contamination detection (EUROPEAN PHARMACOPOEIA PH. EUR. COMMISSION 2019). 
1.9 – Medical application 
Despite the different studies and outcomes of FMT, FDA approval in North America has not 
been granted. At the beginning, FMT was considered as investigational new drugs (INDs), and 
FDA authorization was mandatory. Currently, patients unresponsive to standard antibiotic CDI 
therapies can opt for FMT after completing an informed consent, where they are notified that 
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FMT is still under investigation. However, SERES 109 and RBX2660 have been granted the 
Orphan Drug designation by the FDA (Rebiotix Media 2015; Seres Therapeutics 2015). As for 
the EMA in Europe, the use of FMT for the treatment of CDI has not been yet regulated (van 
Nood et al. 2014; Lowes 2016). Yet, FMT is regularly applied to curb infections across Europe, 
and it is considered in clinical trials for many other pathologies. In the search for safe FMT 
alternatives, research on microbiotic medicinal products (MMP) is in full development and 
novel applications are continuously being considered. These MMP developments require novel 
views and strategies from the scientific world, the industry, the medical field, and the regulatory 
bodies. In this context, platforms like the Pharmabiotic Research Institute have been created, 
to facilitate discussion between different stakeholders ("Pharmabiotic Research Institute" 
2017). Overall, additional research needs to be conducted before using FMT alternatives 
containing characterized microbial communities and next generation probiotics, to guarantee 
their safety and reproducible efficacy. 
1.10 – Conclusion  
In conclusion, FMT may be replaced with a characterized multispecies bacterial mixture that 
can be safer, free of allergens or viruses, and capable of treating CDI. With the current in vitro 
and in vivo data, next generation probiotics hold promise to treat diverse medical conditions, 
and they can be more effective than single or multi strains of the commercial probiotics. 
Microdiversification is an important process by which a bacterial population can maximize its 
niche coverage, and thus ubiquity, in an ecosystem through modification of its trait space.  
Moreover, several different strains with proven health benefits can also be considered 
candidates for next generation probiotics and other microbiota-based drugs. However, 
additional research is required for an increased understanding of the interactions among those 
strains, aiming at producing a successful therapeutic formulation. Research should be 
conducted to demonstrate whether these probiotics can be applicable to humans, as safety 
assessments have only been completed in animals. Effective carriage of bacterial strains in 
food matrices is critical for survival. Thus, optimisation of the growing conditions, and even 
encapsulation must be considered to promote delivery and release of the live product in the 
colon. The development of next generation probiotics and microbiotic medicinal products hold 
promise for innovation in both the food/feed sector and the pharmaceutical industry. A close 
interaction between academia, industry and regulatory agencies is essential for developing 
safe and health-promoting products, as both prophylactic and therapeutic strategies.  
1.11 - Research goal and outline. 
The goal of this research is to introduce a synthetic microbial community that is composed of 
different commensal bacteria from the human gut, and that can act as a potential therapeutic 
for metabolic disorders. As propionate, a major short chain fatty acid in the gut, has been 
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proven to have adverse beneficial effects on metabolic disorder, enhancing its production in 
the gut would be an interesting approach for preventing associated risk factors.The established 
bacterial community is validated for its propionate production after co-culturing seven different 
commensal bacterial strains. The research was divided into two major sections that cover the 
establishment, optimization, and activity experiments, and subdivided in three research 
chapters, as presented in Figure 1.1. 
The selection of the strains was performed by considering the different metabolic pathways for 
propionate production (acrylate pathway, succinate pathway, and propanediol pathway) 
(Chapter 2). The propionate-producing consortium was prepared in a fed-batch experiment by 
co-culturing seven different strains from different phylogenetic origin for 48 hours. As this 
consortium is supposed to be administered orally in the future, it had to survive the upper GI 
tract, so it was tested in “the smallest intestine” (TSI) model which represents the stomach and 
small intestine environments. The survival of the consortium was tested through its passage 
in the three different compartments of the small intestine, duodenum, jejunum, and ileum, and 
the results were presented in Chapter 2.  
As the misuse of antibiotics have been associated with disruption in the gut microbiota and 
leads to different diseases like metabolic disorders, it is important to find a solution that can 
reverse those negative effects. In Chapter 3, the effect of the designed consortium on the 
functionality and community composition after antibiotic induced dysbiosis was tested in an in 
vitro mucosal simulator for the human intestine microbial ecosystem (M-SHIME).  
Finally, in the second section of the research, the activity of the propionate-producing 
consortium was evaluated. In Chapter 4, the in vitro enterohepatic cell model of insulin 
resistance was used to assess the effects of the metabolites from the propionate-producing 
consortium. As Akkermansia muciniphila, a propionate-producing bacterium, has been 
reported to improve metabolic health, the effects of its metabolites on hepatic cells have also 
been assessed. Different markers were measured to understand the role of the gut metabolites 
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CHAPTER 2: Establishment of a propionate-producing microbial 
consortium and its survival in “The Smallest Intestine” in vitro model 
 
2.1 - Abstract. 
Propionate is a major fermentation product in the gut with several health benefits towards 
improving metabolic disorder. In our research, we established a preadapted propionate 
producing microbial consortium from seven strains of the commensal human gut bacteria 
prepared in fed batch experiments. We tested the survival of our designed consortium before 
and after preadaptation in a low volume medium-throughput in vitro model simulating the 
human small intestine and including the ileal microbiota. Samples were collected from the 
different compartments of the small intestine (duodenum, jejunum and ileum). RNA extraction 
was performed to check which bacteria were active at different stages. The propionate 
producing consortium was tested in both fed and fasted conditions. The stringent 
environmental conditions of the small intestine exert selective pressure on commensal 
inhabitants of members of colonic communities. As a result, only Lactobacillus and Blautia 
survived all the three compartments of the small intestine in the fasted condition. Our results 
indicated that fed conditions were harsher on the bacteria. A protection method (eg. 
encapsulation) should be applied to the consortium to guarantee its survival in the upper 




2.2 - Introduction.  
Metabolic syndrome is an emerging public health problem that has been growing in the last 
decades. It has been linked to shifts in the gut microbiota, and thus changes in the short chain 
fatty acid (SCFA) production (Festi et al. 2014).  One of the major SCFAs, propionate, has 
been proven to play a role in reducing obesity, a major risk factor for metabolic syndrome 
(Kasubuchi et al. 2015).  Propionate stimulates anorexigenic hormones like PYY and GLP-1, 
which induce satiety, and reduce energy intake leading to weight loss (Chambers et al. 2014; 
Arora et al. 2011).  
Given the microbial association with health status and even the putative role of microbiota in 
modulating disease risk and/or progression, the last years of scientific research have 
witnessed the evolution of next generation probiotics and microbial medicinal therapies or live 
biotherapeutic products (El Hage et al., 2017). Next generation probiotics are often originating 
from human commensals, and therefore often comprise strict anaerobes. These bacteria are 
different from the conventional probiotics that belong to lactic acid bacteria or yeasts (El Hage 
et al. 2017). To exemplify, studies with Akkermansia muciniphila demonstrated beneficial 
effects on metabolic disorders and several other pathologies (Ploveir et al. 2017). This mucin-
degrading and propiogenic bacterium was therefore proposed as a next-generation probiotic 
candidate (Chia et al. 2018, Plovier et al. 2017). However, the greatest hurdles that candidate 
probiotic strains encounter, affecting their viability, are the nature of the food matrix, the highly 
acidic stomach conditions, membrane-disrupting bile salts and digestive enzymes in the small 
intestine (Mortazavian et al. 2012). Yet, as many of the next generation probiotic products are 
composed of human commensal strains, there is an increased chance of survival and 
colonization among the endogenous gut microbiota once they reach the colon in a viable state 
(Mortazavian et al., 2012). Studies have reported the harsh conditions of the upper GI tract 
and the difficulty for different beneficial strains to survive. However, gastrointestinal behavior 
and colonization of supplemented (probiotic) strains in the small intestine in the presence of a 
residing microbiota is scarce.  
The small intestine consists of three distinct sections: duodenum, jejunum and ileum 
(Schneeman 2002). In the duodenum, bile salts and enzymes from the pancreas are secreted 
to break down and solubilize lipids, carbohydrates and proteins (Riethorst el al. 2016).  The 
duodenal concentration of bile varies from around 4 mM (fasted state) to 10 mM (fed 
conditions) (Riethorst et al. 2016). The jejunum and ileum are mainly responsible for the 
absorption of nutrients and minerals (Kiela and Ghishan 2016). The ileum is populated with a 
community reaching 106 – 108 cells g-1 (Booijink et al. 2007). The knowledge of the composition 
of the small intestinal microbiota is rather scarce, but recent studies indicate that 
Streptococcus, Veillonella, Haemophilus, Escherichia spp. among others are commonly found 
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commensals in healthy subjects (Dlugosz et al. 2015; Chung et al. 2015). As for Lactobacillus, 
its presence in the small intestine community has been controversial among different studies.  
Studies using human subjects have always been the gold standard, but they are invasive and 
tedious and mechanisms of probiotic administration cannot be monitored on real-time.  Animal 
models have been used as an alternative to humans to mimic all physiological aspects of the 
GI tract, but still those models can have limitations (Cieplak et al. 2018). In vitro static and 
dynamic models for the GI tract have been developed (Venema and van den Abbeele, 2013; 
Guerra et al. 2012; Hur et al. 2011). For instance, the INFOGEST working group recently 
published a standardized static in vitro digestion protocol (Minekus et al. 2014), which is now 
widely used. Most of the complex in vitro models reproduce processes occurring in the small 
intestine such as bile salts and small nutrient absorption, dynamic changes of pH, reproduction 
and simulation of enzymes secretion rates and realistic transit times. Nevertheless, none of 
the existing models mimic the small intestine microbiota, which has an important effect on 
health through its ability to metabolize nutrients and influence the absorption of bioactives (El 
Aidy et al. 2015) as well as being involved in energy metabolism (Patrascu et al. 2017; 
Zoetendal et al. 2012). Cieplak et al. (2018) developed The Smallest Intestine (TSI) in vitro 
model that includes duodenum, jejunum and ileum compartments with increased throughput, 
including the small intestine microbiota. This in vitro model could be used as a screening 
platform for studying microbial behavior and survival during small intestine passage.  
We identified the ability of the gut microbiota to produce propionate as a possible target for 
improving health. Our aim was to establish a propionate-producing consortium capable of 
yielding sufficient propionate for prevention of risk factors associated to metabolic disease. 
Moreover, we aimed at testing the passage and survivability of the different bacterial members 
of our designed propionate-producing consortium in the TSI model, under simulated fasted 
and fed conditions. 
2.3 - Materials and methods. 
2.3.1 – Selection of strains for the propionate-producing consortium (PPC) 
The strains used in the propionate producing consortium were selected according to the three 
different reported metabolic pathways for propionate production (succinate, acrylate, and 
propanediol pathways) (Reichardt et al. 2014) (Figure 5.2). Veillonella parvula, Bacteroides 
vulgatus, and Bacteriodes thetaiotaomicron were reported to follow the succinate pathway in 
which they use succinate to produce propionate. Coprococcus catus has been reported to 
participate in the acrylate pathway for propionate production, in which lactate is consumed 
(Louis, Hold and Flint 2014). We supplied the consortium with Lactobacillus plantarum, a lactic 
acid bacteria, which produces lactate and acetate and can support the acrylate pathway for 
Coprococcus catus. Finally, Ruminococcus obeum uses the propanediol pathway (Louis, Hold 
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and Flint 2014) fermenting fucose for propionate production. Fucose can be produced from 
mucin degradation, and as Akkermansia muciniphila is a mucin-degrader producing 
propionate, we used this bacterium to initiate the fucose delivery for the propanediol pathway.  
The single strains produced between 0.4-3 mM of propionate (Figure 2.1), and the final 
propionate for the consortium was 34.5 mM on average (Figure 2.2). 
 
Figure 2.1: Short chain fatty acids concentrations produced by the seven individual 
strains used to design the propionate-producing consortium. The propionate 
concentrations of each of the seven strains was 0.4-3 mM. Cell counts for each strain 
have been obtained using the flow cytometry, and they were presented above each 
































Figure 2.2: Production of SCFA after 24h and 48h of a fed batch for the seven strains of 
the propionate producing consortium. One dose of the consortium was prepared fresh 
on a daily basis for each day of the treatment of the SHI ME run (n=3). Four replicates 
of the fed batch on 4 different days (A, B, C and D) are presented with an average of 34.5 
mM. 
 
2.3.2 – Assembly of the preadapted propionate-producing consortium 
Gut commensal strains were selected based on the reported metabolic pathways for 
propionate production (Reichardt et al. 2014; Table 2.1). Culturing of bacteria was performed 
in Reinforced Clostridium Medium (Oxoid Ltd, Basingstoke, Hampshire, UK), using the 
Hungate tube method and under anaerobic conditions (90% N2/ 10% CO2). Reinforced 
Clostridial Medium is a commonly used, nonselective enrichment medium where various 
anaerobic and facultative bacteria can be grown when incubated anaerobically. This medium 
was used to standardize the culture procedure because it has been demonstrated that this 
medium is highly successful in enabling growth from small inocula, in comparison to five other 
media tested. In a further comparison, the highest viable count obtainable was the criterion 
used, and again, RCM proved superior. All strains were incubated at 37⁰C for 48 h except for 
L. plantarum, which was incubated for 24 hours. All strains were collected for preadaptation 
when in stationary phase. At the end of the incubation, cell number was measured using flow 
cytometry, and standardised to 108 cells ml-1 (Hernandez-Sanabria et al. 2017).  
In order to adapt the different bacterial strains to representative conditions of the human gut, 







from the SHIME® model (UGent/Prodigest NV, Zwijnaarde, Belgium) was subjected to pre-
digestion simulating the passage through the upper GI tract. Gastric digestion was mimicked 
by maintaining pH 2 for 2 h, followed by an intestinal digestion through addition of pancreatic 
juice [0.9 g L-1 pancreatin (Sigma-Aldrich, St. Louis, USA), 6 g L-1 oxgall bile salt (BD, 
Erembodegem, Belgium), and 25 g L-1 NaHCO3 (Carl Roth GmbH, Karlsruhe, Germany)]. pH 
was adjusted to 6.8, and medium was incubated for 2.5 h at 37⁰C to simulate the small intestine 
digestion. If pH had shifted at the end of the incubation, pH was again adjusted to 6.8 prior to 
addition of the bacterial cocktail.  
Then, 5 ml of each strain were mixed under anaerobic conditions. The consortium was 
prepared by transferring 5 ml of the bacterial cocktail (10 % v/v) to an anaerobic glass bottle 
containing 45 ml of pre-digested medium. Co-culturing occurred for 48 h, and 40% of the 
medium was replaced after 24h. The consortium was harvested after 48 hours, when the 
average propionate production was 34.5 mM (Figure 2.2). The viable cell count of the 
consortium was 108 cfu mL-1 when administered to the M-SHIME. The seven strains were 
cultured together for 48 hours in order to form the preadapted bacterial consortium in which 
they would act as a community after they have done the cross-feeding together.  
 
Table 2.1: Bacterial strains used to prepare the propionate-producing consortium 
according to the different metabolic pathways for propionate production (Acrylate, 
Succinate, Propanediol).  
Bacterial species  Source  Pathway for propionate production 
Bacteroides vulgatus LMG17767 Succinate pathway 
Bacteroides thetaiotaomicron  DSM 2079 Succinate pathway 
Coprococcus catus  ATCC 27761 Acrylate pathway 
Veillonella parvula DSM 2007 Succinate pathway 
Ruminococcus obeum (Blautia) DSM 25238 Propanediol pathway 
Akkermansia muciniphila DSM 22959 Propanediol pathway 
Lactobacillus plantarum LMG 9211 Acrylate pathway 
 
2.3.3 - Assembly of freshly mixed bacterial cocktail  
Similar to the preparation of the PPC, the same strains were cultured in Hungate tubes 
containing 10 ml of RCM under the same conditions. Then, 5 ml of each strain were mixed as 
described above.  
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2.3.4 - Difference between a preadapted and a freshly mixed bacteria cocktail 
As described above, the preadapted bacterial consortium is prepared after growing each of 
the strains separately and co-culturing them in a new medium with the SHIME feed for 48 
hours. During these 48 hours, the feed was replaced once a day, and the bacteria were cross-
feeding to produce propionate. After the 48 hours, the consortium was harvested as a 
preadapted community in which all seven strains got adapted to each other during the fed 
batch. Preadaptation was important as it mimics the concept of a preadapted bacterial 
community in a fecal inoculum in which the bacteria were already fermenting together and 
formed a community.  The freshly mixed consortium is the mixture of all the seven strains in 
which each strain was cultured separately. These seven were not co-cultured with each other, 
and in this context they do not form a community that has been preadapted. In fact, the freshly 
mixed consortium was used as the inoculum to start the fed batch that lead to the preadapted 
community.  
2.3.5 - Semi-continuous incubation of the bacterial consortium 
Bacterial consortium was inoculated in a total volume of 50 ml of SHIME nutritional medium 
(10 vol%) and incubated at 37°C. Feed replacement was performed twice a day (40% v/v), first 
exchange was completed before 16 h to prevent a strong pH drop and the next replacing was 
done after 24h. Oxygen was displaced from needles and syringes using nitrogen gas, to 
preserve the anaerobic atmosphere.  
2.3.6 – Optimizing the semi-continuous fermentation for enhanced propionate production 
Duration of the incubation for reaching the maximum amount of short chain fatty acids 
produced by our bacteria in SHIME medium was optimized. We ran the semi-continuous 
incubation for 10 days, and samples were collected twice a day in the morning and evening, 
and feed was replaced twice a day as well. Short chain fatty acids were determined from all 
samples to verify the exact time point at which SCFA production was stable and reached the 
maximum concentration. We concluded that the semi-continuous batch can run for 5 days and 
that the maximum amount of SCFAs was produced at day 4 and stabilized between days 5 
and 7. However, since our fed batch experiments were inoculated only with our designed 
bacterial consortium of seven strains, this would not cause a drastic drop in pH after 16 hours 
as in the case of a fecal inoculum. For this reason, we validated the propionate production by 
our consortium by performing triplicate fed-batch incubations for 5 days, and replacing the feed 
only once a day. We sampled every 24 hours and measured the SCFAs produced during a 5-
day incubation period. Our results indicated that the maximum production of SCFAs was 
obtained after 48 hours. Cell number and integrity was confirmed with a benchtop Accuri C6 
cytometer (BD Biosciences, Erembodegem, Belgium). Samples were diluted and stained with 
10 ul/ml combination of SYBR green I and propidium iodide (SGPI) as a viability indicator. The 
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samples were then measured in the flow cytometer as described by Hernandez-Sanabria et 
al. (2017). 
2.3.7 – PCR-DGGE analysis of the propionate producing consortium 
PCR amplifications of the V2-V3 region (200 bp) of the 16S rRNA gene of bacteria were 
performed with universal bacterial primers 338F-GC and 518R using the program outlined by 
Boon et al. (2003). PCR products were subjected to Denaturing Gradient Gel Electrophoresis 
(DGGE) using the DCode universal mutation detection system (Bio-Rad Laboratories, Inc., 
Hercules, CA). The procedure for DGGE was described by Hernandez-Sanabria et al. (2010). 
To effectively assign the band positions for each gel, a common ladder was included in each 
gel as an internal control. The ladder was generated by mixing PCR products of each of the 
single strains from the consortium, following the protocol described in Hernandez-Sanabria et 
al. (2010).  
2.3.8– Selection and growth of the strains for the small intestine microbiota  
The selection of the small intestine microbiota and the assembly of the TSI were developed by 
Cieplak et al. (2018). Seven bacterial strains representing prominent members of the ileal 
microbiota were obtained from the German Collection of Microorganisms and Cell Cultures 
(DSMZ) and mentioned by Cieplak et al. (2018). All strains selected were cultured 
anaerobically at 37oC in Gifu Anaerobic Medium (GAM Broth, NISSUI) and stored at -80 °C 
until use (Cieplak et al. 2018). Gifu Anaerobic Medium (GAM) is recommended as a general 
culture medium for cultivation and isolation of anaerobic bacteria. Prior to the experiments 
each strain from the small intestine microbiota was inoculated in 10 ml GAM broth and cultured 
in 37⁰C for the time appropriate for each strain (Cieplak et al. 2018). After strain growth, the 
tubes were centrifuged (5,000 g for 2 min), the supernatant was discarded, and the pellet was 
re-suspended in the volume of phosphate buffered saline (pH 7.4) appropriate to obtain a 
suspension of 108 CFU ml-1 according to growth curves developed for each strain (OD vs. CFU 
ml-1). All strains were mixed together before addition to the reactor (Cieplak et al. 2018). 
2.3.9 – Assembly of The Smallest Intestine in vitro model 
The Smallest Intestine in vitro model (TSI) simulates the passage through the human small 
intestine by an adjustment of pH and concentration of bile salts, pancreatic enzymes and 
dialysis to mimic absorption. Each TSI unit consist of 5 reactors, each with a working volume 
of 12 ml. Cieplek et al. (2018) depicts the experimental flow in which they display the system 
simulating passage of duodenum, jejunum and ileum. Parts of the model (outer cabinet, 
temperature and pH control) were adapted from the design of the recently developed 
CoMiniGut in vitro colon model (Wiese et al. 2018). During simulated small intestinal passage, 
temperature, pH levels and bile salt concentrations are controlled at physiologically relevant 
levels. The main unit of TSI is a composite climate box where temperature is controlled (37⁰C) 
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by flow of water from a circulating water bath (A10/AC150, ThermoScentific) through a 
copper/aluminium heat exchanger placed inside of the box. An external temperature sensor 
connected with the water bath and placed inside of the main unit constantly monitors the 
temperature. During the whole experiment, temperature was recorded by an independent 
temperature data logger (Temp 101A MadgeTech). Each box contained five stirred fused 
quartz glass reactors (AdValue Technology, USA), where each one represented the passage 
through the small intestine of one individual. Reactors were separately closed in PVC 
chambers and anaerobic conditions were achieved by using anaerobic sachets (Oxoid 
AnaeroGen, ThermoScientific). Anaerobic conditions were verified by color change of Oxoid 
Anaerobic Indicator (BR0055, Oxoid), which is impregnated with a resazurin redox indicator 
solution. Reactors were placed on a 5-unit magnetic stirrer plate (R05, IKA), which assured 
equal mixing of samples inside of the reactors. The reactors were closed with a septa lid (GR-
2 rubber, Sigma-Aldrich) containing a pH probe inlet and needle inlets for the supply of 
enzymes and bile salts, as well as sampling, input and output for the dialysis chamber. Bile is 
absorbed by a dialysis process, which takes place in dialysis cassettes (Slide-A-Lyser G2, 
ThermoScientific). The dialysis chamber was filled with dialysis fluid (Milli-q water). A 
multichannel peristaltic pump (205S, Watson-Marlow) was connected to ensure constant flow 
of the chyme between the reactor and the dialysis cassettes (2.64 ml min-1). Beakers were 
stirred continuously (170 rpm) to facilitate effective dialysis. In addition, the dialysis process 
simulated the absorption of small nutrients and electrolytes from the chyme with a size smaller 
than the cut-off of the dialysis cassette specified as 10 kDa. The pH in each module was 
measured every 20 seconds using SP28X (Consort) pH electrodes. The reading was sent to 
the computer that adjusted the pH through acid and base pumps according to the pre-set pH 
value. In the TSI model, pH was controlled with 0.1M NaOH according to the pre-programmed 
experimental setup using syringe pumps (NE-500, WPI). The syringe pumps were 
automatically controlled by a computer using in-house made scripts in the 162 Matlab software 
(ver. R2015a, TheMathWorks, Inc.). 
To simulate the electrolyte composition and osmotic pressure occurring in the human GIT -
Simulated Gastric Fluid (SGF) and Simulated Intestinal Fluid (SIF) were used (Minekus et al. 
2014). The SIF composition was modified by removal of sodium bicarbonate to allow more 
precise pH control during experiments. The TSI reactor was prepared by adding 4.1 ml of SGF, 
3 ml or 4.5 ml of SIF depending if the experiment was conducted as simulating fed or fasted 
state, and 10 μl of 0.6M CaCl2. To simulate the duodenum, pancreatic juice, bile solution and 
feed/water were added. Pancreatic juice was added as a mixture (100 mg ml-1) of SIF and 
8xUSP pancreatin from porcine pancreas (Sigma-Aldrich). This provides an enzyme 
composition close to what is found in humans (Minekus et al. 2014). The amount of pancreatic 
juice added was established according to the activity of trypsin which was at a level of 100 U 
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ml-1 in fed conditions (McConnell et al. 2008) and 40 U ml-1 in fasted state. A stock of 80 g l-
1 was prepared and the exact concentration of bile salts was determined using a commercially 
available kit (Total Bile Acids Assay, Diazyme). To simulate conditions after ingestion of a 
meal, “fed state” was mimicked by the presence of 10 mM bile salts in the reactor and with 
addition of 1.4 ml of food replacement (Nutrison Energy Multi Fibre, Nutricia) as a source of 
nutrients (Cieplak et al. 2018). Small intestinal passage without the presence of food 
components was simulated by a “fasted state” by presence of 4 mM bile acids and 1.4 ml of 
water. Finally, pH was adjusted (by syringe) to 6.5 by titrating with 1 M NaOH (Cieplak et al. 
2018). During the duodenal passage (2 hours) pH was elevated from 6.5 to 6.8 in steady 
increments (Cieplak et al. 2018). Next, the absorption of small nutrients and bile salts in the 
jejunum was simulated by continuously pumping the samples through the dialysis chambers 
with a 10 kDa membrane cut-off at a pumping rate of 2.64 ml min-1 for 4 hours, as specified 
above. During the 4-hour simulation of the jejunal passage pH was increased from 6.8 to 7.2. 
To simulate ileum, fresh SIF with a pH of 7.2 was added to the reactor to obtain a chyme to 
SIF ratio of 50:40 (v/v). Moreover, 1 ml of small intestine microbiota inoculum was added. The 
inoculum was adjusted to obtain 107 CFU ml-1 in the reactor. During simulated ileal passage 
(2 hours) pH was kept constant at 7.2 (Cieplak et al. 2018). 
The amount of base used to control pH was constantly recorded in order to compare inter and 
intra-variability between samples and experimental conditions (Cieplak et al. 2018). An 
illustration of the TSI model had been presented by Cieplak et al. (2018). 
2.3.10 - Survival of single strains of the propionate-producing consortium in the TSI 
Each strain (Table 2.1) was inoculated in 10 ml Reinforced Clostridium medium (RCM) broth 
medium and cultured for 24-48 hours. Cells were harvested by centrifugation (10,000 g for 2 
min) after which the supernatant was discarded and the pellets resuspended in 10 ml of 
phosphate buffered saline (pH 7.4). The bacterial solution was plated on Gifu Anaerobic 
medium (GAM) plates to confirm the concentration at time zero. Four reactors were inoculated 
with 0.5 ml of the bacterial solution, while the fifth was kept to monitor contamination of any of 
the compartments used along the experiment. When checking the survival of the single strains, 
the small intestine microbiota was not added to the TSI. Survival was evaluated after the period 
of simulated digestion in the duodenum and ileum compartments via colony plate counts on 
GAM agar medium (37°C, 24-48 hours incubations at anaerobic conditions) after serial dilution 
using a saline solution (0.9% NaCl in water). Experiments were conducted separately for each 
strain in the fasted state.  
2.3.11 - Survival of the propionate-producing consortium in the TSI  
Preadapted propionate producing consortium and the freshly mixed bacterial cocktail were 
separately inoculated in the TSI in the fasted and fed conditions. Samples (0.5 ml) were 
collected at the end of each compartment (duodenum, jejunum, and ileum) and RNA protect 
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(Qiagen, Venlo, The Netherlands) was added following the manufacturer’s instructions and 
stored at -80⁰C for later RNA extraction with the RNeasy Mini Kit (Qiagen, Venlo, The 
Netherlands). Presence of transcriptionally active bacteria was assessed by transcribing the 
RNA using the Qiagen kit and performing 16S rRNA amplicon sequencing of the cDNA libraries 
using the Mi-Seq Illumina platform. Thus, we confirmed which of the strains of our consortium 
successfully survived the small intestine passage and stayed transcriptionally active. Each 
experiment was performed in duplicates (n = 2). Only cDNA sequencing was used in this 
experiment to determine the active strains. Flow cytometry analysis was not used in this 
experiment due to unavailability of a flowcytometer in the lab where in the experiment took 
place.  
2.3.12 - Community composition and dynamics  
Sequencing data was imported into R using phyloseq (McMurdie and Holmes 2013), and taxon 
abundances were rescaled by calculating the taxon proportions and multiplying them by the 
minimum sample size (n = 77893) present in the data set (McMurdie and Holmes 2014). Alpha 
diversity was estimated within each sample using inverse Simpson index. Pielou index was 
used as indicator of evenness in the community (Grunert et al. 2016). Differences in alpha 
diversity and evenness measures among compartments and between preadapted and fresh 
mix were compared using a repeated measures mixed model in GraphPad (GraphPad Prism 
7.04, La Jolla, CA, USA). Comparisons between fasted and fed condition were performed 
using a 2-way Anova (Sidak’s method) and between different compartments using Tukey’s 
method (Annex I, Table S1 and S2).  
Beta diversity estimates based on Chao and Bray-Curtis indices were used to examine 
dissimilarity and determine the impact of compartment on microbial community structure. 
Principal Coordinate Analysis (PCoA) was employed to visualize the differences among 
samples, using the vegan package in R (Oksanen et al. 2007) (Annex I, Figure S1). Stratified 
permutational multivariate analysis of variance (PERMANOVA) with 999 permutations was 
conducted to indicate the significance of condition and compartment on the microbial 
community differences. 
 
2.4 - Results. 
The main objective of this study was to test the survival of the bacterial strains composing the 
propionate-producing consortium in the TSI model under fasted and fed conditions. When 
reporting the results, we could see that some strains that do not belong to the consortium 
appeared suggesting the presence of contamination in the TSI model. The relative abundance 




2.4.1 - Optimization of the preadapted propionate-producing consortium 
The consortium was harvested after 48 hours, when the average propionate concentration was 
34.5 mM (Figure 2.2). Cell count was measured using flow cytometry at the end of the 
incubation, and standardised to 108 cells ml-1 (Figure 2.3). The PCR-DGGE results revealed 
that the DNA for all the strains was present in the samples from the preadapted propionate-
producing consortium after 48 hours (Figure 2.4). 
 
Figure 2.3: Flow cytometry revealed that the number of intact cells from the designed 








Figure 2.4: Denaturing Gradient Gel Electrophoresis (DGGE) reveals the bands of each 
of the seven single strains in the preadapted propionate-producing consortium after 
generating the ladder belonging to the consortium. The last four colomns are presenting 
the replicates from the PPC after the seven strains had been preadapted together. The 
samples from PPC show the bands from the different strains included in the consortium.   
 
2.4.2- Feeding conditions affect survival of single strains in the TSI model  
The survival of the seven strains involved in the propionate-producing consortium was tested 
in TSI model in two different feeding conditions: conditions mimicking a “fasted” small intestine 
(i.e. before food ingestion; bile salts = 4 mM; pancreatic juice = 40 U ml-1) and a “fed” small 
intestine (i.e. after a meal; bile salts = 10 mM; pancreatic juice = 100 U ml-1). The influence of 
the small intestinal microbiota consortium was tested in both feeding states.  
High concentrations of bile salts in the fed condition fostered harsh environment and differential 
survival of the different consortium members. Thus, survival of single strains was only tested 
under the fasted condition (Figure 2.5). Samples were collected before and after duodenal and 
after ileal passage. Plate cell counts revealed that R. obeum and C.catus did not grow before 
being introduced to the TSI model and did not survive the passage through any of the 
compartments of the TSI. L. plantarum and B. thetaiotaomicron were able to grow before 
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1.74×109 cfu mL-1 (cfu g-1) respectively, and through the ileum with cell count of 1.36×1010 and 
2.62×108 cfu mL-1 (cfu g-1) respectively. V. parvula, B. vulgatus, and A. muciniphila grew before 
before administering to the TSI and survived duodenum compartment with cell counts of 
2.66×108, 5.46×106, and 2.21×105 cfu mL-1 (cfu g-1) respectively. 
 
 
Figure 2.5: Survival of the seven strains after duodenum and ileum compartments 
during the passage in the simulated small intestine in the fasted state. Survival was 
evaluated by obtaining bacterial cell counts via colony plate counts after incubation 
period in each of duodenum and ileum compartments.  
 
2.4.3- Fasted conditions present lower stress to the propionate-producing consortium than the 
fed conditions  
At time 0, the abundant genera of the fresh mix inoculum included Lactobacillus, Bacteroides, 
Blautia, Clostridium, and Veillonella with Lactobacillus, Bacteroides, and Blautia having the 
highest relative abundances. Sequencing analysis revealed the active presence of additional 
strains in duodenum and jejunum, besides those initially introduced in the fresh mix (Figure 
2.6). The presence of these additional genera indicate that additional colon commensals such 
as Clostridium sp. were capable of invading the TSI model, as their spore-forming capacity 
may have enabled them to endure the stringent conditions of the small intestine and further 
colonise this environment. As the aim of this experiment was to test the survival of the active 
genera included in our propionate-producing consortium, all the results reported will only 
include the relative abundance of the genera included in our consortium. After the duodenum 
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and fed conditions, while the relative abundance of Blautia remained higher in the fasted 
condition than in the fed. The relative abundance for Bacteroides decreased in both the fasted 
and fed conditions. In the jejunum compartment, we observed a decrease in most of the 
genera, where only Lactobacillus and Blautia appeared in the fed condition with Lactobacillus 
being the most dominant. As for the fasted state, there was a decrease in Blautia and 
Bacteroides and an increase in Lactobacillus. In the ileum compartment, we observed loss of 
most of the bacterial genera included in our fresh mix, and there was an increase in the relative 
abundance of the genera included in the ileal bacterial community like Enterococcus, 
Enterobacteriacea, and Streptococcus in both fasted and fed conditions. The relative 
abundance of genera related to the ileal community was higher in the fasted condition while 
the relative abundance of Lactobacillus decreased in this case, and the presence of Blautia 
was detected in this condition. Blautia disappeared in the fed condition, and only two genera 
related to the ileal bacterial community were observed:  Enterococcus and Enterobacteriacea 
in addition to Lactobacillus from our consortium  with Lactobacillus having the highest relative 
abundances.  
According to the cDNA sequencing results, relative abundance plot revealed that more genera 
of our preadapted consortium were abundant in duodenum and jejunum compared to the ileum 
compartment (Figure 2.6).  At time 0, the abundant genera of the preadapted consortium 
inoculum included Lactobacillus and Bacteroides, with higher relative abundance of 
Lactobacillus. After the duodenum compartment, the relative abundance of Bacteroides 
decreased in both fasted and fed conditions and the relative abundance for Lactobacillus 
increased in both fed and fasted conditions. In the jejunum compartment, we observed a 
decrease in Bacteroides and increase in Lactobacillus in the fasted condition. As for the fed 
state, there was loss of Bacteroides and increase in the relative abundance of Lactobacillus. 
In the ileum compartment, we observed loss of Bacteroides in fasted condition and dominant 
relative abundance of the genera included in the ileal bacterial community like Enterococcus, 
Enterobacteriacea, and Streptococcus. As for the fed condition in the ileum, the relative 
abundance of Lactobacillus was the most dominant, in addition to an increased relative 





Figure 2.6: Relative bacterial abundances of the transcriptionally active bacteria in 
different compartments of TSI (Inoculum: before entering the TSI, duodenum, jejunum, 
and ileum) and in fasted and fed conditions were determined after sequencing of cDNA.   
Different genera with the different relative abundances were observed in fresh mix and 
preadapted bacterial consortium. Two replicates per condition were averaged to get the 
results in each compartment. 
2.4.4 - Community characteristics of the propionate-producing consortium changed among the 
different compartments of the TSI  
Alpha diversity was significantly different between the community inoculated at time 0 and after 
the duodenum transit under fed conditions (P<0.05). There was a significant difference in the 
alpha diversity between the preadapted inoculum and duodenum in the fasted condition 

















Figure 2.7: Differences in alpha diversity between the different compartments 
(Inoculum: before entering the TSI, duodenum, jejunum, and ileum) for Fresh mix and 
Preadapted bacterial consortium in both fasted and fed conditions.  
 
There was a significant difference in evenness between the preadapted inoculum at time 0 and 
when the preadapted consortium reached the duodenum in the fasted condition (P<0.05). 
However, there was no significant difference in the evenness between the different 




Figure 2.8: Differences in evenness between the different compartments (Inoculum: 
before entering the TSI, duodenum, jejunum, and ileum) for Fresh mix and Preadapted 
bacterial consortium in both fasted and fed conditions. 
 
2.5 - Discussion. 
Several natural barriers challenge the viability of probiotics during their passage through the 
upper GI tract, from the stomach acidity to the length of exposure to bile salts, the level of bile 
salt activity, presence of oxygen, and other environmental characteristics (Bezkorovainy 2001; 
Lee and Salminen 2009). Bile salts are the most challenging obstacle in the small intestine 
(Bezkorovainy 2001). The most ideal case for a probiotic is to survive the passage through the 
GI tract and launch itself in the small intestine and the colon and exert its functionality that 
eventually results in its putative health benefits (Bezkorovainy 2001). Therefore, one of the 
crucial properties of the probiotic bacteria is the bile tolerance, since it determines the ability 
of the bacteria to survive the small intestine (Ruiz, Margolles and Sánchez 2013).  
Although there is no common agreement on the minimum satisfactory level of viable probiotic 
cells per gram or millilitre of probiotic product, the concentrations of 106 and 107-108 cfu mL-1 
(cfu g-1), have been generally acceptable. Our in vitro experiments using the TSI model showed 
that many variables can determine the degree to which bacteria survive passage through the 
upper gastrointestinal tract (Corcoran et al. 2005).  
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When testing the survival of the single strains of our consortium, we observed that L. plantarum 
could survive the duodenum and the ileum with a 1.36×1010 cfu mL-1 (cfu g-1). Lactobacillus is 
intrinsically resistant to acid environments (Corcoran et al. 2005) and bile salts (Ruiz, Margolles 
and Sánchez 2013). Moreover, L. plantarum produces bile salt hydrolase enzyme which can 
also explain its survival through the different small intestine compartments (Begley, Hill and 
Gahan 2006). Additionally, B. thetaiotaomicron survived the duodenum and ileum 
compartments with 2.62×108 cfu mL-1 (cfu g-1). B. thetaiotaomicron possesses selective bile-
salt hydrolase (BSH) activity (Yao et al. 2018). BSHs are crucial in opposing the toxic effect of 
the glycoconjugated bile salts at low pH, and they are also important for having slight acidic 
pH optima (Begley, Hill and Gahan 2006). They are able to optimize the pH when bile enters 
the duodenum leading to acid reflux from the stomach or in specific microenvironments in the 
intestines when lactic acid bacteria cause a drop in the pH (Begley, Hill and Gahan 2006). 
Moreover, BSH-active strains may detoxify unconjugated bile acids (De Smet et al. 1995), or 
they could associate with 7- dehydroxylating bacteria that would dehydroxylate unconjugated 
bile acids (De Boever and Verstraete 1999; Begley, Hill and Gahan 2006). As a result, BSH 
activity can take a role in the survival and colonization of the strains within the GI tract (Moser 
and Savage 2001).  
As for V. parvula, B. vulgatus, and A. muciniphila, we observed that those three strains 
survived the duodenum but did not survive the ileum compartment. Long-term exposure to bile 
salts through jejunum and ileum compartments may lead to strain death. Nevertheless, 
Veillonella sp. can hydrolyze conjugated bile salts (Wei et al. 2013) and B. vulgatus possesses 
BSH activity (Elkins and Savage 1998 ; Kawamoto et al. 1989). Therefore, oxygen toxicity may 
indeed play a role in viability and activity when the strains are tested in the suitable culture 
medium and at the optimal temperature (37°C) (Talwalkar and Kailasapathy 2004). However, 
the impact of oxygen on cell viability of probiotic bacteria is inconclusive (Talwalkar and 
Kailasapathy 2004). The abundance of A. muciniphila in presence of bile was positively 
correlated to circulating primary bile in mice (Pierre et al. 2016), and the addition of porcine 
bile extract in its growth medium led to increased growth (van der Ark et al. 2017). In contrast, 
addition of purified bile salts resulted in inhibited growth of A. muciniphila (van der Ark et al. 
2018; Geerlings et al. 2018), which was not observed in our study.  
pH values and different bile concentrations should be tested for several times for each strain 
to determine its survival in those conditions, and the results for viability are species and strain 
dependent (Lee and Salminen 2009). Cross-resistance between low pH and bile salts has 
been reported in some bile-adapted strains (Noriega et al. 2004) (Duwat et al. 2000). For 
instance, the strain may  survive the bile in the duodenum when the stress response is already 
induced. Indeed, survival of candidate isolates can be guaranteed if tolerance, rather than 
direct resistance is observed (O’Sullivan 2006; Mortazavian et al. 2012).  
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Lower relative abundance and loss of some strains from the duodenum to the ileum under fed 
condition may be related to the higher concentration of bile salts during the fed condition. 
Blautia was persistent while Bacteroides decreased in all compartments in the case of the 
fresh mix in the fasted condition, probably because high levels of bile salts favour the 
proliferation of Gram-positive bacteria and reduction of the Gram-negative Bacteroides 
(Urdaneta and Casadesús 2017). However, the only genus that was consistently appearing 
was Lactobacillus, a facultative anaerobe resistant to bile salts. Moreover, the genera related 
to the ileal community were appearing in the ileum compartment since it was just introduced 
there as described by Cieplak et al. (2018) and did not have to pass through the duodenum 
and jejunum.   
In addition, sequencing results revealed that only Lactobacillus and Bacteroides were 
abundant in the preadapted consortium at time 0, while other genera of the consortium were 
not active. This could suggest that the optimal propionate production (34.5mM) was achieved 
with only these two genera of the preadapted consortium being active after the cross-feeding 
and interacting during the 48 hours of incubation. In the fresh mix, Bacteroides decreased in 
the duodenum compartment, suggesting that we might not achieve the same amount of 
propionate production if the strains were supplied as a fresh bacterial cocktail. These 
observations propose the importance of having a protectant carrier to ensure the survival of 
the preadapted consortium in the upper GI tract. 
This study highlights the importance of standardised administration guidelines for 
biotherapeutics. Our bacterial consortium was likely to have increased viability when 
administered under fasted conditions, which was also suggested in previous studies (Fredua-
Agyeman and Gaisford, 2015).  Microencapsulation has been applied to increase the survival 
of probiotics in food products like yogurts and other dairy products through protection from 
lyophilisation and rehydration, and from the acidity of the product (Dinakar and Mistry 1994; 
Kebary et al. 1998; Shah 2000; Talwalkar and Kailasapathy 2004). However, even if viability 
was ensured during the product formulation, it is crucial that live bacteria survive the upper GI 
tract (Mortazavian et al. 2012). Microencapsulation has been reported to protect probiotics 
from the detrimental factors during the passage in the GI tract like low PH (Sun and Griffiths 
2000) bile salts (Lee and Heo 2000), and molecular oxygen in case of obligatory anaerobic 
microorganisms (Mortazavian et al. 2012).  
Sufficient viable numbers must survive the upper GIT and reach the host colon to get beneficial 
effects (Bosnea et al. 2009). For this reason, in vitro experiments are essential to demonstrate 
their potency before piloting expensive and complex experiments (Millette et al. 2013). 
However, presence of food matrix (Millette et al. 2013) and interindividual differences in bile 
production and different foods can lead to contradictory outcomes (Millette et al. 2013). For 
instance, Begley et al. (2005) reported that bile acid levels in the intestine are not constant, 
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and they are relatively low until a fatty meal is ingested. The survival of bacteria is affected by 
the presence of food in the intestine as bacteria may not be exposed to bile in certain 
microenvironments created by the food matrix, or food constituents can even bind bile acids 
and prevent them from exerting toxicity. Furthermore, the tolerance of strains in bile broth in 
vitro systems may not truly imitate their ability to tolerate bile in vivo. Like any other 
physiological stresses, it is challenging to mimic exact in vivo conditions in a laboratory setting 
especially that all parameters that can affect survival are not being taken into account (Begley, 
Gahan and Hill 2005).  
  
2.6 - Conclusions 
The in vitro model revealed that a protectant is needed to help the consortium to reach the 
colon. Similar to probiotics, our propionate-producing consortium would be administrated orally 
and has to survive the passage through the harsh environment of the upper GIT and further 
exert its positive effect on the host. Microencapsulation may be an alternative to ensure 
integrity of the biotherapeutic, and future work is essential for establishing dosing in terms of 
frequency and viable cell number. In addition, presence of food matrix may impact the 
characteristics of live consortia, highlighting the urgency of optimising production pipelines for 
commercial and next-generation biotherapeutics.  
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CHAPTER 3 - Propionate-producing consortium restores antibiotic-
induced dysbiosis in a dynamic in vitro model of the human intestinal 
microbial ecosystem 
3.1 - Abstract. 
Metabolic syndrome is a growing public health concern. Efforts at searching for links with the 
gut microbiome have revealed that propionate is a major fermentation product in the gut with 
several health benefits towards energy homeostasis. For instance, propionate stimulates 
satiety-inducing hormones, leading to lower energy intake and reducing weight gain and 
associated risk factors. In (disease) scenarios where microbial dysbiosis is apparent, gut 
microbial production of propionate may be decreased. Here, we investigated the effect of a 
propionogenic bacterial consortium composed of Lactobacillus plantarum, Bacteroides 
thetaiotaomicron, Ruminococcus obeum, Coprococcus catus, Bacteroides vulgatus, 
Akkermansia muciniphila, and Veillonella parvula for its potential to restore in vitro propionate 
concentrations upon antibiotic-induced microbial dysbiosis. Using the mucosal simulator of the 
human intestinal microbial ecosystem (M-SHIME), we challenged the simulated colon 
microbiome with clindamycin. Addition of the propionogenic consortium resulted in successful 
colonization and subsequent restoration of propionate levels, while a positive effect on the 
mitochondrial membrane potential (ΔΨm) was observed in comparison with the controls. Our 
results support the development and application of next generation probiotics, which are 




3.2 - Introduction 
The human gut plays a major role in nutrition, metabolism, pathogen resistance, and regulation 
of immune response (Dethlefsen et al. 2008; Turroni et al. 2012). Microbial fermentation 
processes in the gut leading to production of short chain fatty acids (SCFA), are the result of 
metabolic interactions between different gut species (Dethlefsen et al. 2008). The main SCFAs 
(acetate, propionate, and butyrate) (McOrist et al. 2008) perform important physiological 
functions (Hosseini et al. 2011), occur in molar ratio of 3:1:1 in the colon (Hosseini et al. 2011) 
and are used by the microbiota for growth and maintenance of cellular functions of bacteria 
(Fernandes et al. 2014). Acetate is absorbed and transported to the liver for cholesterol and 
fatty acid synthesis in the host, playing a major role in enhancing ileal motility (Hosseini et al. 
2011), while butyrate is the key energy source for colonocytes. Butyrate prevents proliferation 
of cancerous cells and stimulates differentiation of colon epithelial cells (Hosseini et al. 2011). 
The health effects of propionate go beyond the gut epithelium, as it lowers serum cholesterol 
levels, lipogenesis, and carcinogenesis risk (Fernandes et al. 2014). Propionate may also 
decrease obesity by promoting the secretion of PYY and GLP-1 hormones from human colonic 
cells (Chambers et al. 2014; Psichas et al. 2014; Morrison and Preston 2016; Tolhurst et al. 
2011), inducing satiety and subsequently reducing energy intake and promoting weight loss 
(Arora et al. 2011). Propionate is a particularly interesting metabolite in the context of the 
aetiology and progress of metabolic disorder, which is becoming a public health issue. 
Metabolic syndrome is defined as a cluster of different biological conditions or metabolic 
disorders characterized by obesity, dyslipidemia, and type 2 diabetes (Alberti et al. 2009; 
Halcox and Quyyumi 2005; Moore et al. 2017; Nolan et al. 2017). This syndrome is linked to 
different comorbidities like cardiovascular disease, non-alcoholic fatty liver, arthritis, chronic 
kidney disease, and several types of cancers (Halcox and Quyyumi 2005; Moore et al. 2017; 
Dugas et al. 2016). Recent studies have reported an association between gut microbiota and 
metabolic syndrome, as the gut composition differs between healthy and diseased individuals. 
The gut microbiota is responsible for producing different regulatory peptide hormones (Silva 
and Bloom 2012), depending on the nutrient supply provided, as their interaction with receptors 
at different points in the gut-brain axis leads to satiety (Silva and Bloom 2012). Propionate has 
been reported to have the highest affinity for the free fatty acid receptor 2 (FFAR 2), involved 
in the regulation of metabolic homeostasis. In fact, long-term propionate delivery in the gut 
stimulates anorexigenic gut hormones, reducing intra-abdominal fat accretion, 
intrahepatocellular lipid content, and hepatic cholesterol synthesis in humans (Chambers et al. 
2014; Arora et al. 2011). In addition, propionate is involved in activation of intestinal 





As propionate production is associated with gut microbiome composition and functionality, 
different modulators such as antibiotics, prebiotics, and probiotics (El Hage et al. 2017) can 
impact this metabolite. Antibiotics may foster pathogenic opportunistic bacteria (Francino 
2016), influencing human health (Jin et al. 2016). Long-term antibiotic use can lead to 
increased body mass index and weight gain in both humans and farm animals (Francino 2016), 
alter transcription of genes involved in liver lipid metabolism (Jin et al. 2016), increase insulin 
resistance, and steatosis in patients with fatty liver (Miquilena-Colina et al. 2011). Antibiotic 
use has also been reported to cause bacterial translocation, which may represent an additional 
inflammatory stimulus potentially promoting obesity (Knoop et al. 2015). Hence, antibiotic use 
is considered a risk factor for metabolic disorders (Francino 2016; Economopoulos et al. 2016). 
For instance, the Cl atom present in the clindamycin disrupts the mitochondrial membrane 
potential (Goldhill et al. 1996); similar disruption has been reported following oxidative damage 
in metabolic syndrome (Nicolson 2007). Thus, we applied clindamycin as an agent to simulate 
the conditions of oxidative stress occurring during metabolic syndrome.  
Synthetic microbial communities have been proposed to prevent and treat disease and reverse 
gut dysbiosis more effectively than single strain approaches (El Hage et al. 2017).  Because 
of its beneficial effects on the host metabolism, propionate in our gut could contribute to solve 
the metabolic syndrome puzzle. We therefore aimed at engineering a propionate-producing 
synthetic microbial community, with functional redundancy on the different metabolic pathways 
for propionate production (acrylate, succinate, propanediol) (Reichardt et al. 2014). We then 
evaluated its potential to restore gut functionality after antibiotic-associated dysbiosis, using 
the Simulator of the Human Intestinal Microbial Ecosystem (SHIME). Knowledge regarding 
successful engraftment of functional communities can be applied for developing preventative 
novel probiotic strategies to ameliorate microbiome imbalances associated with metabolic 
syndrome.  
3.3 - Materials and methods. 
3.3.1 - Selection of strains for the propionate-producing consortium (PPC) 
Gut commensal strains were selected based on the reported metabolic pathways for 
propionate production (succinate, acrylate, and propanediol pathways) (Reichardt et al. 2014; 
Table 2.1). The selection of the strains composing the propionate-producing consortium (PPC) 
has been described in section 2.3.1 in chapter 2.  
 
 
3.3.2 - Assembly of propionate-producing community   
Culturing of bacteria was performed in Reinforced Clostridium Medium (Oxoid Ltd, 
Basingstoke, Hampshire, UK), using the Hungate tube method and under anaerobic conditions 
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(90% N2/ 10% CO2). All strains were incubated at 37⁰C for 48 h except for L. plantarum, which 
was incubated for 24 hours. At the end of the incubation, cell count was measured using flow 
cytometry, and standardised to 108 cells ml-1. 
Following, the consortium was subjected to the environmental conditions of the colon.  Thus, 
the consortium culturing medium (L-SHIME medium, Prodigest NV, Zwijnaarde, Belgium) was 
subjected to pre-digestion simulating the passage through the upper GI tract in the fed state. 
Gastric digestion was mimicked by maintaining pH 2 for 2 h, followed by addition of pancreatic 
juice [(0.9 g L-1 pancreatin (Sigma-Aldrich, St. Louis, USA), 6 g L-1 Oxgall (BD, Erembodegem, 
Belgium), and 25 g L-1 NaHCO3 (Carl Roth GmbH, Karlsruhe, Germany)]. pH was adjusted to 
6.8, and medium was incubated for 2.5 h at 37⁰C to simulate the small intestine digestion. pH 
was adjusted to 6.8 prior addition of the bacterial cocktail.  
Then, 5 ml of each strain were mixed under anaerobic conditions. The consortium was 
prepared by transferring 5 ml of the bacterial cocktail (10 % v/v) to an anaerobic glass bottle 
containing 45 ml of pre-digested medium. Co-culture occurred for 48 h, and 40% of the medium 
was replaced after 24h.  The consortium was harvested after 48 hours, when the average 
propionate concentration was 34.5 mM (Annex II, Figure S1). The viable cell count of the 
consortium was 108 cells ml-1when administered to the M-SHIME.  
3.3.3 - Dynamic simulation of the colon environment  
The mucosal simulator of the human intestinal microbial ecosystem (M-SHIME) is an in vitro 
model including both mucosal and luminal microbiota and simulating the digestive processes 
in the human intestinal tract (Van den Abbeele et al. 2012). We initially applied the model to 
evaluate the impact of a single dose of the consortium, in comparison with repeated doses, in 
separate SHIME runs. The experiments using single vs repeated doses were performed using 
fresh faecal material from one female (27 yo), and one male donor (29 yo). Validation of the 
repeated dosing required faecal samples from six more donors of the same age group (30 ± 
5). All donors were healthy with a normal BMI and did not use antibiotics for the last 6 months. 
The M-SHIME setup consisted of double-jacketed reactors representing the stomach, small 
intestine and colon (Truchado et al. 2017). The optimal pH for propionate production is 6.4-6.5 
(Belenguer et al. 2007; Zhuge et al. 2014), therefore, the transverse colon (pH 6.3-6.5) was 
selected where the PPC can optimally act. We simulated the environment of the transverse 
colon and thus, the pH was between 6.3-6.5, and the volume was 660 mL calculated upon 
retention time. Nutritional medium composition was described previously (Truchado et al. 
2017), and each colon vessel had a mucosal environment consisting of 80 mucin agar-covered 
microcosms (AnoxKaldnes K1 carrier; AnoxKaldnes AB, Lund, Sweden), placed in a 
polyethylene netting (Zakkencentrale, Rotterdam, The Netherlands) (Van den Abbeele et al. 
2012). Each M-SHIME vessel was inoculated with 8% (w/v) faecal slurry (Possemiers et al. 
2004; Molly et al. 1993). Static incubation was completed for the first 16 h, to allow for initial 
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stabilization of the system. After 16 hours, the peristaltic pumps were started up to supply each 
colon vessel with 200 mL of pre-digested feed three times per day every 8 hours.  Pre-digestion 
consisted of a 45-minute incubation in the stomach-small intestine compartment. All reactors 
were flushed with N2 to ensure anaerobic conditions. A scheme of the M-SHIME is presented 
in supplementary material (Annex II, Figure S2).  
After 10 days of stabilisation, 33.9 mg L-1 of clindamycin (Sigma-Aldrich, St. Louis, USA) were 
added to all colon vessels twice per day for three days, to trigger dysbiosis. Four days after 
the last antibiotic treatment, a single dose (45 ml, 6.8% of volume) of the propionate-producing 
consortium was added to triplicate treatment vessels, while the other three reactors were kept 
as controls. Three days after the single dose, three consecutive doses of the treatment were 
added again for three consecutive days. The system was monitored for further four days to 
investigate the further effect of the consortium. The whole experiment ran for 27 days in case 
of the first 2 donors and 23 days for the six donors. Samples for SCFA analysis and for DNA 
extraction were collected every day before the first medium replacement. Samples that were 
sent for Illumina sequencing were samples from different days that present the end of the 
different phases of the SHIME run. Lumen samples were collected at days 11, 17, 20, and 23 
representing stabilization phase, antibiotic treatment phase, propionate-producing consortium 
(PPC) treatment phase and washout phase respectively. The mucin samples were collected 
less frequently since mucin beads were changed every other day, so the samples collected 
were at days 9, 14 and 21 presenting stabilization phase, antibiotic treatment phase, and after 
PPC treatment phase respectively. 
3.3.4 - Community functionality and composition 
3.3.4.1- SCFAs extraction 
Short-chain fatty acids were used as benchmarks of community activity, and were collected 
from the luminal compartment, and extracted with diethyl ether (De Weirdt et al. 2017) and 
quantified as described by (De Weirdt et al. 2010). Total SCFA production was defined as the 
sum of the molar concentrations of acetate, propionate, butyrate, valerate, caproate, 
isobutyrate, isovalerate and isocaproate (De Weirdt et al. 2017). The detection limits according 
to CMET protocol were as follows: 30 mg/L Acetate, and 10mg/L propionate and longer VFAs. 
As iso-acids are indicative of proteolytic metabolism; we currently did not focus on shifts 
between carbohydrate – protein metabolism, but focused more on the restoration of propionate 
production in our study.  
Differences in SCFA concentrations among treatments were compared using a repeated 
measures mixed model, with the lsmeans adjustment and Sidak correction for multiple 
comparisons (GraphPad Prism 7.04, La Jolla, CA, USA). Statistical significance was assumed 
at P < 0.05.  
60 
 
3.3.4.2 - DNA extraction and Illumina library generation 
Total DNA from luminal and mucosal samples was extracted using physical disruption with the 
bead beating method (Hernandez-Sanabria et al. 2010). Briefly, samples were thawed, 
manually homogenized, and centrifuged at 14,600 × g for 5 min at 4°C. The pellet was 
resuspended in 1 ml of lysis buffer (100 mM Tris pH8, 100mM Na EDTA pH8, 100 mM NaCl, 
1%(w/v) polyvinylpyrrolidone, 1% PVP40, and 2% (w/v) sodium dodecyl sulphate) and 
transferred to a 2-ml microcentrifuge tube containing 0.3 g of zirconium beads (diameter, 0.1 
mm). The cells were lysed in a Power Lyzer 24 (Mo Bio Laboratories, Carlsbad, CA, USA) for 
3 minutes at 4800 rpm. DNA concentration and quality were verified based on the absorbance 
at 260 and 280 nm, using a DeNovix DS (Thermo Scientific, Waltham, USA).  
The V3-V4 hypervariable region of the 16S rRNA gene was amplified using primers 341F and 
785R. Illumina sequencing adapters and dual-index barcodes were added to the amplicon, 
using a limited-cycle PCR that included an initial denaturation step at 95 ºC for 3 min, 15 cycles 
of a denaturation step at 95ºC for 30 s, an annealing step at 55 ºC for 10s, an extension step 
at 72 ºC for 45 s, and a final extension at 72 ºC for 5 min. Following, a clean-up step was 
performed using the AMPure XP beads (Beckman-Coulter, Krefeld, Germany) to remove free 
primers and primer-dimer species from amplicons. A second PCR to attach the specific 
Illumina multiplexing sequencing primers and index primers, was performed. Thermal cycling 
included an initial denaturation step at 95 ºC for 3 min, 8 cycles of a denaturation step at 95ºC 
for 30 s, an annealing step at 55 ºC for 30 s, an extension step at 72 ºC for 30 s, and a final 
extension at 72 ºC for 5 min. 
These PCR products were verified by gel electrophoresis, purified using the Promega Wizard 
PCR clean-up kit (Promega, Madison, WI, USA) following the manufacturer’s instructions and 
quantified with the QuantiFluor dsDNA System kit (Promega, Leiden, The Netherlands). High-
throughput amplicon sequencing of the V3 – V4 hypervariable region (Klindworth et al. 2013) 
was performed with the Illumina MiSeq platform according to the manufacturer’s guidelines at 
LGC Genomics GmbH (Berlin, Germany). Contigs were created by merging paired-end reads 
based on the Phred quality score (of both reads) heuristic as described by Kozich et al. (2013) 
(Kozich et al. 2013) in Mothur (Schloss et al. 2009) (v.1.33.3). Contigs were aligned to the 
SILVA database and filtered from those with (i) ambiguous bases, (ii) more than 10 
homopolymers, and (iii) those not corresponding to the V3 – V4 region.  
Chimera removal and operational taxonomic unit (OTU) clustering of the sequencing reads 
was performed using UCHIME, with the nearest neighbour clustering algorithm implemented 
in mothur, at 0.03 distance (Edgar 2010). Phylotype representatives were then generated by 
clustering at 97% similarity (1 mismatch), with a confidence level of at least 80 with 
Cyanobacteria, Eukaryota, and Archaea lineages removed. For taxonomic classification, 
sequence composition of the dataset was compared using the RDP Classifier tool (Wang et 
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al. 2007), and the RDP trainset (Cole et al. 2009) version 9. Quality of the sequencing and 
post-processing pipeline was verified by incorporating mock samples (n = 12 species) in 
triplicate into the same sequencing run. After examining read counts, if any OTU was not 
classified up to genus level, the consensus sequence was blasted using the SILVA database 
(Pruesse et al. 2012) to obtain the taxonomic classification. In addition, all OTU sequences 
were aligned with those obtained from the sequencing of the 16S rRNA genes of each species, 
using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). 
3.3.5 - Community composition and dynamics 
Data was imported into R using phyloseq (Mc Murdie et al. 2013), and taxon abundances were 
rescaled by calculating the taxon proportions and multiplying them by the minimum sample 
size (n = 24789) present in the data set (McMurdie et al. 2014). Alpha diversity was initially 
estimated within each sample using Richness, Fisher’s diversity, Shannon, Simpson, and 
inverse Simpson indices. Inverse Simpson was the metric used for final assessment. Pielou 
index was used as indicator of evenness in the community (Grunert et al. 2016). Differences 
in alpha diversity and evenness measures among treatments were compared using a repeated 
measures mixed model in SAS, using the lsmeans adjustments and Bonferroni correction for 
multiple comparisons (version 9.4, SAS Institute, Cary, USA). To confirm these results, 
comparisons between control and treatment were performed using a 2-way Anova (Sidak’s 
method) and between and within time points using Tukey’s method in GraphPad (GraphPad 
Prism 7.04, La Jolla, CA, USA) (AnnexII, Tables S1 and S2).  
Beta diversity estimates based on Chao and Bray-Curtis indices were used to examine 
dissimilarity and determine the impact of treatment and time on microbial community structure. 
Principal Coordinate Analysis (PCoA) was employed to visualize the differences among 
samples, using the vegan package in R (Oksanen et al. 2007) (Annex II, Figure S3). Stratified 
permutational multivariate analysis of variance (PERMANOVA) with 999 permutations was 
conducted to indicate the significance of time and treatment on the microbial community 
differences. ANOVA was applied to reveal whether the distribution of the genera was different 
between treatments over time (Oksanen et al. 2007). Because of the over-dispersion in the 
OTU counts data, a zero-inflated count model was used to assess the effect of time and 
treatment and the interactions between time*treatment on each individual genus. Zero-inflated 
models explain the excess of zeros by modelling the data as a mixture of a Poisson distribution 
or a negative binomial distribution. When a zero count is observed there is the zero-inflation 
probability, because the observation came from the always-zero distribution. When the 
underlying count distribution is a Poisson distribution, the model is called a zero-inflated 
Poisson distribution and if the count distribution is a negative binomial distribution, the mixture 
is called a zero-inflated negative binomial distribution. The final model was selected based on 
the Akaike Information Criterion (AIC). Differences among library size sample were accounted 
62 
 
for with the offset option in proc GLIMMIX in SAS (Paschold et al. 2012). P values for each 
comparison were converted to q-values that were then used to identify differences in relative 
abundances of bacterial genera while controlling false discovery rate (FDR) at the 5% level 
(Storey and Tibshirani 2003).  
Bipartite networks were inferred to highlight functional associations among bacterial genera 
and metabolites, using a pair-wise similarity matrix obtained from a Regularized Canonical 
Correlation Analysis (Lê Cao et al. 2011). Values of the similarity matrix were computed as the 
correlation between the relative abundances of bacterial genera and the metabolic variables, 
projected onto the space spanned by the first components retained in the analysis. Three 
relevant components were obtained setting a threshold of r ≥ 0.7 and genera were 
disseminated in the plot, in close relation with the variables correlated (De Weirdt et al. 2017). 
3.3.6 - Enumeration of microbial cells using flow cytometry 
To assess variation in cell counts in lumen and mucin compartments, we analysed SHIME 
samples collected at different time points from different phases of the SHIME run (stabilization 
phase, after antibiotic phase, after treatment phase and washout phase). 
Cell counts from lumen and mucin samples. Samples used for cell counts were frozen at  
-20°C. All samples were diluted 1:1 in filter-sterilized PBS, and vortexed for 1 minute at 
maximum speed. Mucin samples were disrupted for 40 seconds at 1800 rpm (Power Lyser 24, 
MO BIO Laboratories, Carlsbad, USA), and centrifuged at 500 × g for 4 minutes, while lumen 
samples were centrifuged at 500 × g for 2 minutes. Supernatants were collected and passed 
through 20µm filters (Filcon, BD Medimachine, Erembodegem, Belgium) to remove particulate 
matter. Filtered samples were then diluted 5000 times in filter-sterilized PBS, and 198µl of the 
diluted sample was stained with 2µl of SYBR Green (SG) (10,000× diluted from stock; 
Invitrogen, Carlsbad, USA) in 96 flat-bottom well plate. The plate with the stained samples was 
incubated for 20 minutes at 37°C. Flow cytometric analysis of the microbial cells present in the 
suspension was performed using a C6 plus Accuri flow cytometer (BD Biosciences, 
Erembodegem, Belgium) equipped with a 488 nm laser, following previously described 
methods (Props et al. 2017). Fluorescence events were monitored using the FL1 533/30 nm 
and FL3 > 670 nm optical detectors. Forward and sideways-scattered light was also collected. 
The BD Accuri CSampler software was used to gate and separate the microbial fluorescence 
events on the SSC-A and FITC-A density plot from the lumen and mucin SHIME sample 
background. Gating was evaluated using a 0.2µm filter. A threshold value of 1,000 was applied 
on the FL1 channel. The gated fluorescence events were evaluated on the SSC-FL1 density 
plot, to exclude remaining background events and to obtain an accurate microbial cell count. 
Instrument and gating settings were kept identical for all samples. 
For quantification of absolute numbers of each taxon, samples were rescaled by multiplying 
the relative abundance of each genus by the flow cytometry cell counts. 
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3.3.7 - Assessment of the mitochondrial membrane potential  
Mitochondrial membrane potential (ΔΨM) is a central intermediate in oxidative energy 
metabolism (Gerencser et al. 2012), and it is associated to the metabolic activity of the 
eukaryotic cells. Mitochondrial membrane potential of epithelial cells is fundamental for gut 
motility as well as for cell division, as it modulates the distribution of several conserved cell 
division proteins (Strahl and Hamoen 2010). Propionate promotes flux of Cl- to the mucosa, 
increasing the short-circuit current, hence stimulating colonic contractions through a change in 
potential difference (Yajima 1988). As reduced intestinal motility and low-grade inflammation 
are markers of metabolic syndrome (Müller et al. 2018), we assessed the capability of the 
propionate-producing consortium to change the mitochondrial membrane potential (ΔΨm). We 
used an in vitro model of the gut epithelium to reveal whether the supplementation of the 
consortium could potentially restore disrupted membrane potential, as observed in metabolic 
syndrome. Caco-2 cells were seeded onto opaque clear bottom 96-well plates (Corning, NY, 
USA) at a density of 20000 cells/well and maintained for 72 hours. Then, cell culture media 
was removed, and cells were exposed to the treatments in table 3.1. 
 
Table 3.1: Treatments added to epithelial cell model to assess changes on membrane 
potential. A negative control was used in which the cells did not get any treatment or 
disruption. CCCP was used as a positive control for disruption of membrane potential. 
The metabolites from the propionate-producing consortium (PPC) were added above 
the cells after being filter-sterilized. To assess the ability of the consortium (PPC) to 
restore the disruption caused by clindamycin (CLN), its metabolites were added 
together with clindamycin above the epithelial cells. P/A/B, propionate/acetate/butyrate 
mixture at the ratios produced by the consortium. 
Treatment Concentration Time 
Clindamycin hydrochloride  33.9 mg/L 24 h 
Filter-sterilized PPC (1:5 v/v in DMEM) 2:1 Acetate:Propionate ratio 24 h 
 CLN + PPC  33.9 mg/L + P/A/B 24h 
Cell culture medium (negative control) - 24h 
CCCP (positive control for disrupted ΔΨm) 50µM 2 h 




All the compounds were diluted from the stock solution in DMSO to the corresponding working 
solution in DMEM without supplementation. Filter-sterilized consortium was diluted 1:5 (v/v) in 
DMEM without supplementation. DMSO was used as a control. 
After exposing the cells to the treatments for 24 h at 37ºC, (95% humidity, 10% CO2), cells 
were washed once with 200 µL of PBS with Ca++ and Mg++ (Sigma) and 100 µL of JC-1 stain 
(10 µM in DMEM) (Cayman Chemical, Michigan, USA) were added to the wells and incubated 
for 20 min. Following, wells were washed with PBS supplied with Ca++ and Mg++ and 10% 
FBS, and 100 µL of DMEM were added to each well before measuring with a SpectraMax Plus 
Microplate Reader (Molecular Devices, LLC). Excitation/emission wavelength pairs were set 
at 475/530 nm and 475/590 nm, for JC-1 monomer and aggregate detection, respectively. 
5,5,6,6’-tetrachloro-1,1’,3,3’ tetraethylbenzimidazoylcarbocyanine iodide (JC-1) dye has been 
developed to detect ΔΨM in healthy and apoptotic cells across multiple cell types (Sivandzade, 
Bhalerao and Cucullo 2019). In healthy cells, the dye localizes in the mitochondria where it 
forms aggregate the fluoresce red. When the mitochondria is disrupted and the mitochondrial 
membrane collapses, the dye diffuses in the cytosol in monomeric form which fluoresces 
green. Thus, the ratio red to green fluorescence (aggregate/monomer) reflects mitochondrial 
membrane integrity (McGill et al. 2011). As a result, a low aggregate/monomer ratio indicates 
mitochondrial membrane disruption.  
The background (A590 of non-stained cells) was subtracted from the test signals. Results were 
expressed as the ratio between aggregate/monomer. All Pairwise Multiple Comparison 
Procedures and Statistical analysis was done using Holm-Sidak method in GraphPad 
(GraphPad Prism 7.04, La Jolla, CA, USA). 
 
3.4 - Results. 
We assessed the reproducibility of the simulated clindamycin-induced dysbiosis using the 
Mucosal Simulator of the Human Intestinal Ecosystem (M-SHIME), before evaluating the 
potential of the propionate-producing consortium to restore functionality. Two M-SHIME runs 
were separately conducted with faecal microbiota from two volunteers, and treatments were 
supplied to triplicate reactors. Concentrations and profiles of SCFA in the luminal content of 
the proximal colon compartments across the three technical replicate reactors were found to 
be reproducible (Annex II, Figures S4 and S5).    
3.4.1 - Gut microbiome functionality is improved when a propionate-producing consortium is 
supplied after antibiotic use in single donor experiments 
Altered production of SCFA is considered one of the hallmarks of dysbiosis, and thus, we 
validated that clindamycin disrupted the fermentation pattern of the simulated gut ecosystem. 
Upon antibiotic supplementation, propionate and butyrate decreased by approximately 57% 
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and 95% respectively and remained consistently and significantly low (P < 0.05) across all 
triplicate experiments for both donors 1 and 2 (Annex II, Figures S4 and S5). In the single 
donor experiments, we found that one single dose of the propionate-producing consortium did 
not promote functional recovery on either of the donors (Annex II, Figures S4 and S5), whereas 
three consecutive doses of the consortium triggered a significant increase in propionate 
production only in donor 1 (14.84 ± 1.06mM; P < 0.05, Annex II, Figure S4,). This positive 
outcome remained consistent across the three replicates until the end of the experiment 
(Annex II, Figure S4, Table S3). As the impact of one single dose of the consortium seemed 
to be marginal, we decided to use three consecutive doses in a multiple-donor experiment. We 
conducted an extra M-SHIME run with faecal samples from six different donors of the same 
age group (30 ± 5 yo). Functional recovery and inter-individual variability were assessed, and 
all the following results presented were from the multiple-donor experiment.  
3.4.2 - Modulation of microbiota functionality by a propionate-producing consortium upon 
antibiotic induced dysbiosis 
After disruption with clindamycin, there was a significant and consistent decrease in butyrate, 
propionate, and acetate by 88%, 46% and 16% respectively (P < 0.05) (Figure 3.1). Higher 
decrease was observed in propionate and butyrate due to the decrease in Akkermansia, 
Blautia, and Lachnospiraceae than are main producers for propionate or butyrate. Lower 
decrease in acetate might be due the fact that acetate production pathways are widely 
distributed among bacterial groups while propionate, butyrate and lactate pathways are more 
highly conserved and substrate specific (Morrison and Preston 2016). Inter-individual 
differences in SCFA production were observed upon dosing the propionate-producing 
consortium. Repeated supplementation of the consortium promoted significant increase in 
propionate production (12.47 ± 0.88 mM; P < 0.05), compared with the control (7.57 ± 0.37 
mM), resulting in nearly 100% recovery of the initial propionate concentrations. Restoration of 
butyrate and acetate was variable across the 6 different donors and no significant recovery 
was observed (Figure 3.1). These observations confirm that our designed microbial consortium 




Figure 3.1: Addition of the propionate-producing consortium (PPC) promotes recovery 
of propionate production after antibiotic-associated disruption. CTR: Control, TRT: 
Treatment. (A) Short chain fatty acid production during the 3 different phases of the 
experiment: Stabilization, post-antibiotic disruption, and post-addition of the 
propionate-producing consortium. Days in which antibiotics and PPC were added are 
indicated by arrows. Antibiotic treatment was added on days 11, 12, and 13. Treatment 
was added on days 17, 18, and 19. (B) Propionate was the main short chain fatty acid 
impacted after 2 doses, as propionate levels significantly increased from day 19 in the 
treatment reactors (P < 0.05). No significant difference was detected for acetate (C) and 
butyrate (D) after the treatment was added (P>0.05). 
 
3.4.3 - Propionate-producing consortium supports the partial recovery of the epithelial 
mitochondrial membrane potential after antibiotic disruption 
Mitochondrial membrane potential of epithelial cells is fundamental for gut motility as well as 
for cell division, as it modulates the distribution of several conserved cell division proteins 
(Strahl and Hamoen 2010). Carbonyl cyanide m-chlorophenylhydrazone (CCCP) was used as 
a positive control for the disruption of the membrane potential, because it rapidly disperses the 
proton motive force (pmf) or membrane potential (Strahl and Hamoen 2010). The 
concentration used for triggering a membrane disruption was set high (50 uM) to ensure the 
desired effect. The CCCP dose was adjusted based on the response of Caco-2 cells, within 
the range of concentrations and times previously reported in literature (Rainbolt, Saunders and 
Wiseman 2014; Yang et al. 2001; Ikeda et al. 2015; Sgarbi et al. 2014; Wang et al. 2017; Liu 
et al. 2017; Panina et al. 2019). Lower doses could be used in the future as decribed by Ruas 
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et al. (2016). A significant decrease in membrane potential was observed when CCCP was 
added to our cell model, confirming the negative effect of the CCCP on the membrane potential 
(Annex II, Table S4, P < 0.05), (Figure 3.2). Clindamycin decreased the membrane potential 
by approximately 80% (P < 0.05), confirming the negative effect of the antibiotic towards 
epithelial cells. When clindamycin was added together with the propionate-producing 
consortium, the ratio of the aggregate monomer of the JC1 was increased by 40% (P < 0.05), 
indicating partial recovery of the membrane potential after clindamycin disruption.  
 
Figure 3.2: Propionate-producing consortium triggered a partial recovery for the 
membrane potential after clindamycin disruption. Following clindamycin (CLN) 
supplementation, membrane potential tended to be higher when one dose of the 
propionate-producing consortium (PPC) was provided, in comparison with exposure to 
clindamycin alone. Protonophore carbonyl cyanide m-chlorophenylhydrazone (CCCP) 
was used as a positive control to distrupt membrane potential. All Pairwise Multiple 
Comparisons between treatments were assessed using Holm-Sidak method with overall 
significance level equal to 0.05. Significant differences were indicated using different 
superscripts. Presence of the same letter in the superscript indicates that samples are 
not significantly different (P>0.05). 
3.4.4 - Antibiotic use significantly decreased the bacterial cell load 
A workflow for the quantitative microbiome profiling can be built through parallelization of 
amplicon sequencing and flow cytometric enumeration of microbial cells (Vandeputte et al. 
2017). Flow cytometry revealed a significant decrease in the cell count after antibiotic use in 




consortium did not impact the total cell load (P >0.05). However, cell count decreased in the 
reactors that were not supplemented (Annex II, Figure S6).  
3.4.5 - Propionate-producing consortium shaped the bacterial community based on number of 
doses and host influence 
As shifts in bacterial taxa and decrease in community diversity are benchmarks of dysbiosis, 
we dynamically monitored both luminal and mucosal communities using the M-SHIME. Alpha 
diversity was unchanged in control and treatment reactors in the multi-donor experiment upon 
consortium supplementation (Figure 3.3A).  
Clindamycin significantly decreased richness in all luminal compartments (Figure 3.3B) (Annex 
II, Table S1), but consecutive doses of the propionate-producing consortium triggered a 
significant recovery of this metric in the lumen compartment (P < 0.05). The difference in 
richness between the control and treatment was not significant until the end of the washout 
period, when the treatment reactors had significantly higher total number of species than the 
control reactors (P < 0.05, Figure 3.3B) (Annex II, Table S1). Total number of species tended 
to be higher in the mucin compartment as well. As the mucosal communities are in close 
contact with the host, successful function transfer in the mucosal compartment may be relevant 
for possible host effects (Figure 3.3E) (Annex II, Table S2). Antibiotics have stronger effect on 
the activity of mucosal microbial communities, as the washout of clindamycin is somewhat 
delayed compared to washout from the luminal environment. This is due to the fact that the 
mucin beads were changed every other day, in which only half of the mucin beads were 
changed during every replacement to mimic the in vivo mucus layer turnover. In contrast, the 
luminal compartment experiences a washout that is far more frequent as the feed is being 
replaced 3 times per day. This results in a longer persistence of antibiotics in the mucin 
compartment, and this is also a confirmation of previous in vivo observations studies (Rashid 
et al. 2015; Brismar et al. 1990). In addition, evenness of mucosal communities following 
antibiotic-induced dysbiosis tended to be lower in comparison with that at the end of the 
stabilization period (Figure 3F, Table S2). In contrast, evenness in the lumen community after 
dysbiosis remained constant, suggesting that mucus bacteria are more sensitive to antibiotics 
than bacteria in the lumen environment (Figure 3.3C) (Annex II, Table S1). We observed that 
antibiotic supplementation promoted both loss of bacterial richness and increased relative 
abundance of Enterobacteriaceae and Escherichia-Shigella, albeit not significant for the latter 
in the mucin (Figure 3.4) (Annex II, Table S5D). Importantly, relative abundance of Escherichia-
Shigella was significantly decreased in the lumen when the consortium was supplied (Annex 
II, Table S5C). Pathologies characterized by microbial dysbiosis have in common a decrease 
in the community composition complexity, as well as an increase in aero-tolerant genera such 
as Enterobacteriaceae (Vonaesch et al. 2018). Although microbial community can be deeply 
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disrupted upon antibiotic use, our results indicate that the propionate-producing consortium 
shaped the community based on the number of treatment doses and donor. 
 
Figure 3.3: Propionate-producing consortium triggered an increase of total number of 
species after the washout period only in the lumen compartment. Relative abundance 
was quantified at the end of stabilization phase, antibiotic treatment phase, propionate-
producing consortium phase, and washout phase. Control and treatment compartments 
were indicated with orange and blue respectively. The propionate producing 
consortium was added only in the treatment compartments. No effect of the consortium 
on the alpha diversity of lumen (A) and the mucin (D) were detected. Antibiotic 
supplementation triggered significant decrease in the total number of species (P < 0.05) 
only in the lumen compartment (B), but not in mucin compartment (E). The propionate-
producing consortium significantly increased the total number of species at the end of 
the washout (B). No effect of the consortium on the evenness of the community in the 
lumen (C) and the mucin (F) was observed. 
Repeated doses of the consortium confirmed a potential recovery of the community, both 
through direct engraftment and through indirect reinforcement of other propionate producers. 
For instance, unclassified Lachnospiraceae, Akkermansia and Bacteroides increased their 
relative abundance in both compartments, indicating that some members of our consortium 
(Coprococcus catus, Akkermansia muciniphila, Bacteroides thetaiotaomicron and B. vulgatus) 
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may have been successfully engrafted in the mucin compartment (Figure 3.4) (Annex II, Table 
S5B). Moreover, the presence of these genera even after the washout may suggest that 
indirect positive reinforcement of the overall community may have ensued. Long-lasting 
increased relative abundance of Akkermansia species seem to be consistent across 
individuals, as indicated by the community composition at the end of the washout period 
(Figure 3.4). Moreover, the relative abundance of other species, such as Veillonella (Annex II, 
Table S5A), indicate that the intra-individual engraftment and indirect reinforcement of the 
consortium may be enduring.  
 
Figure 3.4: Relative bacterial abundances on the luminal and mucosal compartments 
shifted among end of stabilization, after antibiotic use, after 3 doses of PPC and after 
washout. Genera with the highest relative abundances across time points were 
uncovered in the (A) lumen compartment and (B) mucosal compartment. Six replicates 
(donors) were averaged to highlight the inter-individual effect of the propionate-
producing consortium. 
 
3.4.6 - Addition of the propionate-producing consortium amends community metabolic 
networks following environmental disruption 
Relevance networks analyses indicated that SCFA-production networks shifted with antibiotic 
treatment. As metabolic products were significantly decreased when the environmental 
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disruption happened, larger networks including bacteria associated with acetate production 
were observed (Annex II, Figure S7A). Increased acetate concentrations seemed to correlate 
with increased relative abundances of Bifidobacterium, Faecalibacterium, Flavonifractor and 
Anaerotruncus (Annex II, Figure S7A and Table S5C). With respect to butyrate, a positive 
association was only found with increased relative abundance of Bacteroides. No genera were 
significantly associated with high concentrations of propionate, after antibiotic was provided 
(Annex II, Figure S7A) (P < 0.05).  
The relevance network for the control reactors displayed intermingled propionate and butyrate 
networks (Figure 3.5B). This may suggest that the community competes for the substrate 
available, preventing from significantly increasing propionate production. Upon repeated 
dosage of the consortium, the propionate network showed that higher relative abundances of 
Unclassified Lactobacillaceae, Morganella, Hungatella, Erysipelatoclostridium, Unclassified 
Lachnospiraceae and Bilophila were associated with higher concentrations of propionate 
(Figure 3.5A) (Annex II, Table S5C). The increased relative abundance of these and other 
genera such as Parabacteroides in the mucin (succinate producer) may confirm the indirect 
positive reinforcement of the propionate-producing consortium on the overall community 
(Annex II, Table S5C). Moreover, Hungatella has been reported to thrive on medium used to 
produce probiotic bacteria (Kaur et al. 2013).  
Finally, the enduring indirect impact of the consortium was validated on the propionate network 
at the end of the washout period (Annex II, Figure S7B). We observed that higher relative 
abundance of Unclassified Lactobacillaceae was positively associated with increased 
concentrations of propionate (P < 0.05), potentially revealing that acetate-producing bacteria 
belonging to this family (Lactobacillus sp.) actively participate in the functional recovery of the 
community. The lasting effect of the consortium may as well indicate the successful 
engraftment of one of the genera comprised in this community. Higher abundances of 
Akkermansia were associated with higher concentrations of acetate at the end of the washout 
(Annex II, Figure S7B). This could be an additional indicator of the successful adaptation and 




Figure 3.5: Bacterial interactions networks influenced the production of the major short 
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propionate consortium, (B) Control vessels at day 20. These bipartite networks are 
based on the regularised canonical correlations between relative bacterial abundances 
and relative concentrations of the main SCFA. Interactions have been filtered for an 
absolute correlation above 0.8 and are coloured following the key shown. Significant 
interactions are shorter lines, and genera with similar abundances within SHIME 
compartment tend to cluster closely.  
3.4.7 - Variations in cell densities confirmed the impact of the propionate-producing consortium 
in the compositional dynamics of the community 
We performed absolute quantification of the taxa detected in our study, to comprehensively 
explain the differences observed in the relative abundances. Our results confirmed the direct 
engraftment of one of the members of our consortium, as the absolute abundance of Veillonella 
significantly increased in in both luminal and mucosal compartments of the treatment reactors 
after providing 3 doses of the consortium (P < 0.05) (Figure 3.6) (Annex II, Tables S6 and S7). 
As for the indirect reinforcement, relevance networks initially suggested that some genera were 
linked to propionate production. We observed a significant increase in absolute abundance of 
unclassified Lactobacillaceae after adding the 3 doses of the consortium in both lumen and 
mucin (P < 0.05) (Figure 3.7) (Annex II, Tables S8 and S9). Moreover, unclassified 
Lachnospiraceae significantly increased in the treatment vessels after the washout period in 
the lumen compartment (P < 0.05) (Figure 3.7) (Annex II, Table S8). Although Bilophila showed 
increased relative abundance after adding the 3 doses of the consortium, absolute abundance 
was not increased (Figure 3.7) (Annex II, Tables S8 and S9). The combined approach of 
relative and absolute abundances assisted to elucidate the course of action of the propionate-
producing consortium. Thus, the observed positive effect of the consortium may be explained 
as a synergic impact on the cell counts and on the relative abundances of taxa involved in 





Figure 3.6: Absolute abundance of the seven genera included in the propionate-
producing consortium. Quantification of absolute abundances revealed the direct 
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engraftment of specific genera in the lumen (A) and mucin (B) compartments.  
Veillonella showed a significant increase (P < 0.05) in both lumen and mucin 




Figure 3.7: Absolute abundance of genera involved propionate production upon 
consortium supplementation. Quantification of absolute abundance validated the 
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indirect reinforcement of specific genera in the lumen (A) and mucin (B) compartments.   
Lactobacillaceae was significantly increased in both lumen and mucin compartments 
(P < 0.05) upon administration of the propionate-producing consortium. 
Lachnospiraceae showed a significant increase only in the lumen compartment at the 
end of the washout phase (P < 0.05). 
 
3.5 - Discussion 
In our study, we aimed at engineering our propionate-producing consortium considering the 
three major pathways for propionate production (acrylate, succinate, and propanediol 
pathways) (Reichardt et al. 2014). The consortium positively impacted functionality and 
composition of the microbial community and supported the partial recovery of membrane 
potential after clindamycin disruption.   
SCFA analysis from the luminal SHIME samples revealed a significant drop in bacterial 
metabolic activity after clindamycin-induced dysbiosis. Previous studies reported the ability of 
antibiotics to significantly influence taxonomic richness, diversity and evenness (Dethlefsen et 
al. 2008; Francino 2016; Rojo et al. 2017; Dethlefsen and Relman 2011), as observed in the 
lumen and mucosal communities of our experiment. In addition, flow cytometry analysis 
confirmed the negative effect of dysbiosis on bacterial cell counts, as they significantly 
decreased upon antibiotic administration. We used clindamycin since the Cl atom present in 
clindamycin disrupts the mitochondrial membrane potential (Goldhill et al. 1996); similar 
disruption has been reported following oxidative damage in metabolic syndrome (Nicolson 
2007). Thus, we applied clindamycin as an agent to stimulate the conditions of oxidative stress 
occurring during metabolic syndrome. We did not aim for a therapeutic treatment as the 
protocol applied for a C. difficile infection. We aimed only for a disruption of the microbial 
community without complete suppression of the bacterial population. In the single donor 
experiment, one single dose of the propionate-producing consortium did not impact neither 
functionality measured by SCFA production nor microbial community. The dose we provided 
may have not been enough for a beneficial effect, as in the case of probiotic strategies that 
can only confer a positive effect when administered in adequate amounts (Ouwehand 2017). 
Repeated doses of our consortium showed a significant effect on the functionality in one of the 
2 donors of the single-donor experiments, and in all six donors in the multiple-donor 
experiment, with full recovery of propionate production. Resident bacteria potentially interacted 
with the supplied propionate-producing consortium, as those administered may have provided 
metabolites like acetate, lactate, and propionate. Thus, resident bacteria cross-feeding on 
these metabolites eventually led to the production of propionate (Derrien and van Hylckama 
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Vlieg 2015). Our results suggest that restoration of propionate production by our engineered 
consortium was successful. 
Despite the positive impact of the propionate-producing consortium, some elements of 
dysbiosis remained unchanged. For instance, the consistent relative abundance of 
Proteobacteria like Escherichia-Shigella and Bilophila before and after treatment, indicates that 
those bacteria can act as opportunistic pathobionts in cases of dysbiosis. Bilophila may have 
utilized mucin-degradation products from our consortium to produce propionate. The positive 
correlation between Bilophila and propionate may be an indicator of the inflammatory status of 
the environment that resulted after antibiotics (Feng et al. 2017). However, absolute 
abundance of this genus was not increased when the consortium was provided. Instead, 
members from our propionate-producing consortium like Bacteroides and Akkermansia may 
have occupied the niche of primary carbohydrate degradation and subsequently promoted 
fermentation by resident bacteria, as is the case for mucin metabolism. Mucin degradation can 
liberate sugars, amino acids, sialic acids, and sulphate that can be consumed as substrates 
by the resident commensals (Derrien and van Hylckama Vlieg 2015) or even by the provided 
bacteria. Our consortium contained a strain of Akkermansia muciniphila, a specialized mucin-
degrading bacterium (Chia et al. 2018), which could have provided sugar monomers from 
mucin upon degradation. Mucin-derived sugars like fucose could be utilized by Akkermansia 
muciniphila (Ottman et al. 2017) or by Ruminococcus obeum (Lachnospiraceae) to produce 
propionate through the propanediol pathway (Reichardt et al. 2014; Flint et al. 2014). This 
could explain the increase in the relative abundance in Akkermansia and Lachnospiraceae 
after administering the three doses of our consortium.  
Ingested bacteria can impact resident communities through at least three different 
mechanisms: through trophic interactions, a direct alteration in fitness, or an indirect alteration 
in fitness through altered production of host-derived molecules (Derrien and van Hylckama 
Vlieg 2015). One of the markers considered for successful colonization from bio-therapeutics 
is engraftment (Smillie et al. 2018). Engraftment originally refers to ‘‘incorporation of grafted 
tissue into the body of the host’’ (Miller et al. 2005), and it has been applied to explain the 
stable establishment of a bacterial strain in the human gut (Maldonado-Gómez et al. 2016). In 
our SHIME model, the complexity of the simulated colonic ecosystem allowed for analysing 
the impact of the administered bacterial community on microbial interaction networks, 
independently of host inputs. To ensure engraftment, long-term persistence of the different 
species of the live microbes in the consortium should be monitored in different donors, as 
described by Maldonado-Gómez et al. (Maldonado-Gómez et al. 2016). The beads coated with 
mucin in our model provided a comprehensive overview of the bacterial colonization process. 
For instance, we observed an increase in the relative abundance of unclassified 
Lachnospiraceae, Akkermansia and Bacteroides in the mucosal compartment, after repeated 
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doses. This indicated that some members of the consortium (Akkermansia muciniphila, 
Coprococcus catus, Ruminococcus obeum and Bacteroides thetaiotaomicron and Bacteroides 
vulgatus) may have been successfully engrafted in the mucin compartment. In our experiment, 
we attained long-lasting increased relative abundance of Akkermansia species across 
individuals, as indicated by the community composition at the end of the washout period. 
Previous reports suggest that species traits such as functionality are major drivers of bacterial 
colonisation (Smillie et al. 2018). In this way, the functional redundancy of our consortium may 
have ensured prevalence in the lumen following repeated dosage, even after four days. 
Akkermansia is considered a common member of the autochthonous human gut microbiome, 
which may guarantee permanent colonization as opposed to commercial probiotics belonging 
to lactic-acid producing bacteria (Maldonado-Gómez et al. 2016). Nevertheless, whether 
higher engraftment success is a general attribute of autochthonous members of the 
microbiome, or whether it is specific for certain probiotic strains needs to be elucidated 
(Maldonado-Gómez et al. 2016).   
Metabolic syndrome leads to excess cellular oxidative stress and oxidative damage of 
mitochondrial components, impacting mitochondrial membrane potential (Nicolson 2007). 
Clindamycin is a chlorinated analogue of lincomycin and inhibits basal epithelial transport 
(Goldhill et al. 1996), impacting electrical field stimulation (EFS) (Goldhill et al. 1996) and 
mitochondrial membrane potential (Goldhill et al. 1996). Cl is an atom that is chemically bound 
to the molecule and replaces the hydroxyl group at position 7 in the original lincomycin 
molecule (Swayze, Griffey and Bennett 2007). In our epithelial cell model, the presence of a 
Cl atom in the molecule of the drug reduced the basal short circuit current (Goldhill et al. 1996) 
and disrupted the mitochondrial membrane potential upon exposure to clindamycin. Proper 
mitochondrial membrane potential is a requirement for oxidative phosphorylation (Nicolson 
2007; Mitchell 1966) and impaired mitochondrial oxidative phosphorylation is one of the 
contributors to the development of the metabolic syndrome (Ren et al. 2010). Hence, the partial 
recovery of the membrane potential following the addition of the propionate-producing 
consortium suggests that application of our functional community may be a promising strategy 
to amend microbial dysbiosis and confer beneficial effects towards host epithelium.  
Nowadays, next-generation probiotics and live biotherapeutics are being developed based on 
core members of the microbiome (Olle 2013), as in the case of our propionate-producing 
consortium. Endogenous core bacterial strains included in these biotherapeutics may have 
higher ecological fitness when administered to humans compared to the exogenous strains, 
such as commercial probiotics. However, the concept of ecological performance related to 




3.6 – Conclusion  
In conclusion, members of our gut microbiome can be used as new generation probiotics for 
targeting different health aspects. We confirmed that the established propionate-producing 
consortium can impact functionality by restoring the propionate production after antibiotic-
induced dysbiosis. The key question would be if the propionate-producing consortium can 
impact beyond the ecology of the gut microbiome and influence host health. Importantly, as 
such consortia are to be administered orally, developing carrier matrices to ensure survival 
through the harsh conditions of the upper GI tract should be earnestly considered. Further 
research to determine dose-response outcome and long-term benefits will foster our 
knowledge on novel probiotic consortia. Indeed, understanding strain selection and the 
metabolic pathways for producing different SCFA will aid in the development of functional 
consortia targeted for prevention and management of major health concerns, such as 
metabolic syndrome, or even for personalized nutrition strategies.  
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CHAPTER 4 - Supplementation of a propionate-producing consortium 
improves markers of insulin resistance in an in vitro model of gut-liver 
axis   
 
4.1 - Abstract. 
Microbe-host research from recent years has revealed the gut-liver crosstalk to be an important 
determinant of human health with effects, amongst others, on energy homeostasis. While gut 
microbes produce a huge range of metabolites, specific compounds such as short chain fatty 
acids (SCFA) can enter the portal circulation and reach the liver, which is involved in glucose 
homeostasis and diabetes control. Propionate, a major SCFA that goes in the portal circulation, 
is involved in activation of intestinal gluconeogenesis (IGN), thereby regulating food intake and 
enhancing insulin sensitivity leading to metabolic homeostasis. While microbiome modulating 
strategies may target the increased microbial production of propionate, it is not clear whether 
such effects also trickles through to the hepatic cellular level. Here, we designed a propionate-
producing consortium using a selection of commensal gut bacteria, and we investigated the 
impact of their delivered metabolites in an in vitro enterohepatic model of insulin resistance. 
Liver glycogen storage and different inflammatory markers were evaluated to understand the 
role of the gut metabolites on the gut-liver crosstalk in a simulated scenario of subclinical 
metabolic inflammation. The metabolites produced by our designed consortium were able to 
increase liver glycogen by approximately 57% and decrease pro-inflammatory markers such 
as IL-8 by 12%, thus elucidating the positive effect of our consortium on metabolic function and 
low-grade inflammation. Our results suggest that microbiota-derived products can be a 
promising strategy due to their multipurpose and adaptability, and their potential ability to 




4.2 - Introduction.  
The gut and the liver are interconnected organs from the digestive system, with key absorptive 
and metabolic functions. While the liver is exposed to gut bacteria metabolites and ingested 
nutrients (Brandl and Schnabl 2017) via the portal circulation (Das and Makharia 2014; Chen 
et al. 2017), the liver is also crucial for controlling glucose homeostasis and diabetes. When 
excess glucose is diverted to the liver, insulin is unable to control gluconeogenesis and activate 
glycogen synthesis. However, lipogenesis continues occurring (Samuel and Schulman 2012) 
and re-esterification in the liver may further increase insulin resistance, ultimately leading to 
hyperglycemia and metabolic disorders (Savage et al. 2007). Due to its low expression in adult 
liver, little attention has been paid to lipoprotein lipase (LPL). Liu et al. revealed that hepatic 
LPL is involved in the regulation of plasma LPL activity and lipid homeostasis (Liu et al. 2016). 
Moreover, studies have shown that insulin activates LPL promoting hydrolysis of chylomicrons, 
and LPL activity is reduced in patients with type 2 diabetes (Vergès 2015). Insulin resistance 
has also been associated with increased levels of ApoC-III, an inhibitor of LPL (Vergès 2015). 
Short chain fatty acids (SCFAs) are important energy sources for our body and may go into 
the portal circulation. One the major SCFA is propionate; it is involved in activation of intestinal 
gluconeogenesis (IGN) (Vadder et al. 2014) and acts as a direct gluconeogenic substrate 
leading to regulation in  food intake and glucose metabolism (Weitkunat et al. 2016). In addition 
high ratio of propionate reduces hepatic triglycerides and improves insulin sensitivity 
(Weitkunat et al. 2016) which results in metabolic homeostasis (Todesco et al. 1991; Aspey, 
Chambers and Frost 2018). Moreover, propionate stimulates the gut hormones PYY and GLP-
1 leading to satiety (Chambers et al. 2014; Psichas et al. 2014; Morrison and Preston 2016; 
Tolhurst et al. 2011). In fact, long-term propionate delivery in the gut reduces intra-abdominal 
fat accretion, intrahepatocellular lipid content, and hepatic cholesterol synthesis in humans 
(Chambers et al. 2014; Arora et al. 2011). Indeed, protective effects against inflammatory and 
oxidative stimuli in endothelial cells have been attributed to propionate (Aspey et al. 2018).   
Gut microbial fermentation of non-digestible carbohydrates is the main source of circulating 
propionate in humans (Reichardt et al. 2014; Vogt and Wolever 2003). The above pro-
homeostatic actions of propionate emphasize the contribution of SCFAs in maintaining normal 
physiological functions (Hoyles et al. 2018). Hence, propionate represents a model for  
mutually beneficial interactions between the host and microbiota (Hoyles et al. 2018). In fact, 
absence of gut bacteria, and the subsequent lack of SCFA have been associated with 
increased inflammatory response (Maslowski et al. 2009). Evidence of SCFA to counteract 
cardiometabolic risk factors such as insulin resistance has been uncovered. Previous studies 
have reported the impact of synthetic propionate (Canfora et al. 2015) or have sought to shift 
propionate through dietary interventions (Chambers et al. 2015). Moreover, Akkermansia 
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muciniphila, a mucin degrading gut bacterium that produces propionate and acetate (Derrien 
et al. 2011), was able to reverse the effects of the high fat diet that led to metabolic disorders 
like fat mass gain, metabolic endotoxemia, adipose tissue inflammation, and insulin resistance 
(Everard at al. 2013). These findings suggest that A. muciniphila is a promising candidate of 
the next generation beneficial microbes that can be used for the treatment or prevention of 
metabolic disorders (Cani and de Vos 2017). However, assessing the outcome of bacteria-
derived propionate at cellular level has been scarcely described. In this research, we 
engineered a consortium of gut commensal bacteria for propionate production and we 
investigated the impact of their delivered metabolites and metabolites from A. muciniphila in 
an in vitro enterohepatic model of insulin resistance. We evaluated liver glycogen storage and 
inflammatory markers to elucidate the role of the microbiome metabolites on the gut-liver 
crosstalk during a state of subclinical metabolic inflammation. Modulating the gut microbiome-
host links through relatively simple and targeted interventions represents a tantalizing 
therapeutic prospect. Our results suggest that microbiota-derived products are versatile 
messengers with wide applicability and potentially positive impact on the management of 
metabolic diseases. 
4.3 - Materials and Methods. 
All the reagents and chemicals used in this research for cell work were obtained from Merck 
KGaA (Darmstadt, Germany), unless otherwise stated. 
4.3.1 - Selection of strains for the propionate-producing consortium (PPC) 
Gut commensal strains were selected based on the reported metabolic pathways for 
propionate production (succinate, acrylate, and propanediol pathways) (Reichardt et al. 2014; 
Table 2.1) and as described in Chapter 2 section 2.3.1.  
4.3.2 - Assembly of propionate producing community (PPC)  
The propionate-producing consortium was assembled as described in Chapter 3 section 
3.3.2. It was harvested after 48h incubation at 37°C.  
4.3.3 - Metabolic activity of the propionate producing community (PPC) 
Short-chain fatty acids were collected from the co-culture, extracted with diethyl ether and used 
as benchmarks of community activity (De Weirdt et al. 2017). Total SCFA production was 
defined as the sum of the molar concentrations of acetate, propionate, butyrate, valerate, 
caproate, isobutyrate, isovalerate and isocaproate (De Weirdt et al. 2017).  
 
4.3.4 - Construction of the insulin resistance model using Caco-2, HT29-MTX and HepG2 
The Caco-2, HT29-MTX and HepG2 cells were obtained from the European Collection of 
Authenticated Cell Cultures (Caco-2 ECACC 86010202; HT29-MTX-E12 ECACC 12040401, 
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HepG2 85011430; Public Health England, UK). Routine cell maintenance was carried out as 
previously described in Geirnaert et al. (2017). All the cultures were used between passages 
50 and 60. Cell differentiation and the posterior tests were carried out in double chamber wells 
(Corning® HTS Transwell®-24 well, pore size 0.4 µm; Costar, NY).  
In the apical compartment, the Caco-2/HT29-MTX cells (90/10) were seeded at a density of 
7.5 x 104 cells/cm² on the semipermeable membrane and maintained with Dulbecco’s Modified 
Eagle Medium with high glucose (4.5 g/L) (DMEM) and GlutaMAX, supplemented with 10% 
(v/v) heat-inactivated Fetal Bovine Serum (iFBS, Greiner Bio-One, Wemmel, Belgium) and 1% 
(v/v) penicillin/streptomycin (Life Technologies, Merelbeke, Belgium) until differentiation (15 
days). Refreshments of the apical and basal media were performed every 2 days.  
At day 15 post-seeding, HepG2 cells (5 x 104 cells/cm2) were seeded into the basal 
compartment in Minimum Essential Medium Eagle (MEM) supplemented with 10% (v/v) iFBS 
and 1% (v/v) GlutaMAX™. The co-culture was maintained for 5 days, refreshing the apical and 
basal compartments every 2 days with respectively DMEM-HG or MEM without 
antibiotic/antifungal the apical and basal compartment, respectively. Cells were maintained at 
37°C in a humidified atmosphere and 10% CO2.  
4.3.5 - Cell treatments  
HepG2 cells were maintained with two different D-glucose concentrations: 5mM, referred as 
low-glucose or 30mM, referred to as high-glucose (Weil et al. 2009), added to the basolateral 
compartment of the Transwell system. In order to develop a model of insulin resistance, HepG2 
cells were exposed to high glucose treatments and maintained for 24 hours, followed with 100 
nM insulin for 15 min at the end of the incubation as described by Cordero-Herrera et al. (2014). 
High glucose condition was used in the model to mimic a case of insulin resistance that is 
considered one of the parameters of diabetes. Additionally, filter-sterilized supernatants from 
the treatments described in Annex III, Table S1, were diluted 1:5 (v/v) in DMEM without 
supplementation and added to the apical compartment. This dilution ratio was used to avoid 
the cytotoxicity from the bacterial supernatants on the cells. SCFAs from a 48-hour culture of 
the PPC and of A. muciniphila were determined, and used to prepare a synthetic mixture 
without the bacterial background and having identical concentrations of acetate, propionate 
and butyrate (Annex III, Table S1). These mixtures were prepared from their corresponding 
sodium salts, resuspended in DMEM without supplementation and added to the apical 
compartment. Sampled cells were washed twice with PBS, scrapped, snap frozen and stored 
at -80°C for further analyses. 
DMEM without supplementation (control 1), and sterile bacterial medium diluted 1:5 in DMEM 
without supplementation (control 2) were used as controls. When no differences between 
control 1 and control 2 were observed, only control 2 was reported.  
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4.3.6 - Assessment of epithelial barrier function and cellular viability  
The monolayer integrity was assessed by measuring the transepithelial electrical resistance 
(TEER) and the apparent permeability (Papp) of the paracellular transport marker lucifer yellow 
(LY), as previously described in Geirnaert et al. (2017).  
At the end of the assays, the cellular viability was assessed by Trypan Blue staining and 
manual cell count using a Neubauer chamber and a PrimoVert Zeiss Microscope (Zeiss, 
Belgium). All treatments revealed that viable cells were above 80% of the total.  
4.3.7 - Quantification of inflammatory markers  
IL-8, IL-6, and TNF-α were quantified under high and low glucose treatments using the Human 
IL-8 (CXCL8), IL-6, TNF-α and Mini ABTS ELISA Development Kit (PeproTech, Rocky Hill, 
USA). The detection limits according to the manufacturer were as follows  31 pg/ml TNF-α, for 
24 pg/ml IL-6 and 8 pg/ml IL-8.  
4.3.8 - Glycogen quantification and Lipoprotein Lipase (LPL) activity following insulin 
resistance challenge  
Glycogen quantification was performed in HepG2 cells for all treated and control samples 
following the protocol for Glycogen Assay Kit (Cayman Chemical, Item No. 700480).  
LPL Assay Kit was performed for all treated samples and controls following the manufacturer 
instructions (Cell Biolabs, catalog No.STA-610). The detection limits according to the 
manufacturer were as follows 2.5ug/ml (±0.5ug/ml) glycogen, and ~1 mUnits/mL LPL.  
4.3.9 - Statistical analysis 
All multiple pairwise comparisons were done in GraphPad (GraphPad Prism 7.04, La Jolla, 
CA, USA) using one-way Anova and Tukey’s comparison. Statistical significance was 
assumed at P < 0.05. 
4.4 - Results. 
4.4.1 - Metabolites from the propionate-producing microbial consortium increased glycogen 
storage in hepatic cells 
The enterohepatic model was exposed to different treatments under the low and high glucose  
conditions. Treatments included metabolites from the PPC, from A. muciniphila, from PPC-
Akk, and the synthetic SCFA mixture that was prepared without bacterial background and that 
contained the same amounts of the main SCFAs produced by the PPC and by A. muciniphila. 
Control condition was considered when none of the mentioned treatments were added.  
Under control conditions, glycogen levels in the enterohepatic model were 9.4 ± 0.9 µg/mL, 
and no significant differences between low and high glucose treatments were observed (Figure 
4.1) (Annex III, Table S2). HepG2 cells alone, without contact with Caco-2/HT29-MTX cells 
stored significantly lower glycogen when low (3.2 ± 0.1 µg/mL) and high glucose (6.4 ± 0.5 
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µg/mL) were supplied (Annex III, Table S2). This result reveals active cross-talk between cell 
types, which could promote glycogen synthesis or insulin-response in hepatic cells. 
When the enterohepatic model was exposed to PPC treatment and high glucose, HepG2 cells 
stored significantly higher levels of glycogen (22.6 ± 4.3 µg/ml) than the control (9.4 ± 0.9 
µg/ml) (P < 0.001), A. muciniphila (9.4 ± 0.8 µg/ml) (P < 0.001) or PPC-Akk (9.8 ± 0.5 µg/ml) 
(P < 0.01) treatments, which was not observed when low glucose concentrations were supplied 
(Figure 4.1) (Annex III, Table S2). After the exposure of the enterohepatic model to SCFA 
levels comparable to PPC and Akk, the glycogen content in HepG2 varied between 7.7 and 
11.4 µg/ml, without significant differences between high or low glucose treatments (Figure 4.1) 





Figure 4.1: Glycogen levels were significantly higher when the metabolites from the PPC 
were added to the enterohepatic cell model in high glucose treatments. Other 
treatments did not have any significant effect on the glycogen levels neither on the low 
nor in the high glucose treatments. PPC, propionate-producing consortium; PPC-Akk, 
propionate-producing consortium without A.muciniphila ; Akk, A. muciniphila alone; 
SCFA PPC, synthetic mix of SCFA in identical concentrations to those determined in 
the PPC; SCFA Akk, synthetic mix of SCFA in identical concentrations to those 
determined in a pure culture of A. muciniphila. Different letters above the bars indicate 
significant difference (P <0.05).  
 
4.4.2 - Metabolites from PPC promote LPL activity in the hepatic cells  
LPL is a crucial enzyme for catalyzing the hydrolysis of triglycerides (TG) in circulation and 
plays a critical role in regulating plasma LPL activity and lipid metabolism (Liu et al. 2016). 
However, little attention has been paid to LPL because of its low expression in adult liver.  
LPL levels were not significantly different from the control when the metabolites from 
A.muciniphila alone, and the PPC-Akk were added to the enterohepatic model. In contrast, 
when we added the metabolites of the PPC to the enterohepatic cell model, we observed a 
significant increase on LPL levels (21.191 ± 0.658, P<0.05) when cells were exposed to high 
glucose concentrations (Figure 4.2) (Annex III, Table S3). This indicates that the metabolites 
produced by our PPC enhance LPL levels, which in turn may regulate plasma LPL activity and 







































Figure 4.2: LPL levels were significantly higher when the metabolites from the 
propionate-producing consortium (PPC) were added to the enterohepatic cell model in 
high glucose treatments. Other treatments did not have any significant effect on the 
LPL levels neither when low nor when high glucose concentrations were supplied. 
Different letters above the bars indicate significant difference (P <0.05).  
 
 
4.4.3 - Metabolites from PPC tended to decrease inflammation in liver cells without cytotoxic 
effects 
IL-8 levels in the control treatment varied from 3047 ± 36 pg/mL when low glucose was 
supplied to 3532 ± 135 pg/mL in the high glucose treatment (P < 0.01). IL-8 produced by Caco-
2/HT29-MTX alone was not significantly different between low and high glucose treatments, 
but it was lower than that in the enterohepatic model (1256 ± 263 pg/mL, P < 0.001) (Figure 
4.3) (Annex III, Table S4). A lowering effect on IL-8 was only observed in the high glucose 
treatment following addition of the metabolites of the PPC (PPC: 2802 ± 219 pg/mL; Akk: 3034 
± 61 pg/mL) while no change was observed in the low glucose condition (Figure 4.3) (Annex 
III, Table S4). In contrast, the metabolites of the PPC, PPC-Akk or Akk did not significantly 
impact IL-6 levels in the basolateral compartment when compared to the control treatment 
(Figure 4.4) (Annex III, Table S5). As for the inflammatory marker TNF-α, we observed that the 
metabolites from A. muciniphila significantly increased the TNF-α levels in the basolateral 




































indicate that metabolites from the PPC have the tendancy to decrease inflammation markers 
like  IL-8 and TNF-α associated to insulin resistance and diabetes, while counteracting 
cytotoxicity as IL-6 remained unchanged. However, results from the supernatant of A. 
muciniphila indicated the this bacteria can induce inflammation in case of insulin resistance.  
   
Figure 4.3: Metabolites from the PPC tended to decrease IL-8 levels when added on the 
enterohepatic cell model with insulin resistance. Data were compared using one-way 
ANOVA following by Tukeys test to test the difference between the the different 







































Figure 4.4: Metabolites from the PPC did not have any effect on IL-6 levels. Data were 
compared using one-way ANOVA following by Tukeys test to test the difference 




Figure 4.5: Metabolites from Akkermansia significantly increased TNF-α in the insulin 
resistance enterohepatic model. Metabolites from the PPC and other treatments did not 
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following by Tukeys test to test the difference between the the different treatments. 
Different letters above the bars indicate significant difference (P<0.05).  
 
4.4.4 - Epithelial barrier function was maintained upon the addition of bacterial consortia-
derived metabolites 
The epithelial barrier integrity of the enterohepatic model was evaluated by two functional 
measures of the tight junctions: TEER and Papp of LY. Prior to the treatments, the 
enterohepatic model had average TEER values (n = 6) of 682 ± 46 Ω, without significant 
differences between plates. TEER values of Caco-2/HT29-MTX alone were significantly lower 
(483 ± 22 Ω; n = 6, P < 0.01). TEER values were maintained above 80% of the initial TEER 
during the 24 hours of exposure of the cells to the different treatments, indicating that the 
epithelial barrier function was not disrupted during the assay (Annex III, Table S7). 
Low and high glucose levels influenced the TEER values in models not exposed to microbial 
metabolites (630 ± 32 Ω and 575 ± 49 Ω, respectively, P < 0.05). On the contrary, glucose 
concentration did not impact TEER values in the other treatments. However, TEER was 
significantly improved when the PPC metabolites were supplied, in comparison with the 
unexposed controls challenged with low (PPC: 707 ± 33; control: 630 ± 32 Ω) or high (PPC: 
677 ± 16; control: 575 ± 49 Ω) glucose concentrations. The same trend was observed in the 
synthetic mixture of SCFA mimicking the PPC-derived SCFA, with values significantly higher 
than the controls in the low (676 ± 49 Ω) and high (663 ± 12 Ω) glucose levels (P < 0.05). 
However, in the case of A.muciniphila, there was a significant improvement only in the case of 
high glucose (Akk: 639 ± 24; control: 575 ± 49 Ω) (P < 0.05), compared to low glucose (Akk: 
607 ± 11; control: 630 ± 32 Ω). No significant effect on TEER values  for the synthetic mixture 
of SCFAs from Akk was observed neither in low nor high glucose conditions.   
In addition, the percentage of LY transport in the enterohepatic model was below the threshold 
for considering damage in the epithelial barrier (1.7 ± 0.3%), but LY transport was significantly 
higher in the Caco-2/HT29-MTX alone (1.2 ± 0.04%, P<0.01). Small but significant differences 
were observed between the enterohepatic model exposed to low (1.2 ± 0.04 %) and high (1.5 
± 0.1 %) glucose levels in the control treatment (P < 0.05). LY transport in the high glucose 
treatment after exposure to the PPC (1.32 ± 0.09 %) or Akkermansia (1.29 ± 0.06%), was 
significantly decreased (P< 0.01), but not when the PPC-Akk metabolites were added (1.51 ± 
0.05%) (Annex III, Table S8).  
We only consider the epithelial barrier assessment as a proof-of-concept of the impact on the 
epithelial barrier integrity during the assay.  
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4.5 - Discussion 
The gut-liver axis communicates organs of the digestive system through the biliary tract, portal 
vein and systemic cross-talk, hence gut factors can regulate liver glucose and lipid metabolism 
(Tripathi et al. 2018). Our in vitro model may possess some limitations associated to the cancer 
origin of the cell lines, because some differences in protein expression between the in vitro 
models and in vivo samples may be present. However, the stable phenotype, unlimited life 
span and high availability increase the reproducibility and repeatability of the assays. In 
addition, the co-culture of multiple cell lines may change the phenotype and cell behavior, 
generating unique and representative in vitro models. We observed significant differences 
between previously reported cell models like Caco-2/HT29-MTX alone and HepG2 alone and 
our entrerohepatic model in terms of epithelial barrier function and functionality. In addition, 
the model was developed by the combination of simulated epithelial layer of Caco-2 
(enterocyte-like) and HT29-MTX cells (goblet-like) cells, in basolateral contact with HepG2 
(hepatocyte-like). For this reason, the use of our model as an improved tool for mimicking the 
enterohepatic system is representative.  
Previous research demonstrated the relationship between gut microbiome and metabolic 
diseases. Abnormal shifts in the composition of gut microbiota contribute to metabolic 
diseases, including obesity, type 2 diabetes (T2DM) and cardiometabolic diseases (Cani and 
de Vos 2017, Zhao et al. 2018). The main characteristics of obesity and type 2 diabetes are 
altered gut microbiota, gut barrier disruption, and inflammation (Zhao et al. 2017). A key 
element in the gut-liver crosstalk is the intestinal permeability, mainly maintained by tight 
junction complexes (Tripathi et al. 2018). Hyperglycemia and insulin resistance have been 
associated with several inflammatory factors which may lead in reduced epithelial barrier 
function (König et al. 2016; Thaiss et al. 2018). Glucose causes disruption for tight junctions 
increasing insulin resistance. New research published in Science demonstrates that 
hyperglycaemia is linked to and drives intestinal barrier dysfunction and the resultant risk of 
systemic dissemination of enteric infection in animal models (Thaiss et al. 2018). The findings 
pinpoint glucose levels as having a key role in influencing intestinal barrier function, and 
highlight a potential mechanism for the altered intestinal epithelial integrity observed in the 
metabolic syndrome (Thaiss et al. 2018). As a result, there was a disruption in the epithelial 
barrier function that led to its reduction. Therefore, lost of epithelial barrier may allow the 
passage of bacterial metabolites (e.g SCFA) to the basolateral compartment, thus increasing 
the contact of HepG2 cells with bacterial compounds.  
When the enterohepatic model was exposed to glucose levels and insulin mimicking insulin 
resistance  (30 mmol/L), the epithelial barrier function was significantly reduced. However, 
supplementation with PPC- or Akk-derived metabolites restored this parameter, indicating that 
other bacterial metabolites besides SCFA may be relevant for regulating the intestinal barrier 
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function. Pili-like proteins from A.muciniphila can modulate the gut barrier function and 
strengthen the integrity of the epithelial Caco-2 cell layer (Ottman et al. 2017). We observed 
that the metabolites derived from the PPC-Akk did not support the recovery of the intestinal 
barrier, suggesting that A. muciniphila  may be a key element in regulating intestinal 
permeability. Indeed, A. muciniphila has been proposed as a promising candidate for the 
treatment or prevention of metabolic disorders (Cani and de Vos 2017). However, the 
metabolites from A. muciniphila alone or the consortium without A. muciniphila were not able 
to significantly increase glycogen storage or LPL levels in hepatic cells in the case of 
enterohepatic model of insulin resistance. This effect may be caused by the different 
composition of SCFA in the different treatments. This mainly suggests that A. muciniphila is 
not able to accomplish all the jobs the PPC was able to do, signifying the A. muciniphila 
requires the presence of all the other members of our designed consortium in order to achieve 
fully. Moreover, this implies that there is a syntrophic relationship between all the seven 
members of the PPC that lead to their optimal effect. 
We revealed the ability of the metabolites from our PPC to increase glycogen storage, while a 
synthetic mixture of SCFA failed to replicate such effect. This finding confirms that other 
bacterial metabolites beyond SCFA may act as signaling factors in glycogen synthesis. Studies 
have shown that liver glycogen accumulation can protect against the negative effects of high 
fat diet, such as glucose intolerance (López-Soldado et al. 2014). Accumulation of hepatic 
glycogen contributes to decreased food intake and lower body weight and adiposity (Ritter et 
al. 1994; Grill et al. 1995; López-Soldado et al. 2014). For this reason, hepatic glycogen can 
act as a potential target for pharmacological manipulation of diabetes and obesity (López-
Soldado et al. 2014). Our findings stress the importance of the role that microbiota-derived 
metabolites have on the gut-liver crosstalk and ultimately on the glycogen regulation and 
energetic metabolism. Gut-derived SCFAs play important roles as substrates for glucose, 
cholesterol and lipid metabolism (den Besten et al. 2013). Propionate can enhance the lipid 
buffering capacity of adipose tissue by increasing LPL-mediated triglyceride extraction, 
resulting in reduced lipid overflow to the adipose tissue (Canfora et al. 2015). We observed 
that only the metabolites from the PPC significantly contributed to increased LPL levels in 
hepatic cells. While A.muciniphila alone mainly produced acetate, the PPC contained a mixture 
of propionate and acetate. Acetate has been reported to act as lipogenic substrate, but 
propionate suppresses lipogenesis through decreased expression of fatty acid synthase 
(Canfora et al. 2015). Thus, the optimal effect of the PPC was obtained when all seven 
members of the consortium including A.muciniphila were present. Successful cross-feeding 
interactions between gut microbes may be fundamental for de novo gluconeogenesis (den 
Besten at al. 2013) and attenuation of lipogenesis.  
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IL-8 levels in the enterohepatic model were higher than in the Caco-2/HT29-MTX co-culture, 
indicating an active production of IL-8 by HepG2 cells (Gómez-Quiroz at al. 2003). The 
supernatant from our designed PPC tended to decrease IL-8 levels, implying the presence of 
potential anti-inflammatory properties. IL-8 is a pro-inflammatory adipocytokine linked to insulin 
resistance, and its reduction may prevent diabetes (Kobashi et al. 2009). TNF-α has also been 
reported as key molecule contributing to metabolic syndrome features such as obesity and 
insulin resistance (Hotamisligil et al. 1993, Miyazaki et al. 2003). Similarly, IL-6 is another 
cytokine that may contribute to the pathogenesis of obesity and insulin resistance (Jung and 
Choi 2014) but this correlation is still controversial (Di Gregorio et al. 2004). Propionate 
supplementation has been reported to reduce mRNA expression and secretion of TNF-α 
(Canfora et al. 2015). Studies have also reported that TNF-α is increased during insulin 
resistance, and Akkermansia is able reduce TNF-α  levels (Zhang et al. 2018). Surprisingly, 
we could observe that supernant of A.muciniphila increased TNF-α levels in the insulin 
resistance enterohepatic model indicating a pro-inflammatory property. Ottman et al. (2017) 
previously reported that A. muciniphila induced TNF-α in human derived peripheral blood 
mononuclear cells (PBMCs),  indicating that A. muciniphila  cannot be strictly defined as anti- 
or pro- inflammatory,  but may instead play a major role in preserving the balance of the gut 
ecosystem. In addition,  We uncovered that IL-6 levels were not affected by any of our 
treatments. As IL-6 is an important inducer of the acute phase response and infection defense, 
our results indicate that the PPC- and the A.muciniphila -derived metabolites are not cytotoxic 
and do not produce liver injury.   
4.6 - Conclusion. 
In conclusion, our findings provide a novel overview on the gut microbiome-liver crosstalk and 
its positive effect on metabolic function and low-grade inflammation. The optimal effect of the 
consortium was obtained when all members were present and successfully cross-feeding, but 
longer supplementation periods and higher number of doses may be required for a long-term 
effect. Targeted interventions for managing metabolic diseases have become relevant on the 
past years. Nevertheless, using members of our native microbiome may represent a promising 
strategy, as their adaptability and functional versatility can be sourced for engineering 
multipurpose consortia to prevent and counteract risk factors of metabolic disease.  
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CHAPTER 5 - GENERAL DISCUSSION. 
5.1 - Positioning the research 
Metabolic syndrome is defined by the WHO as a pathologic condition characterized by 
abdominal obesity, hypertension, insulin resistance, and hyperlipidemia (Saklayen 2018). This 
syndrome is associated with other risk factors such as type 2 diabetes, cardiovascular disease, 
stroke and other comorbidities (Alberti el al. 2006; Saklayen 2018). It has been reported by the 
International Diabetes Federation (IDF) that the prevalence of metabolic syndrome is around 
25% of the world’s adult population (O'Neill and O'Driscoll 2015) and this percentage can vary 
with ethnicity, age, gender, and race (Kaur 2014). Higher prevalence of metabolic syndrome 
leads to higher morbidity and mortality (Moreira et al. 2014). Moreover, patients with metabolic 
syndrome have a fivefold higher risk to develop diabetes than people without metabolic 
syndrome (Alberti et al. 2006). As a result, this non-communicable disease has become a 
major public health issue (Saklayen 2018).  
Studies in animals and humans have confirmed that the gut microbiota exerts a significant role 
in the pathogenesis of the metabolic syndrome (Festi et al. 2014). Research has provided 
evidence that the gut microbiota can impact host metabolic balance by modulating energy 
absorption, appetite, gut motility, glucose and lipid metabolism, in addition to hepatic fatty 
storage (Festi et al. 2014). Gut microbial composition and functions are influenced by different 
factors such as diet, use of antibiotics, mode of delivery at birth, genetics and other 
environmental factors (Wen and Duffy 2017). Therefore, dysbiosis in the human gut microbiota 
caused by any of those factors impacts the host energy balance leading to metabolic disorders 
(He et al. 2018). Studies have shown that the manipulation of the gut microbiota by the 
administration of probiotics can reduce intestinal low-grade inflammation and improve gut 
barrier integrity thereby enhancing metabolic balance and endorsing weight loss (Festi et al. 
2014). However, the phylogenetic origin of probiotics is currently limited to conventional 
formulations of Bifidobacterium, Lactobacillus species and other lactic acid bacteria (LAB) 
(Govender et al., 2013) or yeast strains. This may decrease the probiotic effectiveness in the 
prevention or therapy of diseases entailing severe dysbiosis. Hence, a functionally and 
phylogenetically diverse probiotic product may be desirable when alterations in the gut 
microbiota composition are present (Marotz and Zarrinpar 2016; El Hage et al. 2017). 
Propionate, a major short chain fatty acid in the gut that has been less studied compared to 
the other metabolites, provides different health-promoting effects (Hosseini et al. 2011). 
Propionate has anti-lipogenic, cholesterol-lowering, glucose-controlling (Kasubuchi et al. 
2015), anti-inflammatory and anti-carcinogenic effects (Hosseini et al. 2011; Vinolo et al. 
2011). Moreover, propionate can enhance satiety as it can upregulate the postprandial plasma 
peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) hormones from colonic cells and 
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induce leptin production (Hosseini et al. 2011) which could be very interesting in the time in 
which the incidence of obesity is increasing around the world due to different factors. Studies 
that involved proteomic work suggested that the effects of propionate at the cellular level can 
differ from the action of butyrate (Kilner et al. 2012; Reichardt et al. 2014). The SCFA receptors 
FFA2 and FFA3 can mediate some of the actions of propionate, but still more investigation is 
needed to determine the exact mechanisms (Ulven 2012). Evidence showed that propionate 
can activate FFAR3 leading to increase in heart rate and energy expenditure through 
sympathetic activation. This sympathetic activation by FFAR3 leads to the release of 
noradrenalin from the sympathetic neurons (Inoue et al. 2012) indicating that FFAR3 regulates 
sympathetic activity by sensing the nutritional state, thus maintaining body energy homeostasis 
(Kasubuchi et al. 2015). For this reason, enhancing propionate production in the gut is an 
fascinating approach to increase satiety and maintain metabolic health (Reichardt et al. 2014). 
Our research aimed at establishing a propionate-producing consortium composed of seven 
different strains of the human commensal gut bacteria. This designed consortium could be 
used as synthetic community that can boost propionate production in the gut and improve 
metabolic health.  
Our research questions were: 
1) Would our designed propionate-producing bacterial consortium restore the propionate 
production after the antibiotic-induced dysbiosis  in the colon? 
2) How do metabolites from our designed consortium act on an enterohepatic cell model 
of hyperglycaemia? 
To unravel this puzzle, we tested the effect of our engineered propionate-producing 
consortium on an antibiotic-dybiosed bacterial community in vitro, and we investigated the 
effect of the metabolites from our consortium on an enterohepatic in vitro cell model of 
hyperglycaemia. Moreover, we studied the survival of our consortium in an in vitro model 
of the upper GIT under its harsh conditions. Three research chapters elaborate on the 
different outcomes of our research.  
5.2 – Main research outcomes  
The main research outcomes are summarized in figure 5.1.  
In Chapter 2, we discussed the establishment of the propionate-producing consortium (PPC) 
and investigated in vitro survival through the upper gastrointestinal tract. Our candidates for 
the consortium were selected to cover all the different metabolic pathways that lead to 
propionate production. All the strains were grown separately and then co-cultured together in 
a fed batch experiment for 48 hours to perform the possible cross-feeding leading to high 
propionate production (average of 34.5 mM). The PPC was always freshly prepared and 
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harvested after 48 hours to perform all the different tests throughout this research. After testing 
the survival in the upper GIT in vitro (TSI model), we observed that not all the strains survived 
the harsh conditions of the upper GIT, especially with the different concentrations of bile salts 
throughout the small intestine. This suggests the importance of having a protectant carrier, 
such as an encapsulation technique, to protect the consortium through its passage in the upper 
GIT and release it in the colon, where the consortium should take action.  
Chapter 3 investigated the functionality of our propionate-producing consortium following 
antibiotic induced dysbiosis in the M-SHIME system. Our designed consortium has proven to 
restore functionality in terms of propionate production for the dysbiosed microbial community 
in vitro. Moreover, the PPC restored functionality by either direct engraftment of some of its 
members or indirect reinforcement for other genera involved in propionate production. In 
addition, our designed consortium supported the partial recovery of the epithelial mitochondrial 
membrane potential after antibiotic disruption. 
The gut-liver crosstalk was investigated in Chapter 4, where the supernatant from our 
designed consortium was added on an enterohepatic cell model of hyperglycaemia. Liver 
glycogen storage and inflammatory markers were evaluated to assess the role of the gut 
microbiota metabolites on the gut-liver crosstalk under subclinical metabolic inflammation. 
Glycogen storage and LPL activity in the hepatic cells were increased when the supernatant 
from the PPC was added. Furthermore, the metabolites from the PPC decreased inflammation 
in the hepatic cells. The effects of the supernatant from the  PPC were compared to those of 
Akkermansia muciniphila, and the results indicated that the PPC without A. muciniphila or A. 
muciniphila alone lacked the same positive effects. This indicates that A. muciniphila can only 
effectively act when combined together with all the other members of the consortium, and the 
optimal effect of the consortium is only obtained when all members are present and 
successfully cross-feeding. For long-term effect, longer supplementation periods and higher 




Figure 5.1: Schematic overview of the main outcomes of the research chapters and 
their main outcomes. 
 
5.3 – Connecting antibiotic-associated dysbiosis to metabolic syndrome 
The intestinal microbiota plays a critical role in the aetiology, development and modulation of 
several diseases. Amongst the important global and public health diseases are obesity and 
metabolic syndrome (Economopoulos et al. 2016). The role of gut microbiota in metabolic 
syndrome includes several mechanisms such as increased energy harvest, production of toxic 
metabolites, and an increase in intestinal permeability leading to high levels of 
lipopolysaccharides (LPS) in the systemic circulation, and thereby low-grade inflammation 
(Economopoulos et al. 2016). Metabolic syndrome in adults can be caused by a disturbance 
in the gut community as a result of excessive and misuse of antibiotics in early life 
(Economopoulos et al. 2016).  
Antibiotics can improve human lives by treating or preventing diseases and they are prescribed 
in most countries (Quigley 2011). However, antibiotic consumption can alter gut microbial 
ecology and the interaction with the host metabolism (Perez-Cobas et al. 2013). In Chapter 3, 
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the negative effects on the gut microbiota upon antibiotic addition were evaluated, and we 
observed a decrease in diversity in the colon community in addition to decrease in cell count. 
Moreover, we detected that addition of clindamycin caused disruption of the mitochondrial 
membrane potential when it was added to the caco-2 cells.  
5.4 - Restoration of dysbiosis with “microbial-based” products  
The intestinal microbial community contributes to important functions in the body such as 
nutrient metabolism, calibration of metabolic functions, education of the immune system, and 
host defence against pathogens (Flint et al. 2012; Maranduba et al. 2015). For this reason, gut 
dysbiosis, or the disturbance in the gut microbiome balance can lead to several pathologies. 
During dysbiosis, there is loss of overall microbial diversity and parallel overgrowth of 
pathobionts (Schippa et al. 2012; Petersen and Round 2014; Carding et al. 2015; Gagliardi et 
al. 2018) as we could observe in our case upon addition of clindamycin in Chapter 3. To 
maintain the eubiotic state of the gut microbiome, several strategies have been followed 
including administration of probiotics, prebiotics, symbiotic, faecal microbial transplant, and 
bacterial consortium transplant (Gagliardi et al. 2018). All of these strategies aim to replace 
the harmful microbes with favourable ones to restore the balance.  
Preclinical studies have been conducted and proven that there are promising results with 
strains that are different from the classic Lactobacillus and Bifidobacterium strains (Neef and 
Sanz 2013; Patel and DuPont 2015). These strains could be related to next generation 
probiotics including Akkermansia muciniphila, members of Clostridium clusters IV, XIVa, and 
XVIII, and F. prausnitzii (Schneeberger et al. 2015). As next-generation probiotics must include 
strains belonging to major gut microbiota groups, should be safe and possess potential 
beneficial effects (Martín et al. 2017), more strains with the mentioned characteristics could be 
considered potential candidates for next generation probiotics (Gagliardi et al. 2018). Since 
the cooperating nature of microbiomes seems to be an indispensable trait of the gut microbiota 
in health and disease, studies should consider developing multi-species consortia impacting 
this system of cooperating organisms and that ensures the strong and long-term restoring 
effect. For instance, a live biotherapeutic was developed by selecting 100 different commensal 
strains with a range of abundant numbers in the microbiota and successfully modulated the 
intestinal microbiota of elderly people (Le 2017). In addition to this successful biotherapeutic, 
other studies were conducted with multi-strain bacteria and showed promising results. These 
studies included the combination of 17 Clostridium strains of human origin, which reduced the 
severity of colitis in rodents, and the mixture of VSL#3 (composed of Lactobacillus casei, 
Lactobacillus plantarum, Lactobacillus bulgaricus, and Lactobacillus acidophilus; 
Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis; and S. thermophilus) 
that showed positive effects in ulcerative colitis treatment (Madsen 2001). Moreover, other 
multi-species consortia showed positive effects on IBS and other diseases (Gagliardi et al. 
104 
 
2018). This indeed emphasizes the importance of having a multi-species biotherapeutic that 
can actually modulate the gut microbiome and not to be restricted to using bacteria with 
incomplete functionality and single phylogenetic origin. In addition, omics technologies could 
assist to establish networks of bacterial consortia that work jointly to influence human 
physiological processes (Gagliardi et al. 2018).  
5.5 – Importance of tailored therapies to restore gut dysbiosis 
Bacterial consortium transplant  can modulate the gut microbial ecosystem, and studies have 
confirmed a complete recovery from antibiotic-induced intestinal dysbiosis with either FMT or 
bacterial consortium transplant, indicating that the effects of bacterial consortium transplant 
were similar to those of the FMT (Li et al. 2015; Petrof and Khoruts 2014). Therefore, a 
characterized community developed from faecal bacteria can be used to substitute FMT (Sbahi 
and Di Palma 2016). RePOOPulate, is a bacterial consortium established from 33 different gut 
bacteria isolates from a healthy human donor, and it was used to treat recurrent CDI (Petrof et 
al. 2013). As a result, biotherapeutics or synthetic microbial consortia for treatment or 
prevention of disease can be assembled from native commensal gut bacteria with beneficial 
properties (Olle 2013; Ding et al. 2016). Bacterial consortia are usually well defined and 
characterized and may guarantee standardization when the proportions of each bacterium in 
the consortium are defined. They could also be tailored to the type and level of dysbiosis 
(Gagliardi et al. 2018). Furthermore, patients’ safety could be ensured with an in-depth 
characterized community such as the bacterial consortium transplant, rather than the 
uncharacterized nature of the FMT. Several studies have been conducted to determine 
personalised therapies to rebalance the intestinal ecosystem; however, the challenge is that 
there is no universal cure due to different factors impacting the gut microbiome homeostasis. 
Prescription of tailored microbial therapies specific for different types of dysbioses should 
carefully consider the gut microbiota in each patient by assessing data from “omics” 
technologies (Gagliardi et al. 2018). These platforms could allow for characterizing the 
microbial community in each patient and its functions and examining the genetic potential of 
the community (Gagliardi et al. 2018).  
The low-diversity dysbiosis in the gut is characterized by the changes in bacterial metabolic 
flux, and decreased relative abundance of many species including Lachnospiraceae and 
Ruminococcaceae (Kriss et al. 2018). Similar scenario was observed upon the addition of 
clindamycin during our SHIME run. Our tailored propionate-producing consortium restored the 
in vitro propionate production altered upon the clindamycin-induced gut dysbiosis, and it was 
also able increase the relative abundance of Lachnospiraceae (Chapter 3). However, diversity 
and richness of the adult microbiome may be a poor marker of dysbiosis, as this could also be 
caused by different factors such as transit time (Bajaj et al. 2017). Nevertheless, dysbiosis can 
also come in many different forms, some of which have no change or increase in diversity, so 
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efforts to reverse the low-diversity dysbiosis must consider the different attributes of the 
specific diseases detected (Kriss et al. 2018). For this reason, considering tailored bacterial 
consortia for specific diseases is also crucial.  
5.6 – Practical considerations for microbial-based products  
5.6.1- Interactions between bacteria in the synthetic microbial consortium 
The human microbiota refers to a microbial ecosystem living in the human body that has been 
linked to human health and disease status (Wang et al. 2017). The development of 
biotherapeutics is rapidly evolving, and their potential benefits have been recognized for some 
time although their effectiveness is not completely demonstrated yet (Chapman, Gibson and 
Rowland 2011). In fact, synthetic microbial consortia could perform better than monocultures, 
thus providing a new frontier for synthetic biology (Brenner, You and Arnold 2008; Gerchman 
and Weiss 2004; Purnick and Weiss 2009). The design principles for the synthetic microbial 
consortia are based on the interactions between microbes including the cell-to-cell 
communication and metabolites exchange (Ding et al. 2016). It is important to focus on the key 
signal molecules, on the production, diffusion, absorption, consumption, and response of 
metabolites in order establish and improve the synthetic microbial consortium (Ding et al. 
2016). In addition, selecting phylogenetically distant species for co-culturing leads the 
consortium to gain novel functionality and higher production efficiency (Lindemann et al. 2016). 
Thus, fitness mechanisms and cross-feeding interactions are the main considerations to obtain 
a stable, efficient and controlled synthetic microbial consortium (Ding et al. 2016). As a result, 
preadaption of the seven strains in our consortium was important as it mimics the community 
characteristics in terms of the different competitive and cooperative interactions that occur 
between bacteria in communities. Ecological studies have reported that organisms in nature 
interact in different modes that range from competitive or predatory behaviors to commensal 
and mutualistic exchanges (Mitri and Foster 2013). Microbes that live within communities 
interact concurrently by competing for some resources while exchanging others. Over time, 
these microbial behaviors create interspecies dependencies which is established by differing 
specialized phenotypes across various microbes. These facts cause a key challenge for 
engineering consortia with stable interactions as functions across a microbial population has 
to be understood in order to achieve desirable population-level behaviors (Johns et al. 2016). 
When designing our propionate producing consortium, the different metabolic pathways for 
propionate production were considered. The selected seven different strains (Figure 5.2) from 
different phylogenetic origin were supposed to cross-feed using the metabolites described in 
Chapter 2. Moreover, to optimize and get a reproducible propionate-producing consortium, 
different incubation durations and feeding patterns were assessed to obtain the optimal 




Figure 5.2: The different pathways for propionate production (Acrylate, Succinate, and 
Propanediol). The seven different bacteria that we selected are specified in each 
pathway they take to produce propionate. This figure has been adapted from Louis et 
al. (2014). 
 
5.6.2 – Required dosing 
The doses of probiotics needed to achieve the clinical efficacy is variable. Recommendation 
for the products containing probiotics is a minimum viable cell number of 106 and 108 CFU/g 
of the product final or 108–1010 CFU/day (Champagne et al. 2011).  Although probiotics are 
generally labelled as safe, they could also cause unfavourable events in some cases, such as 
systemic infections, altered metabolic pathways, intensified immune stimulation, gene transfer, 
and gastrointestinal disorders. Thus, additional studies are needed to specify the occurrence 
and severity (Doron and Snydman 2015; Gagliardi et al. 2018). Additionally, the minimal dose 
or numbers required to achieve a probiotic effect have not been described. The dose required 
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to treat an acute illness with a specific probiotic can be lower or higher in order of 10-100 folds 
or more in terms of CFU (Minelli and Benini 2008). For instance, in acute infectious diarrhoea, 
higher doses for short term seem to be more effective than low doses, while in chronic or 
immunological disease, the effect also counts on the durations of the treatment (Minelli and 
Benini 2008). As a result, it can be deduced that probiotic effects seem to be dose-dependent. 
Nevertheless, since most of the studies are done in vitro, the dose effect stays controversial. 
It has also been reported that the usual effective dose for probiotics in humans is 107-109 
CFU/mg per day (Minelli and Benini 2008). Studies have indicated that dose, timing and 
duration of the treatment are important to determine the optimal effect of the probiotic (Minelli 
and Benini 2008). It could also be possible that the probiotic colonization is impacted by the 
quantity of the native microbiome present (BC Dairy 2019) that can differ between individuals. 
In this context methods for quantification of numbers coupled to beneficial bacterial activity are 
needed. In Chapter 3, we described how we quantified the absolute numbers of each taxon, 
upon rescaling the relative abundance of each genus based on flow cytometry cell counts, as 
described by Props et al. (2017). Moreover, Vandeputte et al. also reported that a workflow for 
the quantitative microbiome profiling can be built through parallelization of amplicon 
sequencing and flow cytometric enumeration of microbial cells (Vandeputte et al. 2017). 
However, as our study has been conducted in vitro, no final conclusion can be made about the 
required dose of the PPC that is needed to reach the long-term positive effect. Yet, the positive 
effect on the mitochondrial membrane potential with only one dose of PPC supernatant 
(Chapter 3), suggests that a full recovery may be achieved with more doses. This proposal of 
multiple doses could also apply to the hyperglycaemia-induced cell model, where the 
supernatant from only one dose of PPC promoted positive effects (Chapter 4). 
5.6.3 - How to protect the biotherapeutic from the harsh conditions during the passage in the 
GI tract? 
Overall, biotherapeutics or synthetic consortia need to maximize its accumulation in the 
targeted compartment as any administered drug.  This would require four key components: the 
delivery vehicle, the necessary stability to reach the target site, retention within the intended 
site, and proper timing for the release of the consortium to function effectively (Bae and Park 
2011). 
To reach its target site, which is the colon, the biotherapeutic or the synthetic microbial 
consortium has to pass the harsh conditions of the upper GI tract including gastric acid and 
bile salts. In the case of the propionate-producing consortium, the strains used were anaerobic 
and cannot survive the acidic conditions, so they will need a protectant carrier. 
Microencapsulation is a protectant technique that has been reported to protect probiotics 
during their passage in the gastrointestinal tract; it also allows the diffusion of substrates and 
metabolites in and out of the capsule (Mortazavian et al. 2012). Microencapsulation also aims 
108 
 
to make the probiotic reach the target site in the gastrointestinal tract, and it guarantees 
immunomodulation, thus there will be no interaction between the immune system and the 
entrapped bacteria (Prakash and Jones 2005; Prakash and Martoni 2006). It has been reported 
that microencapsulation can preserve probiotic cells from detrimental conditions such as low 
pH and high acidity (Sun and Griffiths 2000), bile salts (Lee and Heo 2000), molecular oxygen 
in case of obligatory anaerobic microorganisms, and heat and cold shocks during processing 
techniques (Mortazavian et al. 2012). This enhances the survival of bacteria in foods and dairy 
products (Solanki et al. 2013). In our study, the testing took place in the transverse 
compartment, as this consortium is supposed to be protected by a certain capsule that releases 
its content in the transverse colon where the consortium is supposed to take action.  
5.7 – Postbiotics: New concept for gut health  
Studies have delivered evidence of several mechanisms leading to the health-promoting 
effects of selected gut bacteria. These mechanisms include, the modification of gut microbiota, 
the competitive adherence of epithelium and the mucosa, enhancement of epithelial barrier 
function, and the modulation of the immune system (Bermudez-Brito et al. 2012; Vyas and 
Ranganathan 2012). Although these mechanisms have been linked to bacterial viability 
(Sanders 2009), recent evidence suggests that viability is not essential to accomplish the 
health-promoting effects, as not all the mechanistic or clinical benefits are related to this 
characteristic (Aguilar-Toalá et al. 2018). As a result, the term of paraprobiotic and postbiotic 
emerged, indicating that viability is not necessity for the health benefits, and this would offer a 
potential for their use in functional foods (Aguilar-Toalá et al. 2018). Parabiotics, also referred 
to as non-viable probiotics or ghost probiotics, can confer health benefits when administered 
in adequate amounts (Taverniti and Guglielmetti, 2011; Tsilingiri and Rescigno 2013). Bacterial 
cell inactivation leads bacteria to be unable of growing, and thus they can retain the beneficial 
health effects that their viable form provided (de Almada et al. 2016). The term postbiotics can 
also refer to the metabiotics, biogenics, or metabolites like cell-free supernatants that are 
considered soluble factors or metabolic by-products secreted by live bacteria or released after 
bacterial lysis (Aguilar-Toalá et al. 2018). These by-products can provide physiological benefits 
to the host by offering supplementary bioactivity (Aguilar-Toalá et al. 2018).  For instance, 
bacterial metabolites such SCFAs are considered pivotal mediators of the host-microbiota 
communication and can elicit several modulatory effects on the host (De Vadder et al. 2014; 
Vieira, Fukumori and Ferreira 2016). Other soluble by-products resulting from postbiotics are 
enzymes, peptides, teichoic acids, organic acids, cell surface proteins, peptidoglycan-derived 
muropeptides, vitamins, endo- and exo-polysaccharides, and plasmalogens (Konstantinov et 
al. 2013; Oberg et al. 2011; Tsilingiri and Rescigno 2013). Although the health benefits of 
postbiotics are not fully clarified, scientific records have provided evidence that postbiotics 
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have different functional properties such as antioxidants, antimicrobial and immunomodulatory, 
yet not limited to those only. These properties can have a positive impact of microbiota 
homeostasis or the host signalling and metabolic pathways which impact the physiological, 
immunological, regulatory and metabolic reactions (Sharma and Shukla 2016; Shenderov 
2013). Few studies have reported the findings on postbiotics mainly from Lactic acid bacteria 
(Cicenia et al. 2014; Konstantinov et al. 2013; Patel and Denning 2013). Aguilar-Toalá et al. 
(2018) reported some new outcomes on postbiotics coming from next-generation probiotics 
such as Faecalibacterium prausnitzii. Postbiotics are differentiated by their elemental products 
such as lipids (e.g. butyrate, propionate, dimethyl acetyl-derived plasmalogen), proteins (e.g. 
lactocepin, p40 molecule), carbohydrates (e.g. galactose-rich polysaccharides, and teichoic 
acids), vitamins/co-factors (e.g., B-group vitamins), organic acids (e.g., propionic and 3-
phenyllactic acid) and complexes molecules such as peptidoglycan- derived muropeptides, 
lipoteichoic acids (Konstantinov et al. 2013; Tsilingiri & Rescigno 2013). They are also 
differentiated by their physiological functions which include immunomodulation, anti-
inflammatory, hypocholesterolemic, anti-obesogenic, anti-hypertensive, anti-proliferative, and 
antioxidant effects (Nakamura et al. 2016; Shin et al. 2010). Shenderov (2013) reported that 
postbiotics have favourable absorption, metabolism, and excretion abilities, which could 
indicate high capacity to signal several organs and tissues in the host thereby provoking 
biological responses. Studies have stated that SCFAs produced by gut microbiota can act as 
signalling molecules to improve glucose homeostasis and insulin sensitivity and regulate lipid 
metabolism. These can be achieved through the activation of G protein-coupled receptors 
(GPRs) which leads to regulation of energy balance thus metabolic homeostasis (Canfora, 
Jocken, and Blaak 2015; Kimura et al. 2013). The bioactive properties revealed in postbiotics 
propose that these compounds contribute to human health by enhancing particular 
physiological effects. The combined effects of postbiotics with other biological metabolites and 
live microorganisms can result in the protective effect (Thanh et al. 2010). As the exact 
mechanisms have not been fully elucidated, additional studies and research are needed to 
explore and characterize new postbiotics, which may contribute to the understanding of the 
modulation of signalling pathways (Aguilar-Toalá et al. 2018). 
 In our research (Chapter 3), when the supernatant from the PPC was added together with the 
clindamycin to the Caco-2 cells, it caused partial recovery to the epithelial mitochondrial 
membrane potential disrupted when clindamycin was added alone. In addition, in Chapter 4, 
we detected positive effects of the PPC supernatant when it was added to the enterohepatic 
cell model of hyperglycaemia. As postbiotics are also referred to as metabolites or cell free 
supernatants with beneficial health effects, then the supernatant resulting from our propionate-
producing consortium has an indication of postbiotic structure. However, in this case the 
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metabolites are resulting from a designed bacterial consortium that involved seven strains of 
the commensal gut bacteria and not from conventional probiotic strains. 
 
5.8 – Necessity of Akkermansia muciniphila in the propionate-producing consortium 
Studies have provided evidence indicating that the lack of liver glycogen increases liver fat 
accumulation and leads to insulin resistance, while increased liver glycogen improves glucose 
tolerance (Ros et al. 2010) independently of insulin signalling (Irimia et al. 2017). Gut 
microbiota has been reported to be involved since different microbial communities can 
contribute to the pathogenesis and progression of liver diseases (Wu et al. 2017). Thus, 
modulating the composition and the function of gut microbiota can be a potential intervention 
for liver injury.  
A. muciniphila, a candidate for next generation probiotic, has been reported to have a cross-
talk with host metabolism due to its beneficial roles in metabolic and immunological disorders 
(Shin et al. 2014; Plovier et al. 2017). This bacterium has been proven to improve glucose 
tolerance, insulin sensitivity, and ameliorate metabolic system inflammation (Everard et al. 
2013; Shin et al., 2014; Plovier et al. 2017; Zhao et al. 2017). In addition, pre-treatment with 
A. muciniphila could alleviate liver damage through altering the transaminase activities and 
histologic injuries (Wu et al. 2017). Studies reported that supplementation of A. muciniphila 
reduced inflammation signalling in the muscle and liver and decreased metabolic endotoxemia 
(Zhao et al. 2017). Thus, A. muciniphila can reshape the gut microbial community and induce 
a protective profile (Wu et al. 2017) and could be a promising probiotic candidate with beneficial 
effects on liver diseases. Furthermore, Zhang et al. (2018) reported that A. muciniphila could 
improve liver function, reduce oxidative stress, alleviate gluco/lipotoxicity, inhibit inflammation, 
and regulate intestinal microbiota, thus managing type 2 diabetes (Zhang et al. 2018). A. 
muciniphila has a mucolytic activity, and it can produce oligosaccharides, vitamins and SCFAs 
(Lopez-Siles et al. 2018). The metabolites from A. muciniphila could be used by other 
commensal gut bacteria as a source of energy and may change the relative abundance of 
other gut bacteria and regulate commensal interactions (Belzer and de Vos 2012, Wu et al. 
2017; Lopez-Siles et al. 2018).  
In our study, we observed a significant positive effect on glycogen and LPL activity in hepatic 
cells when the metabolites from the PPC were added. However, we could not detect a similar  
result when metabolites from A. muciniphila alone or from our consortium without A. 
muciniphila were added to the enterohepatic cell model of hyperglycaemia. This indicates that 
the propionate-producing consortium needs all the seven bacterial members to be included to 
fully perform its positive effect. A. muciniphila potentially provided different metabolites to 
cross-feed with the seven strains. As reported in a previous study, a syntrophic relationship 
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between A. muciniphila and F. prausnitzii was revealed, and the enrichment or depletion of 
one could imply the same effect in the other (Lopez-Siles et al. 2018). That study also stated 
that F. prausnitzii consumed oligosaccharides derived from the mucin degraded by A. 
muciniphila, and its growth was also stimulated by acetate and other metabolites in the 
medium, which may have been provided by A. muciniphila (Duncan et al. 2002; Lopez-Siles 
et al. 2012; Lopez-Siles et al. 2018). Another co-culture study between A. muciniphila and A. 
caccae showed the ecological dependency between a mucin degrader and a butyrate producer 
(Chia et al. 2018). This study used metatranscriptomics as an explorative approach to decipher 
bacterial interactions in the mucosal environment as both strains were mucosa-associated 
(Chia et al. 2018). These results ensure that there was a positive correlation between all the 
seven strains of the PPC, leading to the optimal results discussed in Chapter 4. To further 
understand the in-depth mechanism of the bacterial interactions that happened between the 
seven strains of our designed PPC, metatranscriptome approaches may be needed in the 
future.  
5.9- Risk-benefit analysis for propionate 
 
Propionate has been proven to promote satiety by stimulating the gut anorectic hormones, the 
PYY and the GLP-1, and prevent long-term weight gain in healthy humans (Chambers et al. 
2014). Chambers et al. (2014) demonstrated that 10g inulin-propionate ester ingestion leads 
to a 2.5-fold increase in daily colonic propionate production, and it also leads to increase in 
plasma propionate levels, and this in turn leads to greater release of PYY and GLP-1 hormones 
and decrease in caloric intake.  
Propionate has also been reported to have the highest affinity for the free fatty acid receptor 2 
(FFAR 2), involved in the regulation of metabolic homeostasis. In fact, long-term propionate 
delivery in the gut stimulates anorexigenic gut hormones, reducing intra-abdominal fat 
accretion, intrahepatocellular lipid content, and hepatic cholesterol synthesis in humans 
(Chambers et al. 2014; Arora et al. 2011). In addition, propionate is involved in activation of 
intestinal gluconeogenesis (IGN), thus regulating food intake and enhancing insulin sensitivity 
(Li et al. 2017). 
In our study we observed that the metabolites from the propionate-producing consortium were 
able to increase glycogen and LPL levels in a insulin resistance-induced enterohepatic model. 
Studies have shown that liver glycogen accumulation can protect against the negative effects 
of high fat diet, such as glucose intolerance (López-Soldado et al. 2014). Accumulation of 
hepatic glycogen contributes to decreased food intake and lower body weight and adiposity 
(Ritter et al. 1994; Grill et al. 1995; López-Soldado et al. 2014). For this reason, hepatic 
glycogen can act as a potential target for pharmacological manipulation of diabetes and obesity 
(López-Soldado et al. 2014). Our findings stress the importance of propionate on the gut-liver 
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crosstalk and ultimately on the glycogen regulation and energetic metabolism. Moreover, 
propionate can enhance the lipid buffering capacity of adipose tissue by increasing LPL-
mediated triglyceride extraction, resulting in reduced lipid overflow to the adipose tissue 
(Canfora et al. 2015).  
On the other hand, propionate has been investigated as a food additive that prevents molds 
and preserves food (Tirosh et al. 2019). The research involved mice and humans used as 
subjects for propionate consumption. In contrast to the previous findings we reported, the study 
in mice found that, the short-term consumption of propionate has led to high blood sugar levels, 
and the long-term consumption led to weigh gain and insulin resistance. In this study, after the 
researchers gave the propionate to the mice, they found that this additive led to an increase in 
several hormones. These hormones were glucagon, that is responsible for giving an order to 
the liver to release glucose in the blood stream, norepinephrine, that is responsible for 
regulating blood pressure and raising blood sugar, and fatty acid-binding protein 4 or (FABP4), 
that is involved in fatty acid metabolism. This rush in hormones led to hyperglycemia, or high 
blood glucose levels, in the mice. For the long-term trial, the researchers gave the mice 
drinking water with low doses of propionate which was equivalent to the amount in the 
processed-food based diet for humans for 20 weeks. This chronic propionate exposure led 
animals to gain more weight and showed increased insulin resistance, as compared to the 
mice that did not consume propionate. 
To determine how those results can translate to humans, the researchers held a small trial that 
involved 14 healthy and lean individuals with no diabetes. The participants that consumed 
propionate experienced temporary increase in insulin resistance over a period of few hours 
compared to those who did not consume this food additive. The amount of propionate that was 
given to subjects in this study was 1 gram which was the typical amount added in a single meal 
of processed food. The participants had blood samples before the meal and after the meal at 
regular intervals for 4 hours.  
After one week of washout, the participants switched meals in which the ones who had 
originally the propionate meal had the placebo and vice versa. This study was double-blinded. 
The results showed that the individuals who received the propionate experienced an increase 
in norepinephrine, glucagon and FABP4 hormone levels similar to what happened in the mice 
study. The participants that received propionate also showed increased levels of insulin and 
insulin resistance. In fact, both groups showed similar blood sugar peaks after the meals, but 
those that received propionate took slightly longer return to baseline. 
However, the authors of this study reported that the current literature suggests that orally 
ingested propionate does not mimic the beneficial metabolic effects attributed to SCFAs 
derived from bacteria in the colon, and that may result in adverse metabolic effects, including 
insulin resistance and glucose intolerance. This divergence may be due to the different doses 
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and routes of administration, and the local effects of propionate on proximal enterocytes versus 
distal colonocytes, as has been recently suggested for acetate (Van de Beek et al. 2016). The 
authors also suggested that this discrepancy may be explained by the interactions of 
propionate and the colonic mucosa with other SCFAs and other gut metabolites. The reported 
results in this study showing that oral propionate in processed foods leads to a potential 
increase in endogenous glucose production is still of a concern, especially that chronic 
hyperinsulinemia can drive obesity and metabolic abnormalities. Nevertheless, this study only 
found only an association and did not exclusively prove that propionate causes insulin 
resistance or diabetes. Those results cannot be applied for general humans as the study was 
conducted in mice and only on 14 healthy individuals. In addition, this suggests that propionate 
might have different effects depending where it enters the body and the site of action. For this 
reason, additional studies in larger human populations, with longer exposure to various doses 
of propionate, are needed to better elucidate the various metabolic effects of propionate in 
humans. 
 
5.10 – Safety and regulatory considerations 
5.10.1 – Safety considerations  
As several types of microbes are used as probiotics, the safety of probiotics is tied to the nature 
of the specific microbe and its intended use, and this requires several considerations (Sanders 
et al. 2010). As probiotics are administered when they are alive, unlike other food products or 
drugs components, they possess the potential for infectivity or in situ toxin production (Sanders 
et al. 2010). Safety considerations should include the potential vulnerability of the patient or 
consumer, the dose and duration of intake, and both the frequency and manner of 
administration (Sanders et al. 2010; Samtiya et al. 2019). Moreover, the bacteria used should 
be completely safe, so the horizontal gene transfer that can result in the acquisition of virulence 
genes or antibiotic resistance genes which comprises a theoretical risk of transfer for less 
innocuous member of the gut microbial community, must also be considered (Sanders et al. 
2010; Wassenaar and Klein 2008). Genetic stability of the probiotic overtime, the potential for 
pathogenicity or toxicogenecity, and the detrimental metabolic activities must also be 
evaluated  to the characteristics of the genus and species of the bacteria used (Sanders et al. 
2010). Immunological effects should also be considered especially in specific vulnerable 
populations like infants with undeveloped immune function (Sanders et al. 2010). The use of 
genomic sequencing technologies to obtain the complete bacterial genome can both resolve 
and create safety issues (Wassenaar and Klein 2008). In addition, to address the safety 
concern, the World Health Organization has developed guidelines for the assessment of 
probiotics in food, which has designated parameters for preclinical testing, clinical trials, and 
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labelling that includes strains identification, safety evaluation,  and efficacy testing in vitro and 
in animal models (Samtiya et al. 2019). For this reason, safety assessment has been procured 
as an important criterion and a primary step for the selection of probiotics strains prior to the 
incorporation in the food chain (Samtiya et al. 2019). 
 
5.10.2 – Regulatory considerations  
For a bacterium to be classified as a “probiotic” or “functional food” that is safe to be 
administered for humans, it should fall in the Qualified Presumption of Safety (QPS) list 
provided by the European Food Safety Authority (EFSA) (Baldi and Arora 2015) or Generally 
Recognized as Safe (GRAS) products that are approved by the FDA in the United States. 
The market for probiotics as functional foods expanded as they have been incorporated in food  
products like yogurts and fermented milk (Baldi and Arora 2015) that mainly contain 
conventional LAB. The QPS list is updated periodically according to the safety assessment 
of the biological products recommended to be added, but not all can be approved (Scientific 
Opinion on The Maintenance of The List of QPS Biological Agents Intentionally Added 
to EFSA Panel on Biological Hazards (BIOHAZ), 2013; Ricci et al. 2017). However, in the 
United States, when the probiotic is used as a dietary supplement, it is considered as “food” 
and should be approved by the Dietary Supplement Health and Education Act (DSHEA). On 
the other hand, if the probiotic was used for therapeutic purpose then it needs to be approved 
by the FDA (El Hage et al. 2017). Both the EFSA and the FDA do not approve probiotics to be 
used in health claims. 
Since the definitions and classifications for probiotics differ by regulatory agents among the 
world, this keeps the status of probiotics uncertain. Hence, doubts about probiotic products 
among regulatory bodies, producers and consumers might arise (El Hage et al. 2017). As most 
probiotics include only LAB which possess limited phylogenetic diversity and functionality, 
critical update of the screenings by required regulatory agents is urgently needed. 
Safety and regulatory assessments on our propionate-producing consortium must be 
completed prior to consideration for incorporation in food products. 
5.11 – Future Perspectives  
Several considerations are fundamental to establish a microbial consortium for human use. 
These include safety, means and purpose of administration, manufacturing process and 
survival of the strains. As we have established, our propionate-producing consortium from 
commensal gut bacteria including one probiotic (L. plantarum), and one next-generation 
probiotic (A. muciniphila), the other strains still need to be tested for their safety before 
commercial use. In addition, since propionate has been reported to stimulate the production of 
the PYY and the GLP-1 gut hormones, measuring these hormones upon addition of the PPC 
in vivo must be tested to ensure their activity on the gut-liver crosstalk. Metagenomics and 
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genomics approaches could be used to determine the different pathways that strains follow to 
produce propionate, as described by Richardt et al. (2014). Moreover, metatranscriptomics are 
needed to understand in-depth the mechanistic interactions between bacteria. 
Metatranscriptomics revealed the trophic interactions between mucosal keystone species A. 
muciniphila and A. caccae during a co-culture experiment (Chia et al. 2018). By testing the 
cross-talk between all systems, many new inducible systems for versatile control of engineered 
communities could be characterized (Scott and Hasty 2016). The characterization of each 
biotherapeutic should be completed considering the relative benefits to the target disease. As 
the PPC supernatant positively reversed insulin resistance effects in the in vitro cell model, the 
PPC must be tested in vivo for safety measurements and also in an obese-induced or diabetes-
induced mice to fully comprehend its effects. Persistence of the outcomes must be further 
assessed in vitro, as well as survival and viability following microencapsulation. As for 
postbiotics, optimized models of the upper GI tract simulator and the SHIME will allow 
assessing their stability in the manufactured products. These considerations highlight the 
urgency of developing representative in vitro model mimicking the whole human 
gastrointestinal tract (Aguilar-Toalá et al. 2018). Special attention should be paid to develop 
uniform and defined culturing procedures to eliminate the variability of postbiotic production, 
as environmental factors may influence bacterial metabolism and lead to transient variability. 
Similar to probiotics, metabolomics and genomic studies could be implemented to support the 
health claims of postbiotics (Aguilar-Toalá et al. 2018). In addition extra cell work with extra 
parameters could be interesting to investigate in the future. For instance, pancreatic cells would 
be of great value to test the effect of the PPC in case of insulin resistance. The pancreas is 
able to maintain blood glucose levels within a very narrow range through its various hormones, 
particularly glucagon and insulin. This could be  accomplished by the opposing and balanced 
actions of glucagon and insulin, referred to as glucose homeostasis (Röder et al. 2016).  The 
effect of the PPC can be tested on these cells to check if it could be aiding in the preventation 
of  diabetes.  Another cell type that could be tested would be the entroendocrine cells. 
Enteroendocrine cells (EEC) have been reported to have a major role in regulating gut motility, 
secretion, and production of peptide hormones that control insulin secretion and food intake. 
Intestinal enteroendocrine cells such as L-cells are responsible for the production of the GLP-
1 and the PYY gut hormones that are responsible for satiety (Covasa et al. 2019). L-cells 
strategically detect the presence of nutrients, microbiota and their metabolites. The microbiota 
controls enteroendocrine cells differentiation and the number of GLP-1 and PYY-secreting L-
cells (Covasa et al. 2019). For this reason, it would be of a great value to test the effect of the 
PPC supernatant on the L-cells and measure the secretion of PYY and GLP-1 hormones. 
Besides, lipid accumulation may be a relevant parameter to test in the proposed cell model, 
enterohepatic model in our case, as de novo lipogenesis may exert impact on glycerol 
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accumulation (Saponaro et al. 2015). Techniques such as red Nile will shed light on the role 
of lipid droplets stored in HepG2 cells and their effect on hyperglycaemia, so this can be 
considered for future studies. Furthermore, the use of metagenomics, metatranscriptomics and 
metabolomics, can reveal the possible secondary metabolites that microorganisms produce, 
indicating the silent genes that can be activated within microbial consortia (Zhang et al. 2018). 
This could also be important for future commercial production of the biotherapeutic.  
 
5.11.1- HepG2 vs HepRG  
 
Studies have reported that primary human hepatocytes are considered the gold standard of 
hepatic culture models due to their close resemblance to in vivo functionality; however, these 
cells have drawbacks. They are limited in availability, and due to the fact that they are from 
different donors, their response to drugs could vary (McGill et al. 2011). In addition, these cells 
have a limited lifespan, have a decreasing functionality in long-term culture (Ragol et al. 2019), 
and they undergo phenotypic changes and display variability in CYP450 expression over time. 
Liver cell lines that are widely used are either obtained from tumor tissue or by genetic 
engineering of primary human hepatocytes (PHH). HepG2 and HepaRG, the presumably most 
prominent hepatic cell lines, and are both generated from human hepatoma (Ragol et al. 2019). 
In contrast to PHH, most hepatoma cells are stable, largely available with low cost, and easy 
to work with, nearly unlimited life-span, and stable phenotype that does not depend on donor 
characteristics (Donato et al. 2015), but their high proliferative potential is accompanied by 
functional losses (Rogal et al. 2019). To start with, HepaRG cells were isolated from a 
hepatoma in a female patient with cirrhosis subsequent to hepatitis C virus infection (HCV). 
HepaRG cells are bipotent progenitors in which two morphologically distinct populations 
become apparent upon differentiation: hepatocyte-like cells and biliary epithelial-like cells. 
Moreover, studies have demonstrated that this cell line is able to highly express xenobiotic 
metabolizing enzymes, which is comparable to primary human hepatocytes, thus suggesting 
their use in drug studies (McGill et al. 2011). As for HepG2, this cell line has extensively been 
used in cell-based metabolic studies; however, as this cell line is of malignant origin, they have 
the tendency to present abnormal metabolic phenotype compared to human primary cells. For 
instance, HepG2 cells have increased rates of de novo lipogenesis and glycolysis (Pereira da 
Silva et al. 2009; Daniels et al. 2014; Nikolaou et al. 2016). In addition, it has been reported 
that HepG2 is best used to model hepatic cancer and its treatment strategies, but it is not ideal 
for studying hepatic biotransformation due to atypical quantities of drug metabolism enzymes 
and deficient metabolic activities (Rogal et al. 2019). In addition, HepG2 express many 
differentiated hepatic functions, like  synthesis and secretion of plasma proteins, lipoprotein 
metabolism and transport, bile acid synthesis, glycogen synthesis or insulin signaling, and 
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cholesterol and triglyceride metabolism (Donato et al. 2014). However, HepG2 cells have a 
major drawback that is their limited ability to express drug metabolizing enzymes and 
transporters (Donato et al. 2014). Furthermore, what makes HepG2 different from liver tissue 
or primary hepatocytes is in particular are the characteristic hepatic transporters sodium-
taurocholate cotransporting polypeptide, organic anion transporting polypeptide C, and bile 
salt export pump that are absent or poorly expressed in HepG2 (Donato et al. 2014). Contrary 
to HepG2, the HepaRG cell line is an alternative to PHHs in the context of metabolic or 
toxicological studies; as a result of its higher grade of differentiation, HepaRG cells retain more 
hepatic metabolic functions, including drug metabolizing cytochrome P450 (CYP) enzyme 
activities (Rogal et al. 2019). Moreover, Richter et al. has reported that the HepaRG provided 
better results than HepG2 regarding their total number and abundance of metabolites. Despite 
that HepG2 were easier to handle, required less complicate cultivation media, and they were 
cost effective, they could not be compared to PHH (Richter et al. 2017).  For this reason, the 
metabolites from our PPC could also be tested on HepaRG cell line in the future to have clearer 
overview and extra information that could relate to the primary hepatic cells.  
 
5.12 – Conclusion  
Beneficial modulation of the gut microbiota using biotherapeutics has gained attention and 
importance over time. Biotherapeutics are characterized bacterial communities from gut 
commensal bacteria and can be used for the prevention or treatment of disease. These 
consortia include different bacterial strains with different phylogenetic origin not limited to a 
narrow selection, as opposed to conventional probiotics belonging to lactic acid bacteria. In 
vitro human gut models such as the TSI and SHIME and the developed cell models allowed 
us to reveal that: 
 The PPC could not survive the three different compartments of the small intestine due 
to either the high concentration of the bile salts or some oxygen diffusion in the system  
 The PPC recovered the functionality of propionate production in the colon after 
antibiotic-induced dysbiosis 
 The administration of PPC led to direct engraftment of some of its members in the 
microbial community in the simulated gut microbial ecosystem, in addition to the 
indirect reinforcement of other bacterial genera involved in propionate production  
 The supernatant from one dose of PPC caused partial recovery of the mitochondrial 
membrane potential of caco-2 cells after being disrupted with clindamycin 
 The supernatant from one dose of PPC increased glycogen storage and LPL activity 
in hepatic cells, and decreased IL-8 which is an inflammatory marker in hepatic cells  
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 The optimal effect of the PPC can only be reached when all the seven members of the 
consortium are interacting together  
 
These findings indicate that the PPC could be a promising therapeutic approach, yet more 
investigation is to be performed. Considering the bacterial metabolic pathways involved in the 
desired outcome is utmost crucial to ensure the exchange of metabolites among the members 













6- Summary- Samenvatting 
Summary 
The gut microbiota has been known to be associated with human health and the onset of 
different diseases. Several factors can lead to the manipulation of the gut microbiota, including 
antibiotics, probiotics, prebiotics and other environmental factors. The excessive and misuse 
of antibiotics causes a disruption for the gut microbiota and thereby a disorder in short chain 
fatty acids production. Dysbiosis has been linked to diseases such as metabolic disorder. 
Studies have shown that propionate, a major short chain fatty acid, is able to stimulate the 
production of PYY and the GLP-1 gut hormones that are able to control satiety thus decreasing 
energy intake and causing weight loss. Propionate can also contribute to metabolic health by 
activating the intestinal gluconeogenesis, which in turn can maintain energy homeostasis by 
regulation of food intake and improvement of insulin sensitivity. As a result, the gut microbiota 
can serve as a therapeutic target for metabolic syndrome. Some studies have shown the 
positive effect of the administration of probiotics and fecal microbial transplant on metabolic 
syndrome. However, the probiotics used are of limited phylogenetic origin mainly belonging to  
lactic acid bacteria, and fecal microbial transplant has an uncharacterized nature of bacteria 
that need several considerations before being administered to humans. As a result, a more 
characterized bacterial consortium including different beneficial strains might be needed as a 
therapeutic for metabolic disorders.  
In the first part of our research, we have worked on developing a multispecies bacterial 
consortium that is able to produce propionate, the beneficial short chain fatty acid. In Chapter 
2, we have described how we designed the propionate-producing bacterial consortium by 
considering the three different metabolic pathways that lead to propionate production (acrylate 
pathway, succinate pathway, and propanediol pathway). Seven different strains were selected 
taking into account the possible cross-feeding mechanisms that could occur leading to 
propionate production. The seven strains were co-cultured together in a fed-batch experiment 
for 48 hours yielding a propionate concentration of 34.5mM. The aim of the co-culturing was 
to have a preadapted bacterial consortium that can be harvested as a bacterial community in 
which strains have already done their different cross-feeding. Moreover, since the propionate-
producing consortium is supposed to be administered orally and take action in the colon, it has 
to pass the harsh conditions of the upper gastrointestinal tract. For this reason, it was tested 
in the TSI model that represents “The Smallest Intestine” model and that included a consortium 
of the ileal bacteria. The results showed that the propionate-producing consortium could not 
survive the different parts of the small intestine, and that fed conditions were more harsh than 
fasted conditions. This indicated that a carrier is needed to protect the consortium from the 
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harsh conditions of the bile salts in the small intestine, and that it is recommended that our 
designed consortium is administered in the fasted state.  
To assess the effect of the propionate-producing consortium on the microbial functionality upon 
antibiotic-induced dysbiosis, we used the M-SHIME model, an in vitro simulator for the human 
intestinal microbial ecosystem (Chapter 3). The impact of addition of the propionate-producing 
consortium was tested for six different donors after which the antibiotic was added to induce a 
case of dysbiosis. After adding antibiotics, the concentrations of short chain fatty acids 
produced in the SHIME decreased drastically. The administration of the consortium for three 
consecutive days caused a full recovery for propionate production reaching the normal levels 
before the antibiotic disruption. Moreover, the community composition analysis showed that 
the addition of the propionate-producing consortium was able to cause direct engraftment for 
some bacterial genera related to the introduced strains in addition to the indirect reinforcement 
of other genera associated with propionate production. This revealed that the administration 
of our consortium restored functionality and caused a shift to the microbial community towards 
enhancing propionate production. Furthermore, the effect of the supernatant from the 
propionate-producing consortium was assessed on a caco-2 cell model in which addition of 
clindamycin caused disruption of the mitochondrial membrane potential. The metabolites from 
the consortium were able to cause partial recovery of the mitochondrial membrane potential 
following antibiotic disruption. 
In the second part of the research, the gut-liver crosstalk was studied. In Chapter 4, we 
investigated the impact of the metabolites from the propionate-producing consortium and 
Akkermanisia muciniphila, which is also known to be a propiogenic bacterium, in an in vitro 
enterohepatic model of insulin resistance. Liver glycogen storage, lipoprotein lipase activity, 
and different inflammatory markers in hepatic cells were evaluated to understand the role of 
the metabolites from gut bacteria on the gut-liver crosstalk in a simulated scenario of subclinical 
metabolic inflammation. Only the metabolites produced by our designed consortium of seven 
strains were able to increase hepatic glycogen levels and lipoprotein lipase activity and 
decrease pro-inflammatory markers such as IL-8. These results elucidated the positive effect 
of the propionate-producing consortium on metabolic function and low-grade inflammation. 
Moreover, to observe the optimal effect of the consortium, all seven strains need to be present 
to do the necessary cross-feeding and yield the beneficial metabolites. 
In conclusion, this PhD research showed that the designed propionate-producing consortium 
is a promising strategy to restore dysbiosis and manage metabolic disorders, thanks to its 
versatile mode of action and production of beneficial metabolites. To achieve a long-term effect 
of the designed consortium, more doses and longer periods of administration might be needed. 
Next to this, more advanced techniques such as metagenomics, metatranscriptomics and 
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metabolomics are needed to reveal the bacterial interactions and the possible secondary 
metabolites that microorganisms can produce. 
 
Sumenvatting 
Het is gekend dat de darmmicrobiota verband houdt met de gezondheid van de mens en de 
aanvang van verschillende ziekten. Verscheidene factoren, zoals antibiotica, probiotica, 
prebiotica en andere omgevingsfactoren, kunnen de darmmicrobiota beïnvloeden. Het 
overmatig gebruik en misbruik van antibiotica heeft geleid tot een verstoring van de 
darmmicrobiota en daardoor tot een stoornis in de aanmaak van korte keten vetzuren. 
Dysbiose is gelinkt aan ziekten, waaronder stofwisselingsziekten. Onderzoek heeft 
aangetoond dat propionaat, een belangrijk korte keten vetzuur, de PYY en GLP-1 hormonen 
in de darm kan stimuleren. Deze hormonen dragen bij aan de controle van het  
verzadigingsgevoel, wat leidt tot een vermindering van de energie-inname en gewichtsverlies. 
Propionaat kan ook bijdragen aan de metabole gezondheid door activering van de 
gluconeogenese, wat op zijn beurt de energiehomeostase in stand houdt door het regelen van 
de voedselinname en het verbeteren van insulinegevoeligheid. Hierdoor kan de 
darmmicrobiota dienen als een doelwit voor therapie. Sommige onderzoeken hebben het 
positief effect aangetoond van het toedienen van probiotica en fecale microbiële 
transplantaties op stofwisselingsziekten. De gebruikte probiotica hebben echter een beperkte 
fylogenetische oorsprong en behoren voornamelijk tot de lactobacillen, en fecale microbiële 
transplantaties zijn weinig gekarakteriseerd op vlak van bacteriën die goed in overweging 
genomen moeten worden vooraleer ze worden toegediend aan mensen. Om deze redenen 
kan een beter gekarakteriseerd bacterieel consortium nodig zijn als therapie voor metabole 
ziekten.  
In het eerste deel van ons onderzoek hebben we gewerkt rond het ontwikkelen van een 
multispecies bacterieel consortium dat propionaat, het gezonde korte keten vetzuur, kan 
produceren. In hoofdstuk 2 is beschreven hoe we het propionaatproducerende consortium 
ontworpen hebben door de drie verschillende metabolische pathways te beschouwen die tot 
propionaatproductie leiden (de acrylaat pathway, de succinaat pathway, en de propaandiol 
pathway). Zeven verschillende bacteriële stammen werden geselecteerd met inachtname van 
mogelijke crossfeeding mechanismen die zouden kunnen voorkomen en tot 
propionaatproductie zouden kunnen leiden. De zeven stammen werden voor 48 u 
gecocultiveerd in een fed-batch experiment, wat een propionaatconcentratie van 34,5 mM 
opleverde. De cocultivering had als doel een vooraf aangepast consortium te bekomen dat 
geoogst kan worden als een bacteriële gemeenschap waarin de verschillende stammen reeds 
een crossfeeding netwerk hebben opgezet. Daarenboven, gezien het propionaatproducerende 
122 
 
consortium bedoeld is voor orale inname, maar zijn functie dient uit te oefenen in de colon, 
moet het de moeilijke omstandigheden van het bovenst deel van het gastro-intestinaal kanaal 
zien te overleven. Om deze reden werd het consortium getest in het TSI model, “het kleinste 
darm model”, dat een consortium van ileale bacteriën bevat. De resultaten toonden aan dat 
het propionaatproducerende consortium de passage doorheen de verschillende delen van de 
dunne darm niet kon overleven, waarbij de gevoede toestand moeilijker was dan de gevaste 
toestand. Dit toonde aan dat er een drager nodig is om het consortium te beschermen tegen 
de schadelijke effecten van galzouten in de dunne darm, en dat het aangewezen is om het 
consortium toe te dienen in de gevaste toestand. 
Om het effect na te gaan van het propionaatproducerende consortium op de microbiële 
functionaliteit gedurende antibioticum-geïnduceerde dysbiose, werd het M-SHIME model 
gebruikt, een in vitro simulator voor het humaan intestinaal microbieel ecosysteem (hoofdstuk 
3). De impact van het toedienen van het propionaatproducerende consortium werd getest voor 
6 verschillende donoren, waarna antibiotica werden toegediend om een dysbiotische toestand 
te induceren. Na het toedienen van de antibiotica daalden de concentraties van korte keten 
vetzuren geproduceerd in de SHIME drastisch. Toedienen van het consortium voor drie 
opeenvolgende dagen zorgde voor een volledig herstel van de propionaatproductie, waarbij 
het normale niveau van voor de verstoring door antibiotica bereikt werd. Daarenboven toonde 
kwantificatie van de microbiële gemeenschap aan dat het toedienen van het 
propionaatproducerende consortium zorgde voor implantatie van enkele bacteriële genera 
gerelateerd aan de geïntroduceerde stammen, naast de indirecte versterking van andere 
genera geassocieerd met propionaatproductie. Dit toonde aan dat het toedienen van ons 
consortium zorgde voor herstel van de functionaliteit en zorgde voor een verschuiving van de 
microbiële gemeenschap die leidde tot een verhoogde propionaatproductie. Het effect van 
supernatans van het propionaatproducerende consortium werd eveneens getest in het caco-
2 cel model, waarbij de mitochondriële membraanpotentiaal verstoord werd door clindamycine. 
De metabolieten van het consortium zorgden voor gedeeltelijk herstel van de mitochondriële 
membraanpotentiaal na de verstoring door antibiotica.  
In het tweede deel van dit onderzoek werd de darm-lever crosstalk onderzocht. In hoofdstuk 
4 hebben we de impact van metabolieten van het propionaatproducerende consortium en 
Akkermansia muciniphila, eveneens een propiogene bacterie, bestudeerd in een in vitro 
enterohepatisch model van hyperglycemie. Glycogeenopslag in de lever, lipoproteïne lipase 
activiteit, en verschillende inflammatoire merkers in levercellen werden beoordeeld om inzicht 
te krijgen in de rol van metabolieten van darmbacteriën op darm-lever crosstalk in een 
gesimuleerde toestand van subklinische metabole ontsteking. Enkel de metabolieten 
geproduceerd door het door ons ontworpen consortium van zeven stammen veroorzaakten 
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een stijging van de glycogeenlevels in de lever en van lipoproteïne lipase activiteit, en een 
daling van inflammatoire merkers, waaronder IL-8. Deze resultaten tonen het positieve effect 
aan van het propionaatproducerende consortium op stofwisselingsfuncties en lichte 
ontsteking. Daarnaast bleek dat, om het optimale effect van het consortium te bekomen, alle 
zeven stammen aanwezig moeten zijn om de nodige crossfeeding en productie van gezonde 
metabolieten te bewerkstelligen. 
Samenvattend heeft dit doctoraatsonderzoek aangetoond dat het ontworpen 
propionaatproducerende consortium een veelbelovende strategie is vanwege zijn 
multifunctionaliteit, en potentiële mogelijkheid van zijn metabolieten om stofwisselingsziekten 
te beheersen. Om een lange-termijn effect van het ontworpen consortium te bekomen, zouden 
meerdere doses en langere periodes van toediening noodzakelijk kunnen zijn. Meer 
gespecialiseerde technieken zoals metagenomics, metatranscriptomics en metabolomics zijn 
echter vereist om bacteriële interacties en mogelijke secundaire metabolieten die micro-
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Table S1: Community structure indices for Fresh mix of bacterial cockail. Inverse 
simpson indicates Alpha diversity, and Pielou indicates Evenness. Comparisons 
between Fasted and Fed conditions in the same compartment were performed using 2-
way Anova test (Sidak’s method). Differences between the same condition (Fasted or 
Fed) in different compartments were assessed using 2-way Anova (Tukey’s method), 

















Index Compartment  Condition P value 
Inverse Simpson  Fasted (Mean % ± SEM) Fed(Mean % ± SEM)  
 Inoculum 4.15 ± 0.54a 4.15 ± 0.54b NS 
 Duodenum 8.84 ± 4.16a 4.36 ± 0.54c NS 
 Jejunum  4.63 ± 0.76a 2.59 ± 0.01bc NS 
 Ileum 5.65 ± 0.35a 3.95 ± 0.12bc NS 
     
Pielou Inoculum 0.46 ± 0.04a 0.46 ± 0.04b NS 
 Duodenum 0.57 ± 0.11a 0.43 ± 0.06b NS 
 Jejunum  0.45 ± 0.05a 0.31 ± 0.02b NS 
 Ileum 0.50 ± 0.02a 0.44 ± 0.01b NS 
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Table S2: Community structure indices for Preadapted bacterial consortium. Inverse 
simpson indicates Alpha diversity, and Pielou indicates Evenness. Comparisons 
between Fasted and Fed conditions in the same compartment were performed using 2-
way Anova test (Sidak’s method). Differences between the same condition (Fasted or 
Fed) in different compartments were assessed using 2-way Anova (Tukey’s method), 
and superscripts indicate significance (P<0.05).  
Index Compartment  Condition P value 
Inverse Simpson  Fasted (Mean % ± SEM) Fed(Mean % ± SEM)  
 Inoculum 4.07 ± 0.04a 4.07 ± 0.04b NS 
 Duodenum 13.09 ± 0.44a 8.83 ± 3.21b NS 
 Jejunum  9.87 ± 2.39a 3.84 ± 1.32b NS 
 Ileum 4.25 ± 0.01a 4.05 ± 1.54b NS 
     
Pielou Inoculum 0.50 ± 0.02a 0.50 ± 0.02b NS 
 Duodenum 0.66 ± 0.02c 0.60 ± 0.06b NS 
 Jejunum  0.61 ± 0.04ac 0.38 ± 0.10b NS 
 Ileum 0.46 ± 0.001ac 0.42 ± 0.12b NS 






Table S3: Community structure indices for Fresh Mix and Preadapted bacterial 
consortium in the fasted condition. Inverse simpson indicates Alpha diversity, and 
Pielou indicates Evenness. Comparisons between Fresh Mix and Preadapted 
consortium in the same compartment were performed using 2-way Anova test (Sidak’s 
method). Significance was considered at (P<0.05).  
Index Compartment  Condition P value 
Inverse Simpson  Fresh Mix (Mean % ± 
SEM) 
Preadapted (Mean % ± 
SEM) 
 
 Inoculum 4.15 ± 0.54 4.07 ± 0.04 NS 
 Duodenum 8.84 ± 4.16 13.09 ± 0.44 NS 
 Jejunum  4.63 ± 0.76 9.87 ± 2.39 NS 
 Ileum 5.65 ± 0.35 4.25 ± 0.01 NS 
     
Pielou Inoculum 0.46 ± 0.04 0.50 ± 0.02 NS 
 Duodenum 0.57 ± 0.11 0.66 ± 0.02 NS 
 Jejunum  0.45 ± 0.05 0.61 ± 0.04 NS 
 Ileum 0.50 ± 0.02 0.46 ± 0.001 NS 





Table S4: Community structure indices for Fresh Mix and Preadapted bacterial 
consortium in the fedcondition. Inverse simpson indicates Alpha diversity, and Pielou 
indicates Evenness. Comparisons between Fresh Mix and Preadapted consortium in 
the same compartment were performed using 2-way Anova test (Sidak’s method). 
Significance was considered at (P<0.05). 




 Fresh Mix (Mean % ± 
SEM) 
Preadapted (Mean 
% ± SEM) 
 
 Inoculum 4.15 ± 0.54 4.07 ± 0.04 NS 
 Duodenum 4.36 ± 0.54 8.83 ± 3.21 NS 
 Jejunum  2.59 ± 0.01 3.84 ± 1.32 NS 
 Ileum 3.95 ± 0.12 4.05 ± 1.54 NS 
     
Pielou Inoculum 0.46 ± 0.04 0.50 ± 0.02 NS 
 Duodenum 0.43 ± 0.06 0.60 ± 0.06 NS 
 Jejunum  0.31 ± 0.02 0.38 ± 0.10 NS 
 Ileum 0.44 ± 0.01 0.42 ± 0.12 NS 







Figure S1: PCoA analysis showing the dispersion of the microbial community by fasted 
and fed conditions for the fresh mix and preadapted microbial consortium in the 
different TSI compartments (Inoculum: before entering the TSI, duodenum, jejunum, 









Table S1: Community structure indices in the lumen compartment. 1: End of 
Stabilization phase, 2: After Antibiotic use, 3: After 3 doses of propionate-producing 
consortium, and 4: washout phase. Inverse simpson indicates Alpha diversity, Pielou 
indicates Evenness, and Total Species indicates the total number of Species or 
richness. Comparisons between control (CTR) and Treatment (TRT) at the same time 
point were performed using 2-way Anova test (Sidak’s method). Differences between 
the same treatment at different time points were assessed using 2-way Anova (Tukey’s 
method), and superscripts indicate significance (P<0.05).  
Index TPT Condition P value 
Inverse 
Simpson 
 CTR (Mean % ± SEM) TRT(Mean % ± SEM)  
 1 3.94 ± 0.61a 3.52 ± 0.36b NS 
 2 3.65 ± 0.31a 3.74 ± 0.46b NS 
 3 3.65 ± 0.24a 3.63 ± 0.39b NS 
 4 3.41 ± 0.16a 3.76 ± 0.41b NS 
     
Pielou 1 0.46 ± 0.03a 0.46 ± 0.02b NS 
 2 0.48 ± 0.02a 0.47 ± 0.04b NS 
 3 0.47 ± 0.02a 0.46 ± 0.02b NS 
 4 0.45 ± 0.01a 0.46 ± 0.02b NS 
     
Total species 1 51.33 ± 3.16a 53.67 ± 3.21d NS 
 2 26.00 ± 1.26b 28.33 ± 2.04e NS 
 3 29.17 ± 1.85bc 36.50 ± 2.08f NS 












Table S2: Community structure indices in the mucin compartment. 1: End of 
Stabilization phase, 2: After Antibiotic use, and 3: After 3 doses of propionate-producing 
consortium. Inverse simpson indicates Alpha diversity, Pielou indicates Evenness, and 
Total Species indicates the total number of Species or richness. Comparisons between 
control (CTR) and Treatment (TRT) at the same time point were performed using 2-way 
Anova test (Sidak’s method). Differences between the same treatment at different time 
points were assessed using 2-way Anova (Tukey’s method), and superscripts indicate 
significance (P<0.05).  
Index TPT Condition P value 
Inverse 
Simpson 
 CTR (Mean % ± SEM) TRT(Mean % ± 
SEM) 
 
 1 5.09 ± 0.81a 6.22 ± 1.09b NS 
 2 4.31 ± 0.47a 5.82 ± 1.09b NS 
 3 4.69 ± 0.60a 5.45 ± 0.35b NS 
     
Pielou 1 0.52 ± 0.03a 0.55 ± 0.03b NS 
 2 0.46 ± 0.03a 0.52 ± 0.03b NS 
 3 0.50 ± 0.03a 0.55 ± 0.02b NS 
     
Total species 1 64.00 ± 7.10a 68.33 ± 3.08c NS 
 2 54.50 ± 3.10a 59.67 ± 4.69c NS 





Table S3: Differences in major short chain fatty acid concentrations between control 
and treatment in the lumen at different time points (TPT) in Donor 1. Time point (TPT) is 
expressed in days. Days selected were day 9 (before antibiotic treatment), day 17 (after 
antibiotics), day 18 (after single dose of propionate producing consortium), day 24 (after 
3 doses of propionate producing treatment) and day 27 (end of the washout period).  
SCFA  TPT  Condition   P value 
  
 
CTR (Mean % ± SEM)  TRT(Mean % ± SEM)   
Acetate 9 30.65 ± 5.32 32.59 ± 2.80 
NS 
17 30.08 ± 1.04 31.24 ± 2.20 
18 29.88 ± 1.20 31.25 ± 0.99 
24 34.08 ± 2.95 35.69 ± 1.76 
27 31.90 ± 2.94 34.3 ± 1.74 
Propionate 9 12.87 ± 1.38 15.09 ± 0.22 
NS 17 5.10 ± 0.35 5.75 ± 0.15 
18 4.81 ± 0.13 5.85 ± 0.12 
24 9.62 ± 1.58 14.84 ± 1.06 0,0059 
27 10.14 ± 1.44 14.44 ±0.89 0,0483 
Butyrate 9 9.93 ± 2.46 6.40 ± 1.27 
NS 
17 0.33 ± 0.12 0.24 ± 0.05 
18 0.67 ± 0.09 0.43 ± 0.03 
24 2.52 ± 0.23 2.48 ± 0.22 





Table S4: Ratios of the aggregate monomer of the JC1 values (indicative for membrane 
potential) after the different treatments applied on the epithelial cells. Overall 
significance level = 0.05. Clindamycin treatment (CLN) showed a similar effect to CCCP 
which is the positive control for mitochondrial membrane potential disruption. 
Propionate producing consortium (PPC) showed a significant effect on membrane 
potential when added together with CLN, showing significant difference (P<0.05) with 







Treatment Mean% ± SEM 
Control 0.793 ± 0.035a 
CCCP 0.189 ± 0.008bc 
CLN 0.205 ± 0.011bc 
CLN+PPC 0.461 ± 0.086d 
PPC 0.628 ± 0.083ad 
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Table S5A: Bacterial relative abundances of taxa belonging to the Propionate-producing 
consortium (PPC) in the luminal compartment of the M-SHIME at the end of the 
stabilisation phase (time point 1), after clindamycin supplementation (time point 2), after 
3 days of PPC administration (time point 3) and after 4 days of washout (time point 4). 





Treatment (Mean ± SEM)  Effect 
PPC Control Time Treatment Time*Treatment 
Akkermansia 
1 0.0045 ± 0.002
ab 0.0018 ± 0.0007a 
0.001 0.07 NS 
2 0.0021 ± 0.009a 0.00008 ± 0.00003b 
3 0.0065± 0.004ab 0.0018 ± 0.0006b 
4 0.0123 ± 0.005b 0.0071 ± 0.0044c 
Bacteroides 
1 0.0153 ± 0.001
a 0.0143 ± 0.002a 
0.03 NS NS 
2 0.0136 ± 0.0651a 0.0134 ± 0.001a 
3 0.0125 ± 0.001b 0.0104 ± 0.0009b 
4 0.0126 ± 0.001a 0.0112 ± 0.002b 
Blautia 
1 0.0012 ± 0.005
a 0.0014 ± 0.0006a 
<0.0001 NS NS 
2 0.0008 ± 0.0003b 0.0003 ± 0.0001a 
3 0.0008 ± 0.0002b 0.0003 ± 0.0001a 
4 0.0021 ± 0.0007c 0.0011 ± 0.0004a 
Coprococcus 
1 0.00001 ± 4E-6
a 0.00001 ± 5.4E-6a 
<0.0001 0.0005 <0.0001 
2 2.6E-8 ± 0.0106b 3.1E-6 ± 2.86E-6a 
3 2.2E-8 ± 9.0E-9c 1.9E-6 ± 1.8E-6b 
4 1.2E-7 ± 4.8E-8d 6.9E-6 ± 3.9E-6a 
Lactobacillus 
1   






3   
4   
Veillonella 
1 0.00029 ± 0.0003
a 0.00019 ± 0.0002a 
<0.0001 <0.0001 <0.0001 
2 0.00091 ± 0.0008b 0.0044 ± 0.0004b 
3 0.0074 ± 0.0007c 0.0043 ± 0.0039c 





Table S5B: Bacterial relative abundances of taxa belonging to the Propionate-producing 
consortium (PPC) in the mucosal compartment of the M-SHIME at the end of the 
stabilisation phase (time point 1), after clindamycin supplementation (time point 2), after 
3 days of PPC administration (time point 3). NS= not significantly different. Different 




Treatment (Mean ± SEM)  Effect 
PPC Control Time Treatment Time*Treatment 
Akkermansia 
1 0.0156 ± 0.005
a 0.0078 ± 0.0003a 
0.001 0.09 NS 2 0.0141 ± 0.009a 0.0036 ± 0.0001b 
3 0.051± 0.004b 0.0023 ± 0.0001b 
Bacteroides 
1 0.0060 ± 0.0014 0.0064 ± 0.0014 
0.06 NS NS 2 0.0055 ± 0.0018 0.0049 ± 0.0007 
3 0.0039 ± 0.0011 0.0032 ± 0.0006 
Blautia 
1 0.0007 ± 0.0002
a 0.0007 ± 0.0002a 
<0.0001 NS NS 2 0.0003 ± 0.001b 0.0002 ± 0.00008 b 
3 0.0003 ± 0.00007b 0.0002 ± 0.00006b 
Coprococcus 
1 0.00004 ± 3E-6
a 0.00002 ± 5.8E-6a 
0.008 NS NS 2 0.00003 ± 0.00002a 4.7E-6 ± 2.01E-6b 
3 3.66E-6 ± 1.3E-6b 4.6E-6 ± 5.5E-6ab 
Lactobacillus 
1   
- - - 2 Below detection limit  Below detection limit  
3   
Veillonella 
1 0.00048 ± 0.0007
a 0.00031 ± 0.0004a 
<0.0001 NS NS 2 0.000015 ± 0.00002b 0.00015 ± 0.00002b 





Table S5C: Taxa whose relative abundance was impacted through supplementation of 
the Propionate-producing consortium (PPC) in the luminal compartment of the M-SHIME 
at the end of the stabilisation phase (time point 1), after clindamycin supplementation 
(time point 2), after 3 days of PPC administration (time point 3) and after 4 days of 
washout (time point 4). NS= not significantly different. Different superscripts indicate 




Treatment (Mean ± SEM)  Effect 
PPC Control Time Treatment Time*Treatment 
Anaerostipes 
1 5.8E-7 ± 3.3E-7a 1.2E-6 ± 7.8E-7a 
<0.0001 NS NS 
2 2.4E-9 ± 1.1E-9b 1.4E-9 ± 5.8E-10b 
3 2.2E-9 ± 9.2E-10b 1.4E-9 ± 5.7E-10b 
4 1.7E-6 ± 1.3E-6b 1.9E-6 ± 1.0E-6c 
Bifidobacterium 
1 0.0002 ± 0.00004a 0.0002 ± 0.0001a 
<0.0001 NS NS 
2 0.00006 ± 0.00003b 0.00004 ± 0.00003b 
3 0.00005 ± 0.00004b 0.00001 ± 0.00001c 
4 0.0002 ± 0.0001a 0.00008 ± 0.00006d 
Bilophila 
1 0.0003 ± 0.0004a 0.0005 ± 0.00004a 
<0.0001 NS NS 
2 0.00004 ± 0.00001b 0.00003 ± 0.00001b 
3 0.0001 ± 0.00005b 0.0002 ± 0.0005a 
4 0.0003 ± 0.00004a 0.0003 ± 0.00005a 
Erysipelatoclostridium 
1 9.0E-9 ± 3.7E-9a 2.3E-9 ± 9.3E-10a 
<0.0001 NS NS 
2 1.4E-6 ± 1.3E-6b 1.7E-6 ± 1.5E-6b 
3 5.2E-6 ± 3.4E-6b 2.5E-6 ± 2.3E-6b 
4 1.2E-6 ± 6.7E-7c 1.4E-6 ± 9.7E-7b 
Escherichia-
Shigella 
1 0.0015 ± 0.0004a 0.0027 ± 0.0014a 
NS 0.009 NS 
2 0.0026 ± 0.0002b 0.0052 ± 0.001b 
3 0.0021 ± 0.0005b 0.0064 ± 0.001b 
4 0.003 ± 0.001c 0.0066 ± 0.001b 
Flavonifractor 
1 0.00002 ± 6.E-6a 0.00002 ± 8.7E-6a 
0.009 NS NS 
2 0.00001 ± 8.6E-6b 0.00001 ± 7.7E-6b 
3 0.00004 ± 0.00001c 0.00002 ± 0.00001b 
4 0.00003 ± 0.00001c 6.3E-6 ± 3.5E-6a 
Lachnoclostridium 
1 0.0046 ± 0.0009a 0.0055 ± 0.0011a 
0.02 NS NS 
2 0.0055 ± 0.0011a 0.0043 ± 0.0013b 
3 0.0056 ± 0.0015b 0.0060 ± 0.0018ac 
4 0.0045 ± 0.0013ab 0.0040 ± 0.0011b 
Parabacteroides 
1 0.0012 ± 0.0003a 0.0011 ± 0.0002a 
<0.0001 NS NS 
2 0.0047 ± 0.0014b 0.0041 ± 0.0005b 
3 0.0031 ± 0.0006bc 0.0025 ± 0.004c 
4 0.0031 ± 0.0005c 0.0023 ± 0.0004c 
Unclassified 
Enterobacteriaceae 
1 0.0006 ± 0.0001a 0.0003 ± 0.0001a 
<0.0001 NS NS 
2 0.0019 ± 0.0003b 0.0019 ± 0.0003b 
3 0.0018 ± 0.0005b 0.0022 ± 0.0005b 
4 0.0012 ± 0.0006c 0.0020 ± 0.0003b 
Unclassified 
Lachnospiraceae 
1 1.3E-9 ± 0.0003a 1.0E-13 ± 2.6E-8a 
NS 0.02 NS 
2 0.0003 ± 0.00009b 0.0002 ± 0.00003b 
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3 0.0005 ± 0.00009b 0.0003 ± 0.0001b 
4 0.0011 ± 0.0003c 0.0001 ± 0.0002b 
Unclassified 
Ruminococcaceae 
1 0.00001 ± 0.00001a 0.00004 ± 0.00002a 
<0.0001 NS NS 
2 5.5E-6 ± 3.2E-6b 6.3E-7 ± 2.2E-7b 
3 3.3E-6 ± 1.1E-6b 2.7E-6 ± 1.9E-7b 





Table S5D: Taxa whose relative abundance was impacted through the supplementation 
of the Propionate-producing consortium (PPC) in the mucosal compartment of the M-
SHIME, at the end of the stabilisation phase (time point 1), after clindamycin 
supplementation (time point 2), after 3 days of PPC administration (time point 3). NS= 
not significantly different. Different superscripts indicate significantly different means 




Treatment (Mean ± SEM)  Effect 
PPC Control Time Treatment Time*Treatment 
Alistipes 
1 0.0078 ± 0.0003
a 0.00278 ± 0.0007a 
0.003 0.03 NS 2 0.0044 ± 0.0003a 0.00146 ± 0.0007a 
3 0.0002± 0.00006b 0.00006 ± 0.0002b 
Bifidobacterium 
1 0.00053 ± 0.0014
a 0.00028 ± 0.0014 
<0.0001 NS NS 2 0.00014 ± 0.0005b 0.00092 ± 0.00005 
3 0.00017 ± 0.0001b 0.00007 ± 0.00002 
Bilophila 
1 0.0013 ± 0.0002
a 0.0017 ± 0.0004a 
<0.0001 NS NS 2 0.00006 ± 0.0002ab 0.00003 ± 0.00004 b 
3 0.0006 ± 0.0001b 0.0006 ± 0.0002c 
Erysipelatoclostridium 
1 0.0007 ± 0.0001
a 0.0007 ± 0.0001a 
<0.0001 0.003 NS 2 0.0027 ± 0.001ab 0.0050 ± 0.0009 b 
3 0.0011 ± 0.0002b 0.0009 ± 0.0002c 
Parabacteroides 
1 0.0007 ± 0.0001
a 0.0007 ± 0.0001a 
<0.0001 NS NS 2 0.0027 ± 0.001ab 0.0050 ± 0.0009 b 
3 0.0011 ± 0.0002b 0.0009 ± 0.0002c 
Unclassified 
Enterobacteriaceae 
1 0.0021 ± 0.0007
a 0.0011 ± 0.0003a 
<0.0001 NS NS 2 0.0033 ± 0.0011ab 0.0025 ± 0.0006b 
3 0.0055 ± 0.0010b 0.0074 ± 0.0017c 
Unclassified 
Lachnospiraceae 
1 0.0014 ± 0.0002
a 0.0010 ± 0.0002a 
0.0006 0.01 NS 2 0.00007 ± 0.0003ab 0.0004 ± 0.00005b 
3 0.0005 ± 0.0002b 0.0002 ± 0.00005c 
Unclassified 
Lactobacillaceae 
1 1.74E-8 ± 7.12E-9
a 4.3E-12 ± 2.68E-12a 
<0.0001 <0.0001 <0.0001 2 1.68E-8 ± 6.6E-9b 4.1E-12 ± 2.5E-12a 






Table S6: Differences in absolute abundances of the certain genera included in the 
propionate-producing consortium between control and treatment vessels in the lumen 
compartment. The significant increase in Veillonella in the treatment vessels indicates 
its successful direct engraftment (P<0.05). The differences were assessed by 2-way 
Anova test using Holm-sidak method with significance at P<0.05. Time point (TPT) 
indicates the different phases at which the samples were analysed (1: End of 
stabilization phase, 2: After antibiotic treatment, 3: After 3 doses of propionate 
producing consortium, and 4: Washout phase).   
Genus  TPT CTR (Mean % ± SEM)  TRT(Mean % ± SEM) P value 
Veillonella 1 0 0 NS 
NS  2 0 0 
 3 0 4.95e+06 ± 7.56e+05 <0.0001 
 4 0 4.09e+04 ± 1.98e+04 NS 




 2 0 1.14e+04 ± 1.14e+04  
 3 5.69e+06 ± 4.28e+06 9.47e+04 ± 7.44e+07 





Table S7: Differences in absolute abundances of the certain genera included in the 
propionate-producing consortium between control and treatment vessels in the mucin 
compartment. The significant increase in Veillonella in the treatment vessels indicates 
its successful direct engraftment (P<0.05). The differences were assessed by 2-way 
Anova test using Holm-sidak method with significance at P<0.05. Time point (TPT) 
indicates the different phases at which the samples were analysed (1: End of 
stabilization phase, 2: After antibiotic treatment, and 3: After 3 doses of propionate 
producing consortium).   
Genus TPT CTR (Mean % ± SEM) TRT (Mean % ± SEM) P value 
Veillonella 1 3.80e+04 ± 2.56e+04 8.57e+03 ± 8.57e+03  NS 
 2 0 0 NS 
 3 0 2.66e+06 ± 8.69e+05 <0.0001 
     
Akkermansia 1 1.13e+07 ± 6.66e+06 9.95e+06 ± 4.64e+06 NS 
 2 1.22e+06 ± 5.78e+05 7.28e+06 ± 5.48e+06 NS 





Table S8: Differences in absolute abundances of the certain genera that were involved 
in propionate production after adding the propionate-producing consortium in the 
lumen compartment. The significant increase in unclassified Lactobacillacea and  
unclassified Lachnospiraceae in the treatment vessels indicates successful indirect 
reinforcement of those genera (P<0.05). The differences were assessed by 2-way Anova 
test using Holm-sidak method with significance at P<0.05. Time point (TPT) indicates 
the different phases at which the samples were analysed (1: End of stabilization phase, 
2: After antibiotic treatment, 3: After 3 doses of propionate producing consortium, and 
4: Washout phase).   
Genus TPT CTR (Mean % ± 
SEM) 
TRT(Mean % ± 
SEM) 
P value 
unclassified_Lactobacillacea 1 0 0 NS 
 2 0 0 NS 
 3 0 5.41e+05 ± 
1.44e+05 
<0.0001 

















































Table S9: Differences in absolute abundances of the certain genera that were involved 
in propionate production after adding the propionate-producing consortium in the 
mucin compartment. The significant increase in  unclassified Lactobacillacea in the 
treatment vessels indicates successful indirect reinforcement of this genus in the 
mucin (P<0.05). The differences were assessed by 2-way Anova test using Holm-sidak 
method with significance at P<0.05. Time point (TPT) indicates the different phases at 
which the samples were analysed (1: End of stabilization phase, 2: After antibiotic 
treatment, and 3: After 3 doses of propionate producing consortium).   
Genus TPT CTR (Mean % ± 
SEM) 
TRT(Mean % ± 
SEM) 
P value 
unclassified_Lactobacillacea 1 0 0 NS 
 2 0 0 NS 








































Figure S1: Production of SCFA after 48h of a fed batch for the 7 strains of the propionate 
producing consortium. One dose of the consortium was prepared fresh on a daily basis 
for each day of the treatment on the SHIME run. Four replicates of the fed batch are 












Mucin beads/ mucin compartment Lumen compartment 
Days 1-10 (stabilization)
Days 11-13 (addition 
of AB)
Days 17 (addition of 
single dose of PPC)
Days 20-23 (addition 
of 3 consecutive 
doses of PPC)
Washout  (days 24-
27)
Figure S2: Scheme of SHIME setups used in our experiments with the timeline of 
each experiment. M-SHIME setup for the single-donor experiment in which the fecal 
sample from one donor was tested at a time. Control and treatment vessels were in 
triplicates (A). A timeline is provided under the SHIME setup showing the different 
phases of the SHIME run at different days for the total of 27 days (A). M-SHIME setup 
for the multiple-donor experiment in which the fecal samples from six different 
donors were inoculated in separate vessels considering control and treatment 
condition as shown in (B). A timeline is provided under the SHIME scheme showing 







Figure S3: PCoA analysis showing the dispersion of the microbial community by 








Figure S4: Addition of the propionate producing consortium (PPC) promotes recovery 
of propionate production after antibiotic-associated disruption in donor 1. (A) Short 
chain fatty acid production during the 4 different phases of the experiment: 
Stabilization, post-antibiotic disruption, post-addition of a single dose of the propionate 
producing consortium,  and post-addition of 3 doses of the propionate producing 
consortium. Single dose of  treatment was added on day 17, and the 3 doses were added 
on days 20, 21, and 22. (B) Propionate was the main short chain fatty acid impacted 
already after 2 doses (Days 21-27) in the treatment reactors (P < 0.05). No significant 





Figure S5: Addition of the propionate producing consortium (PPC) did not have any 
significant effect propionate production after antibiotic-associated disruption in donor 
2.  (A) Short chain fatty acid production during the 4 different phases of the experiment: 
Stabilization, post-antibiotic disruption, post-addition of a single dose of the propionate 
producing consortium,  and post-addition of 3 doses of the propionate producing 
consortium. Single dose of  treatment was added on day 17, and the 3 doses were added 
on days 20, 21, and 22. (B) Propionate was the main short chain fatty acid was not 
impacted after any of the treatment doses (Days 21-27) in the treatment reactors (P 
>0.05). No significant difference was detected for acetate (C) and butyrate (D) after the 





Figure S6: Cell counts were significantly lower after antibiotic use in both lumen and 
mucin compartments (P<0.05). Cell counts for lumen SHIME samples significantly 
decreased after antibiotic treatment (P<0.05). Cell counts for lumen samples were 
compared at 4 different time points for 4 different SHIME phases: 1-Stabilization phase, 
2-after antibiotic phase, 3-after PPC treatment phase, and 4-the last day of the SHIME 
run that is the washout phase. There was no significant increase for the cell load after 
PPC treatment (A). Cell counts for mucin SHIME samples significantly decreased after 
antibiotic treatment (P<0.05). Cell counts for mucin samples were compared at 4 
different time points for 3 different SHIME phases: 1-Stabilization phase, 2-after 
antibiotic phase, and 3-after PPC treatment phase. There was no significant increase for 





Figure S7: Network of bacterial interactions influencing the production of the major 
short chain fatty acids over time. (A) Treatment reactors after antibiotics treatment and 
before adding 3 doses of the propionate consortium, (B) Treatment reactors after 3 days 
period of washout after the propionate consortium dosing. These bipartite networks are 
based on the regularised canonical correlations between relative bacterial abundances 
and relative concentrations of the main SCFA. Interactions have been filtered for an 
absolute correlation above 0.8 and are coloured following the key shown. Significant 
interactions are shorter lines, and genera with similar abundances within SHIME 
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compartment tend to cluster closely. Networks depict genera potentially performing 









Table S1: Different treatments with different SCFA amounts that were  added on the 
enterohepatic cell model. Treatments were diluted 5 fold in DMEM before adding to the 
cell model.  
 
Treatment Acetate (mM) Propionate (mM) Butyrate (mM) 
PPC 37.65 34.49 0 
PPC-Akk 35.73 33.64 0 
Akk 26.66 0.80 0.38 
SCFA PPC 37 34 0 
SCFA Akk 27 0.8 0.4 
 
Table S2: Differences in glycogen storage in the hepatic cells between different 
treatments and between high and low glucose conditions. The significant increase in 
glycogen when the supernatant from the PPC was added indicates positive effect of 
PPC towards increasing glycogen storange in the case of high glucose (P<0.05). The 
differences between treatments were assessed by one-way Anova test using Tukey’s 
method with significance at P<0.05. Values are presented in ug/ml. 
Treatment Condition  
  High Glucose (Mean % ± SEM)  Low Glucose (Mean % ± SEM) 
PPC 22.60 ± 2.18a 9.55 ± 0.12b 
SCFA PPC 8.53 ± 0.19b 7.70 ± 0.22b 
SCFA Akk 10.93 ± 0.15b 11.40 ± 0.24bd 
Akk 9.38 ± 0.42b 8.13 ± 0.10b 
PPC-Akk 9.83 ± 0.23b 5.98 ± 0.13c 
Control 9.30 ± 0.45b 9.48 ± 0.64b 






Table S3: Differences in lipoprotein lipase (LPL) activity levels in the hepatic cells 
between different treatments and between high and low glucose conditions. The 
significant increase in LPL when the supernatant from the PPC was added indicates 
positive effect of PPC towards increasing LPL activity storange in the case of high 
glucose (P<0.05). The differences between treatments were assessed by one-way 
Anova test using Tukey’s method with significance at P<0.05. Values are presented in 
mU/mL.  
Treatment Condition  
  High Glucose (Mean % ± SEM)  Low Glucose (Mean % ± SEM) 
PPC 21.67 ± 0.58a 16.06 ± 0.80ab 
SCFA PPC 15.73 ± 1.29bc 10.65 ± 0.90bc 
SCFA Akk 18.38 ± 2.76abc 10.40 ± 0.71cd 
Akk 13.25 ± 0.38bd 10.57 ± 0.74bd 
PPC-Akk 16.47 ± 1.04abce 13.52 ± 0.70bcde 
Control 17.69 ± 1.17abce 11.11 ± 0.73bcde 
 
 
Table S4: Differences in IL-8 levels in the hepatic cells between different treatments and 
between high and low glucose conditions. The decrease in IL-8 when the supernatant 
from the PPC was added indicates the potential positive effect of PPC towards 
decreasing imflammatory markers in the case of high glucose. The differences between 
treatments were assessed by one-way Anova test using Tukey’s method with 
significance at P<0.05. Values are presented in pg/ml.  
Treatment Condition  
  High Glucose (Mean % ± SEM)  Low Glucose (Mean % ± SEM) 
PPC 2802.67 ± 219.83a 2478.89 ± 203.32a 
SCFA PPC 3213.33 ± 461.96a 2930.00 ± 380.79a 
SCFA Akk 2872.89 ± 348.43a 2586.00 ± 270.41a 
Akk 3034.00 ± 61.23a 2819.33 ± 86.43a 
Control 3532.00 ± 135.57a 3047.33 ± 36.56a 








Table S5: Differences in IL-6 levels in the hepatic cells between different treatments and 
between high and low glucose conditions. There was no significant difference between 
treatments (P>0.05) indicationg no effect of any treatment on IL-6 levels. The differences 
between treatments were assessed by one-way Anova test using Tukey’s method with 
significance at P<0.05. Values are presented in pg/ml. 
Treatment Condition  
  High Glucose (Mean % ± SEM)  Low Glucose (Mean % ± SEM) 
PPC 628.22 ± 26.51 682.33 ± 15.32 
SCFA PPC 612.44 ± 27.26 658.22 ± 39.83 
SCFA Akk 651.11 ± 41.20 585.44 ± 51.10 
Akk 585.56 ± 22.82 598.44 ± 71.28 




Table S6: Differences in TNF-α levels in the hepatic cells between different treatments 
and between high and low glucose conditions. There was no significant difference 
between treatments (P>0.05) indicationg no effect of any treatment on TNF-α levels. The 
differences between treatments were assessed by one-way Anova test using Tukey’s 
method with significance at P<0.05. Values are presented in pg/ml. 
Treatment Condition  
  High Glucose (Mean % ± SEM)  Low Glucose (Mean % ± SEM) 
PPC 170.63 ± 10.72bc 166.89 ± 6.66bc 
SCFA PPC 175.44 ± 7.88bc 167.59 ± 0.77bc 
SCFA Akk 159.19 ± 8.81bc 148.82 ± 2.80b 
Akk 226.41 ± 12.04a 170.78 ± 4.31bc 








Table S7: TEER values (Ohms) are expressed as as mean ± SEM (n =6). 
 
 
Table S8: Values of LY transport (%) to the basolateral compartment of the Transwell 
system are expressed as mean ± SEM (n =6). 
 
Low glucose High glucose 
Control 1,46 ± 0,10 1,14 ± 0,20 
Caco-2/HT29-MTX 1,44 ± 0,30 1,84 ± 0,15 
PPC 1,37 ± 0,03 1,32 ± 0,09 
PPC-Akk 1,42 ± 0,07 1,51 ± 0,05 
Akk 1,35 ± 0,08 1,50 ± 0,23 
SCFA PPC 1,34 ± 0,04 1,57 ± 0,11 










Low glucose High glucose 
Control 630 ± 32 575 ± 49 
Caco-2 566 ± 32 563 ± 36 
PPC 707 ± 33 677 ± 16 
PPC-Akk 643 ± 27 548 ± 62 
Akk 607 ± 11 639 ± 24 
SCFA PPC 676 ± 25 663 ± 12 
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